<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Hum Vaccin Immunother</journal-id><journal-id journal-id-type="iso-abbrev">Hum Vaccin Immunother</journal-id><journal-id journal-id-type="pmc-domain-id">1765</journal-id><journal-id journal-id-type="pmc-domain">hvi</journal-id><journal-title-group><journal-title>Human Vaccines &amp; Immunotherapeutics</journal-title></journal-title-group><issn pub-type="ppub">2164-5515</issn><issn pub-type="epub">2164-554X</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11864319</article-id><article-id pub-id-type="pmcid-ver">PMC11864319.1</article-id><article-id pub-id-type="pmcaid">11864319</article-id><article-id pub-id-type="pmcaiid">11864319</article-id><article-id pub-id-type="pmid">39999432</article-id><article-id pub-id-type="doi">10.1080/21645515.2025.2461844</article-id><article-id pub-id-type="publisher-id">2461844</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Pneumococcal</subject></subj-group></article-categories><title-group><article-title><italic toggle="yes">Streptococcus pneumoniae</italic> serotype distribution in low- and middle-income countries of South Asia: Do we need to revisit the pneumococcal vaccine strategy?</article-title><alt-title alt-title-type="left-running-head">P. DHAWALE ET AL.</alt-title><alt-title alt-title-type="right-running-head">HUMAN VACCINES &amp; IMMUNOTHERAPEUTICS</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Dhawale</surname><given-names initials="P">Priya</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref><xref rid="an0002" ref-type="author-notes">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shah</surname><given-names initials="S">Sanket</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref><xref rid="an0002" ref-type="author-notes">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sharma</surname><given-names initials="K">Kaushal</given-names></name><xref rid="aff0003" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sikriwal</surname><given-names initials="D">Deepa</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kumar</surname><given-names initials="V">Varnik</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bhagawati</surname><given-names initials="A">Arnabjyoti</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dhar</surname><given-names initials="S">Sakshi</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shetty</surname><given-names initials="P">Pratiksha</given-names></name><xref rid="aff0005" ref-type="aff">
<sup>e</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ahmed</surname><given-names initials="S">Syed</given-names></name><xref rid="aff0006" ref-type="aff">
<sup>f</sup>
</xref><xref rid="an0001" ref-type="corresp"/><xref rid="an0002" ref-type="author-notes">
<sup>*</sup>
</xref><xref rid="b0001" ref-type="bio"/></contrib><aff id="aff0001"><label>a</label>Global Business Development, <institution-wrap><institution>Techinvention Lifecare Private Limited</institution></institution-wrap>, <city>Mumbai</city>, <country>India</country></aff><aff id="aff0002"><label>b</label>Strategic Medical Affairs, <institution-wrap><institution>Techinvention Lifecare Private Limited</institution></institution-wrap>, <city>Mumbai</city>, <country>India</country></aff><aff id="aff0003"><label>c</label>Strategic Projects, <institution-wrap><institution>Techinvention Lifecare Private Limited</institution></institution-wrap>, <city>Mumbai</city>, <country>India</country></aff><aff id="aff0004"><label>d</label>Research and Development, <institution-wrap><institution>Techinvention Lifecare Private Limited</institution></institution-wrap>, <city>Mumbai</city>, <country>India</country></aff><aff id="aff0005"><label>e</label>Regulatory Affairs, <institution-wrap><institution>Techinvention Lifecare Private Limited</institution></institution-wrap>, <city>Mumbai</city>, <country>India</country></aff><aff id="aff0006"><label>f</label>Business Development and Strategy, <institution-wrap><institution>Techinvention Lifecare Private Limited</institution></institution-wrap>, <city>Mumbai</city>, <country>India</country></aff></contrib-group><author-notes><corresp id="an0001">CONTACT Syed Ahmed <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:syed@techinvention.biz">syed@techinvention.biz</email> Business Development and Strategy, Techinvention Lifecare Private Limited, <addr-line>#1004, The Summit Business Park, Off WEH Metro Station, Andheri Kurla Road</addr-line>, <city>Andheri</city> East, Mumbai <postal-code>400093</postal-code>, <country>India</country>.</corresp><fn id="an0002"><label>*</label><p>These authors contributed equally to this work and share first authorship.</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><volume>21</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">477458</issue-id><elocation-id seq="81">2461844</elocation-id><pub-history><event event-type="pmc-release"><date><day>25</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>26</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-27 10:25:14.960"><day>27</day><month>02</month><year>2025</year></date></event><event event-type="tagger"><event-desc>Integra</event-desc><date><day>24</day><month>2</month><year>2025</year></date></event><event event-type="final"><event-desc>Integra</event-desc><date><day>24</day><month>2</month><year>2025</year></date></event><event event-type="received"><date><day>30</day><month>8</month><year>2024</year></date></event><event event-type="revised"><date><day>20</day><month>1</month><year>2025</year></date></event><event event-type="accepted"><date><day>30</day><month>1</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s). Published with license by Taylor &amp; Francis Group, LLC.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="KHVI_21_2461844.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="KHVI_21_2461844.pdf"/><abstract><title>ABSTRACT</title><p><italic toggle="yes">S. pneumoniae</italic> serotypes responsible for pneumococcal disease differ with respect to disease severity, invasiveness, antimicrobial susceptibility, geographies, immunization history, age groups, and with time. Although PCVs have blunted the pneumococcal disease burden, they are plagued with numerous challenges, especially the emergence of NVTs. In this review, we show that there are diverse serotypes, especially NVTs, responsible for causing pneumococcal diseases in LMICs of South Asia across different studies conducted between 2012 and 2024. We propose that pharmaceutical/biotech companies should tailor/customize the PCVs as per the region-specific serotype prevalence based on surveillance data. Furthermore, protein-based vaccines, or WCVs, have been explored and can serve as viable alternatives to address the limitations associated with PCVs. However, robust studies are warranted in different geographies to demonstrate its efficacy and safety in clinical trials as well as the real-world effectiveness of these promising candidates.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd><italic toggle="yes">Streptococcus pneumoniae</italic></kwd><kwd>invasive pneumococcal disease</kwd><kwd>pneumococcal vaccines</kwd><kwd>antimicrobial resistance</kwd><kwd>South Asia</kwd></kwd-group><support-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></support-group><counts><fig-count count="0"/><table-count count="9"/><ref-count count="282"/><page-count count="1"/><word-count count="11245"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" disp-level="1" id="s0001"><title>Introduction</title><p><italic toggle="yes">Streptococcus pneumoniae</italic> (<italic toggle="yes">S. pneumoniae</italic>) is a gram-positive bacteria that colonizes the upper respiratory tract of humans.<sup><xref rid="cit0001" ref-type="bibr">1</xref>,<xref rid="cit0002" ref-type="bibr">2</xref></sup> Globally, it represents an important cause of morbidity and mortality in children and adults.<sup><xref rid="cit0003" ref-type="bibr">3</xref></sup> It is responsible for causing invasive pneumococcal disease (IPD), viz., meningitis, septicemia, bacteremia, and bacteremic pneumonia, as well as non-IPD, such as acute otitis media (AOM) and non-bacteremic pneumonia, in both adults and children.<sup><xref rid="cit0004" ref-type="bibr">4</xref>,<xref rid="cit0005" ref-type="bibr">5</xref></sup> The disease burden (incidence and mortality rates) is highest in children &lt;5&#8201;years and adults &gt;65&#8201;years, as well as in individuals with compromised immune system or chronic medical conditions.<sup><xref rid="cit0005" ref-type="bibr">5</xref>,<xref rid="cit0006" ref-type="bibr">6</xref></sup> The World Health Organization (WHO) estimates that <italic toggle="yes">S. pneumoniae</italic> is responsible for killing&#8201;&gt;&#8201;300,000 children under 5&#8201;years of age globally every year, with the majority of them occurring in developing countries.<sup><xref rid="cit0007" ref-type="bibr">7</xref></sup> It is also the leading cause of bacterial pneumonia globally.<sup><xref rid="cit0007" ref-type="bibr">7</xref></sup> Antibiotics have been used as front-line agents for the treatment of <italic toggle="yes">S. pneumoniae</italic> infections, but the emergence of antibiotic-resistant strains is a major concern for clinicians.<sup><xref rid="cit0008" ref-type="bibr">8</xref>,<xref rid="cit0009" ref-type="bibr">9</xref></sup> The WHO has included <italic toggle="yes">S. pneumoniae</italic> as one of the 12 priority pathogens, exhibiting increased resistance to antibiotics.<sup><xref rid="cit0010" ref-type="bibr">10</xref>,<xref rid="cit0011" ref-type="bibr">11</xref></sup>
<italic toggle="yes">S. pneumoniae</italic> produces several virulence factors, and the capsular polysaccharide is considered to be the most important one, enabling binding to the cells and evading the host immune system.<sup><xref rid="cit0005" ref-type="bibr">5</xref>,<xref rid="cit0006" ref-type="bibr">6</xref>,<xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0013" ref-type="bibr">13</xref></sup> More than 90 serotypes have been identified based on these capsular polysaccharides, and only a subset of them are responsible for causing pneumococcal disease.<sup><xref rid="cit0005" ref-type="bibr">5</xref>,<xref rid="cit0006" ref-type="bibr">6</xref>,<xref rid="cit0014" ref-type="bibr">14</xref></sup> These serotypes also form the basis of pneumococcal conjugate vaccines (PCVs), and only a fraction of the serotypes are included in the vaccine formulation because of the complexity involved in the manufacturing of PCVs.<sup><xref rid="cit0005" ref-type="bibr">5</xref>,<xref rid="cit0015" ref-type="bibr">15</xref>,<xref rid="cit0016" ref-type="bibr">16</xref></sup> Pneumococcal disease is endemic globally, but the distribution of <italic toggle="yes">S. pneumoniae</italic> serotypes differs with respect to their disease severity, invasiveness, antimicrobial susceptibility, geographies, immunization history of individuals, age groups, and with time.<sup><xref rid="cit0004" ref-type="bibr">4</xref>,<xref rid="cit0005" ref-type="bibr">5</xref>,<xref rid="cit0016" ref-type="bibr">16&#8211;19</xref></sup></p><p>Pneumococcal carriage is seen more frequently in children than adults, and thus children are considered to be the main reservoir and transmitter of this pathogen.<sup><xref rid="cit0013" ref-type="bibr">13</xref></sup> In low- and middle-income countries (LMICs), <italic toggle="yes">S. pneumoniae</italic> has three times higher colonization as compared to those in high- income countries (HICs).<sup><xref rid="cit0020" ref-type="bibr">20</xref></sup> The burden of pneumococcal diseases remains high in LMICs.<sup><xref rid="cit0021" ref-type="bibr">21</xref></sup> Globally, there are over 1,400 cases of pneumonia per 100,000 children annually, with the greatest incidence occurring in South Asia (2,500 cases/100,000 children) and West and Central Africa (1,620 cases/100,000 children).<sup><xref rid="cit0022" ref-type="bibr">22</xref></sup> South Asian countries have the highest mortality due to IPD.<sup><xref rid="cit0023" ref-type="bibr">23</xref></sup> Population-based studies in South Asian countries have shown that <italic toggle="yes">S. pneumoniae</italic> was responsible for 12.8% of invasive bacterial diseases, whereas retrospective hospital-based studies showed that 28% of them were due to <italic toggle="yes">S. pneumoniae</italic>.<sup><xref rid="cit0023" ref-type="bibr">23</xref></sup></p><p>The implementation of PCVs has played a significant role in reducing the burden of pneumococcal disease globally through direct protection of vaccinated individuals and indirect protection of unvaccinated individuals by reducing the nasopharyngeal carriage and transmission of vaccine-type (VT) pneumococci.<sup><xref rid="cit0024" ref-type="bibr">24</xref>,<xref rid="cit0025" ref-type="bibr">25</xref></sup> Vaccines also serve as an effective strategy to address the burgeoning issue of antimicrobial resistance (AMR) in <italic toggle="yes">S. pneumoniae</italic>.<sup><xref rid="cit0009" ref-type="bibr">9</xref></sup> As per the VIEW-hub Report: Global Vaccine Introduction and Implementation, 159 countries have introduced PCVs into their national immunization programs (NIPs) as of August 2024.<sup><xref rid="cit0026" ref-type="bibr">26</xref></sup> PCVs have also been introduced in many LMICs with the support of Gavi, the Vaccine Alliance<sup><xref rid="cit0027" ref-type="bibr">27</xref></sup> Evaluating the impact of vaccines in LMICs is of paramount importance because of differences in pneumococcal epidemiology, including transmission rates.<sup><xref rid="cit0028" ref-type="bibr">28</xref></sup></p><p>Despite the remarkable success achieved with PCVs, the prevalence of IPD has increased by non-vaccine serotypes (NVTs), partially offsetting the total disease reduction.<sup><xref rid="cit0004" ref-type="bibr">4</xref>,<xref rid="cit0029" ref-type="bibr">29&#8211;32</xref></sup> This phenomenon, referred to as serotype replacement, is due to the greater serotype diversity observed in developing countries.<sup><xref rid="cit0029" ref-type="bibr">29</xref></sup> Although this phenomenon was initially considered controversial, it is now well established.<sup><xref rid="cit0033" ref-type="bibr">33</xref></sup> These NVTs may replace the VTs in the upper airways, resulting in increased transmission and disease, as well as undermining the effectiveness of the currently available PCVs.<sup><xref rid="cit0019" ref-type="bibr">19</xref>,<xref rid="cit0034" ref-type="bibr">34</xref></sup> They have the tendency to be highly invasive in nature as well as exhibit high levels of resistance to antibiotics.<sup><xref rid="cit0029" ref-type="bibr">29</xref>,<xref rid="cit0035" ref-type="bibr">35</xref></sup> Two mechanisms for serotype replacement have been suggested, which are described in detail by Lo et al. and van Tonder et al.<sup><xref rid="cit0030" ref-type="bibr">30</xref>,<xref rid="cit0036" ref-type="bibr">36</xref></sup> Hence, it becomes imperative to monitor the serotype data post-PCV introduction to identify new emerging serotypes and gain insights into the evolving epidemiology of <italic toggle="yes">S. pneumoniae</italic>.<sup><xref rid="cit0004" ref-type="bibr">4</xref>,<xref rid="cit0037" ref-type="bibr">37</xref></sup> Also, robust vaccine strategies are warranted to address the issue of NVTs.<sup><xref rid="cit0038" ref-type="bibr">38</xref></sup></p><p>In this comprehensive review, we bring forth the distribution and distinctive characteristics of pneumococcal serotypes in LMICs of South Asia. It sheds light on the prevailing trend of NVTs gaining prominence globally, showcasing their distinct features across the region. An elaborate overview of the current pneumococcal vaccine landscape is provided, highlighting the merits and demerits of PCVs, along with alternative strategies (protein-based and whole-cell vaccines [WCVs]) that are being investigated to address the limitations of PCVs. Furthermore, we provide valuable recommendations for future vaccine design and development to mitigate the threat posed by these NVTs.</p></sec><sec disp-level="1" id="s0002"><title>Methods</title><p>We conducted a comprehensive literature search on PubMed to identify relevant studies that were published between 2012 and 2024 (at the time of writing the mansucript) using the keywords, viz., &#8220;pneumococcal disease,&#8221; &#8220;pneumococcal serotypes,&#8221; &#8220;pneumococcal conjugate vaccines,&#8221; &#8220;invasive pneumococcal disease,&#8221; &#8220;non-invasive pneumococcal disease,&#8221; and the respective South Asian country name (Afghanistan, Bangladesh, Sri Lanka, Nepal, Bhutan, Pakistan, India, and Maldives). Studies that were conducted between 2012 to 2024 were included in our analysis. Also, studies that commenced before 2012 but concluded in or after 2012 were also included in our analysis. Studies published in native/regional languages other than English were excluded. <xref rid="t0001" ref-type="table">Table 1</xref> highlights the <italic toggle="yes">S. pneumoniae</italic> serotypes reported in LMICs of South Asia from different studies conducted between 2012 and 2024 (at the time of writing this manuscript). <xref rid="t0002" ref-type="table">Table 2</xref> highlights the different characteristics of NVTs observed in this region.<table-wrap position="float" id="t0001" orientation="landscape"><label>Table 1.</label><caption><p>Pneumococcal serotypes reported in LMICs of South Asia from different studies conducted between 2012 to 2024.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Studies included<sup>1</sup></th><th align="center" colspan="1" rowspan="1">Age groups<sup>2</sup></th><th align="center" colspan="1" rowspan="1">Serotypes/Serogroups<break/>reported<sup>3</sup></th><th align="center" colspan="1" rowspan="1">Serotypes covered under<break/>PCV13<sup>4</sup></th><th align="center" colspan="1" rowspan="1">NVTs</th><th align="center" colspan="1" rowspan="1">Mixed<break/>Serotypes</th><th align="center" colspan="1" rowspan="1">Countries<break/>and references</th><th align="center" colspan="1" rowspan="1">Remarks</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0001"><list-item><p>Serotype distribution and AMR patterns of pneumococcal isolates collected from individuals with IPD and non-IPD and from carriage studies</p></list-item><list-item><p>Customized PCR for invasive pneumococcal serotype determination</p></list-item><list-item><p>Comparison of <italic toggle="yes">S. pneumoniae</italic> serotype distribution, AMR patterns, and carriage from community children and children with clinical pneumonia; health care and non-healthcare workers; and pre- and post-Hajj pilgrims</p></list-item><list-item><p>Carriage of <italic toggle="yes">S. pneumoniae</italic> serotypes in vaccinated and unvaccinated populations</p></list-item><list-item><p>Evaluating the burden of bacterial meningitis</p></list-item><list-item><p>Distribution and comparison of <italic toggle="yes">S. pneumoniae</italic> serotypes in healthy and diseased individuals</p></list-item><list-item><p>Comparison of <italic toggle="yes">S. pneumoniae</italic> serotype distribution in individuals with and without pneumonia</p></list-item><list-item><p>Identification of risk factors associated with nasopharyngeal colonization of <italic toggle="yes">S. pneumoniae</italic></p></list-item><list-item><p>Observation and/or comparison of <italic toggle="yes">S. pneumoniae</italic> serotype distribution, AMR patterns, and genomic changes observed before and after PCV introduction</p></list-item><list-item><p><italic toggle="yes">S. pneumoniae</italic> carriage, serotype distribution, and AMR patterns in other disease conditions</p></list-item><list-item><p>Identifying pneumococcal serotypes and evaluating the prevalence and risk factors for non-IPD</p></list-item><list-item><p>Effect of antibiotics on invasive and non-invasive pneumococcal isolates</p></list-item><list-item><p>Molecular characterization and serotype distribution of antibiotic-resistant IPD isolates</p></list-item></list></td><td align="left" colspan="1" rowspan="1">0 to &gt;65 years</td><td align="left" colspan="1" rowspan="1">1, 2, 3, 4, 5, 6, 7, 8, 11, 13, 14, 15, 16, 17, 18, 20, 21, 24, 27, 29, 31, 33, 34, 36, 37, 38, 39, 40, 41, 42, 45, 46, 48, 10A, 10A/B, 10B, 10C, 10C/F, 10F, 10F/C, 10F/C/33, 10F/C/33C, 11A, 11A/C/D, 11A/D, 11B, 11B/F, 11C, 11D, 11F, 12A, 12B, 12F, 12F/A/44/46, 12F/A/B/44/46, 13/28, 15A, 15A/F, 15B, 15B/C, 15C, 15F, 15F/A, 16A, 16C, 16F, 17A, 17F, 18A, 18A/B, 18A/B/C,18A/B/C/F, 18A/C/B/D, 18B, 18C,18C/F, 18C/F/B, 18C/F/B/A, 18F, 19A, 19B, 19C, 19F, 19V, 21/39, 22A, 22A/F, 22F, 22F/A, 23A, 23B, 23F, 24A, 24A/B/F, 24B, 24F, 24F/A/B, 25A, 25F, 25F/38, 25F/A/38, 28A, 28F, 32A, 32F, 33A, 33A/F, 33B, 33B/C, 33B/C/D, 33C, 33D, 33F, 33F/A/37, 34/47, 35A, 35A/B/C, 35A/C/42, 35B, 35C, 35D, 35F, 35F/47F, 35F/A/37, 37F/47F, 38/25F/A, 41F, 47F, 6A, 6A/B, 6A/B/C, 6A/B/C/D, 6B, 6B/C, 6C, 6C/D, 6D, 6F, 7A, 7A/5, 7B, 7B/C/40, 7C, 7C/B, 7C/B/40, 7F, 7F/A, 7F/A/B, 9A, 9A/L, 9A/V, 9B, 9B/L, 9L, 9N, 9N/L, 9V, 9V/A</td><td align="left" colspan="1" rowspan="1">1, 3, 4, 5, 14, 18C, 19A, 19F, 23F, 6A, 6B, 7F, 9V</td><td align="left" colspan="1" rowspan="1">2, 6, 7, 8, 11, 13, 15, 16, 17, 18, 20, 21, 24, 27, 29, 31, 33, 34, 36, 37, 38, 39, 40, 41, 42, 45, 46, 48, 10A, 10B, 10C, 10F, 11A, 11B, 11C, 11D, 11F, 12A, 12B, 12F, 15A, 15B, 15C, 15F, 16A, 16C, 16F, 17A, 17F, 18A, 18B, 18F, 19B, 19C, 19V, 22A, 22F, 23A, 23B, 24A, 24B, 24F, 25A, 25F, 28A, 28F, 32A, 32F, 33A, 33B, 33C, 33D, 33F, 35A, 35B, 35C, 35D, 35F, 41F, 47F, 6C, 6D, 6F, 7A, 7B, 7C, 9A, 9B, 9L, 9N</td><td align="left" colspan="1" rowspan="1">10A/B, 10C/F, 10F/C, 10F/C/33, 10F/C/33C, 11A/C/D, 11A/D, 11B/F, 12F/A/44/46, 12F/A/B/44/46, 13/28, 15A/F, 15B/C, 15F/A, 18A/B, 18A/B/C, 18A/B/C/F, 18A/C/B/D, 18C/F, 18C/F/B, 18C/F/B/A, 21/39, 22A/F, 22F/A, 24A/B/F, 24F/A/B, 25F/38, 25F/A/38, 33A/F, 33B/C, 33B/C/D, 33F/A/37, 34/47, 35A/B/C, 35A/C/42, 35F/47F, 35F/A/37, 37F/47F, 38/25F/A, 6A/B, 6A/B/C, 6A/B/C/D, 6B/C, 6C/D, 7A/5, 7B/C/40, 7C/B, 7C/B/40, 7F/A, 7F/A/B, 9A/L, 9A/V, 9B/L, 9N/L, 9V/A</td><td align="left" colspan="1" rowspan="1">Afghanistan<sup><xref rid="cit0039" ref-type="bibr">39</xref></sup> Bangladesh<sup><xref rid="cit0040" ref-type="bibr">40&#8211;46</xref></sup><break/>Sri Lanka<sup><xref rid="cit0047" ref-type="bibr">47</xref>,<xref rid="cit0048" ref-type="bibr">48</xref></sup> Nepal<sup><xref rid="cit0049" ref-type="bibr">49&#8211;52</xref></sup>Bhutan<sup><xref rid="cit0053" ref-type="bibr">53</xref></sup> Pakistan<sup><xref rid="cit0054" ref-type="bibr">54&#8211;64</xref></sup> India<sup><xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0040" ref-type="bibr">40</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0064" ref-type="bibr">64&#8211;101</xref></sup></td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0002"><list-item><p>There is no data available for Maldives.</p></list-item></list><break/></td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p><sup>1</sup>Studies included refers to the different types of studies that were carried out in the region and included in the analysis.</p></fn><fn id="tfn0002"><p><sup>2</sup>Age groups refers to the combined age groups under investigation from all the studies carried out in the region.</p></fn><fn id="tfn0003"><p><sup>3</sup>Serotypes/Serogroups reported refers to the serotypes/serogroups reported from all the studies included in the analysis.</p></fn><fn id="tfn0004"><p><sup>4</sup>PCV13 refers to Pfizer&#8217;s Prevnar 13.</p></fn><fn id="tfn0005"><p>Abbreviations: NVTs: Non-vaccine serotypes; AMR: Antimicrobial resistance; IPD: Invasive pneumococcal disease; Non-IPD: Non-invasive pneumococcal disease; PCR: Polymerase chain reaction; <italic toggle="yes">S. pneumoniae</italic>: <italic toggle="yes">Streptococcus pneumoniae;</italic> PCV: Pneumococcal conjugate vaccine.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t0002" orientation="portrait"><label>Table 2.</label><caption><p>Characteristics of NVTs observed in LMICs of South Asia from different studies conducted between 2012 and 2024.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="left" span="1"/></colgroup><thead><tr><th rowspan="2" align="center" colspan="1">NVTs</th><th colspan="5" align="center" rowspan="1">Characteristics<hr/></th><th rowspan="2" align="center" colspan="1">References</th></tr><tr><th align="center" colspan="1" rowspan="1">IPD</th><th align="center" colspan="1" rowspan="1">Non-IPD</th><th align="center" colspan="1" rowspan="1">Drug<break/>resistance<sup>1</sup></th><th align="center" colspan="1" rowspan="1">NP carriage</th><th align="center" colspan="1" rowspan="1">Unspecified<break/>(IPD/Non-IPD)<sup>2</sup></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">2</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0043" ref-type="bibr">43&#8211;45</xref>,<xref rid="cit0049" ref-type="bibr">49</xref>,<xref rid="cit0050" ref-type="bibr">50</xref>,<xref rid="cit0052" ref-type="bibr">52</xref>,<xref rid="cit0058" ref-type="bibr">58</xref>,<xref rid="cit0063" ref-type="bibr">63</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0067" ref-type="bibr">67</xref>,<xref rid="cit0068" ref-type="bibr">68</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0072" ref-type="bibr">72</xref>,<xref rid="cit0076" ref-type="bibr">76</xref>,<xref rid="cit0078" ref-type="bibr">78</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0100" ref-type="bibr">100</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0048" ref-type="bibr">48</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0086" ref-type="bibr">86</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0041" ref-type="bibr">41&#8211;46</xref>,<xref rid="cit0049" ref-type="bibr">49&#8211;52</xref>,<xref rid="cit0057" ref-type="bibr">57&#8211;59</xref>,<xref rid="cit0062" ref-type="bibr">62</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0063" ref-type="bibr">63&#8211;67</xref>,<xref rid="cit0069" ref-type="bibr">69&#8211;75</xref>,<xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0088" ref-type="bibr">88</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0092" ref-type="bibr">92</xref>,<xref rid="cit0093" ref-type="bibr">93</xref>,<xref rid="cit0099" ref-type="bibr">99&#8211;101</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">11*</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0039" ref-type="bibr">39</xref>,<xref rid="cit0086" ref-type="bibr">86</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">13</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0043" ref-type="bibr">43&#8211;47</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;54</xref>,<xref rid="cit0056" ref-type="bibr">56</xref>,<xref rid="cit0058" ref-type="bibr">58&#8211;63</xref>,<xref rid="cit0067" ref-type="bibr">67</xref>,<xref rid="cit0069" ref-type="bibr">69&#8211;71</xref>,<xref rid="cit0073" ref-type="bibr">73&#8211;75</xref>,<xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0083" ref-type="bibr">83&#8211;85</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0092" ref-type="bibr">92</xref>,<xref rid="cit0094" ref-type="bibr">94</xref>,<xref rid="cit0100" ref-type="bibr">100</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">15</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0049" ref-type="bibr">49</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">16</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0049" ref-type="bibr">49</xref>,<xref rid="cit0071" ref-type="bibr">71</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">17</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0059" ref-type="bibr">59</xref>,<xref rid="cit0069" ref-type="bibr">69</xref>,<xref rid="cit0077" ref-type="bibr">77</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">18*</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0039" ref-type="bibr">39</xref>,<xref rid="cit0042" ref-type="bibr">42</xref>,<xref rid="cit0065" ref-type="bibr">65</xref>,<xref rid="cit0092" ref-type="bibr">92</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">20</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0039" ref-type="bibr">39</xref>,<xref rid="cit0041" ref-type="bibr">41</xref>,<xref rid="cit0043" ref-type="bibr">43&#8211;47</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;53</xref>,<xref rid="cit0058" ref-type="bibr">58</xref>,<xref rid="cit0061" ref-type="bibr">61&#8211;63</xref>,<xref rid="cit0065" ref-type="bibr">65</xref>,<xref rid="cit0067" ref-type="bibr">67</xref>,<xref rid="cit0069" ref-type="bibr">69&#8211;71</xref>,<xref rid="cit0074" ref-type="bibr">74</xref>,<xref rid="cit0075" ref-type="bibr">75</xref>,<xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0083" ref-type="bibr">83</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0090" ref-type="bibr">90</xref>,<xref rid="cit0092" ref-type="bibr">92</xref>,<xref rid="cit0094" ref-type="bibr">94</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">21</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0044" ref-type="bibr">44</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0054" ref-type="bibr">54</xref>,<xref rid="cit0056" ref-type="bibr">56</xref>,<xref rid="cit0058" ref-type="bibr">58</xref>,<xref rid="cit0061" ref-type="bibr">61&#8211;64</xref>,<xref rid="cit0067" ref-type="bibr">67</xref>,<xref rid="cit0068" ref-type="bibr">68</xref>,<xref rid="cit0070" ref-type="bibr">70&#8211;73</xref>,<xref rid="cit0083" ref-type="bibr">83</xref>,<xref rid="cit0092" ref-type="bibr">92</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">24</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0041" ref-type="bibr">41</xref>,<xref rid="cit0044" ref-type="bibr">44</xref>,<xref rid="cit0052" ref-type="bibr">52</xref>,<xref rid="cit0053" ref-type="bibr">53</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0069" ref-type="bibr">69</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0084" ref-type="bibr">84</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">27</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0066" ref-type="bibr">66</xref>,<xref rid="cit0071" ref-type="bibr">71</xref>,<xref rid="cit0072" ref-type="bibr">72</xref>,<xref rid="cit0074" ref-type="bibr">74</xref>,<xref rid="cit0075" ref-type="bibr">75</xref>,<xref rid="cit0084" ref-type="bibr">84</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">29</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0045" ref-type="bibr">45</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0066" ref-type="bibr">66</xref>,<xref rid="cit0069" ref-type="bibr">69&#8211;72</xref>,<xref rid="cit0074" ref-type="bibr">74</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0090" ref-type="bibr">90</xref>,<xref rid="cit0094" ref-type="bibr">94</xref>,<xref rid="cit0100" ref-type="bibr">100</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">31</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0044" ref-type="bibr">44</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0056" ref-type="bibr">56</xref>,<xref rid="cit0058" ref-type="bibr">58</xref>,<xref rid="cit0062" ref-type="bibr">62&#8211;65</xref>,<xref rid="cit0067" ref-type="bibr">67</xref>,<xref rid="cit0070" ref-type="bibr">70&#8211;72</xref>,<xref rid="cit0075" ref-type="bibr">75</xref>,<xref rid="cit0078" ref-type="bibr">78</xref>,<xref rid="cit0084" ref-type="bibr">84&#8211;86</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0092" ref-type="bibr">92</xref>,<xref rid="cit0094" ref-type="bibr">94</xref>,<xref rid="cit0100" ref-type="bibr">100</xref>,<xref rid="cit0101" ref-type="bibr">101</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">33</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0049" ref-type="bibr">49</xref>,<xref rid="cit0074" ref-type="bibr">74</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">34</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0039" ref-type="bibr">39</xref>,<xref rid="cit0041" ref-type="bibr">41</xref>,<xref rid="cit0043" ref-type="bibr">43&#8211;47</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;54</xref>,<xref rid="cit0056" ref-type="bibr">56</xref>,<xref rid="cit0058" ref-type="bibr">58</xref>,<xref rid="cit0060" ref-type="bibr">60&#8211;65</xref>,<xref rid="cit0067" ref-type="bibr">67</xref>,<xref rid="cit0070" ref-type="bibr">70&#8211;75</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0083" ref-type="bibr">83&#8211;85</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0093" ref-type="bibr">93</xref>,<xref rid="cit0094" ref-type="bibr">94</xref>,<xref rid="cit0100" ref-type="bibr">100</xref>,<xref rid="cit0101" ref-type="bibr">101</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">36</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0072" ref-type="bibr">72</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0090" ref-type="bibr">90</xref>,<xref rid="cit0094" ref-type="bibr">94</xref>,<xref rid="cit0100" ref-type="bibr">100</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">37</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0071" ref-type="bibr">71</xref>,<xref rid="cit0075" ref-type="bibr">75</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">38</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0044" ref-type="bibr">44</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0065" ref-type="bibr">65</xref>,<xref rid="cit0069" ref-type="bibr">69&#8211;75</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0094" ref-type="bibr">94</xref>,<xref rid="cit0100" ref-type="bibr">100</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">39</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0044" ref-type="bibr">44&#8211;46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;53</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0066" ref-type="bibr">66</xref>,<xref rid="cit0067" ref-type="bibr">67</xref>,<xref rid="cit0069" ref-type="bibr">69&#8211;71</xref>,<xref rid="cit0074" ref-type="bibr">74</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0083" ref-type="bibr">83</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0100" ref-type="bibr">100</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">40</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50</xref>,<xref rid="cit0051" ref-type="bibr">51</xref>,<xref rid="cit0069" ref-type="bibr">69</xref>,<xref rid="cit0072" ref-type="bibr">72</xref>,<xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0084" ref-type="bibr">84</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">41</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0052" ref-type="bibr">52</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">42</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50</xref>,<xref rid="cit0052" ref-type="bibr">52</xref>,<xref rid="cit0080" ref-type="bibr">80</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">45</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0042" ref-type="bibr">42</xref>,<xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0045" ref-type="bibr">45</xref>,<xref rid="cit0051" ref-type="bibr">51</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0072" ref-type="bibr">72</xref>,<xref rid="cit0075" ref-type="bibr">75</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0100" ref-type="bibr">100</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">46</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0067" ref-type="bibr">67</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">48</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0039" ref-type="bibr">39</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0049" ref-type="bibr">49&#8211;52</xref>,<xref rid="cit0070" ref-type="bibr">70&#8211;72</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0090" ref-type="bibr">90</xref>,<xref rid="cit0094" ref-type="bibr">94</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">10A</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0043" ref-type="bibr">43&#8211;46</xref>,<xref rid="cit0049" ref-type="bibr">49&#8211;52</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0068" ref-type="bibr">68&#8211;75</xref>,<xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0083" ref-type="bibr">83</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0090" ref-type="bibr">90</xref>,<xref rid="cit0094" ref-type="bibr">94</xref>,<xref rid="cit0100" ref-type="bibr">100</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">10B</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50</xref>,<xref rid="cit0052" ref-type="bibr">52</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0071" ref-type="bibr">71</xref>,<xref rid="cit0093" ref-type="bibr">93</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">10C</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0069" ref-type="bibr">69</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0074" ref-type="bibr">74</xref>,<xref rid="cit0075" ref-type="bibr">75</xref>,<xref rid="cit0083" ref-type="bibr">83</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0093" ref-type="bibr">93</xref>,<xref rid="cit0100" ref-type="bibr">100</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">10F*</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0043" ref-type="bibr">43&#8211;46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0066" ref-type="bibr">66</xref>,<xref rid="cit0069" ref-type="bibr">69&#8211;74</xref>,<xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0083" ref-type="bibr">83</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0092" ref-type="bibr">92</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">11A</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0043" ref-type="bibr">43&#8211;46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0066" ref-type="bibr">66</xref>,<xref rid="cit0069" ref-type="bibr">69&#8211;75</xref>,<xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0078" ref-type="bibr">78</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0083" ref-type="bibr">83&#8211;85</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0092" ref-type="bibr">92&#8211;94</xref>,<xref rid="cit0101" ref-type="bibr">101</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">11B</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0050" ref-type="bibr">50</xref>,<xref rid="cit0051" ref-type="bibr">51</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">11C</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0075" ref-type="bibr">75</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">11D</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0051" ref-type="bibr">51</xref>,<xref rid="cit0069" ref-type="bibr">69</xref>,<xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0080" ref-type="bibr">80</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">11F</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0080" ref-type="bibr">80</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">12A</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0042" ref-type="bibr">42</xref>,<xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0049" ref-type="bibr">49</xref>,<xref rid="cit0050" ref-type="bibr">50</xref>,<xref rid="cit0052" ref-type="bibr">52</xref>,<xref rid="cit0069" ref-type="bibr">69</xref>,<xref rid="cit0073" ref-type="bibr">73</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0083" ref-type="bibr">83</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">12B</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0075" ref-type="bibr">75</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">12F</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0039" ref-type="bibr">39</xref>,<xref rid="cit0041" ref-type="bibr">41</xref>,<xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0044" ref-type="bibr">44</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0057" ref-type="bibr">57</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0069" ref-type="bibr">69</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0072" ref-type="bibr">72</xref>,<xref rid="cit0074" ref-type="bibr">74</xref>,<xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0083" ref-type="bibr">83&#8211;85</xref>,<xref rid="cit0092" ref-type="bibr">92</xref>,<xref rid="cit0101" ref-type="bibr">101</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">15A</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0043" ref-type="bibr">43&#8211;46</xref>,<xref rid="cit0049" ref-type="bibr">49&#8211;52</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0068" ref-type="bibr">68&#8211;75</xref>,<xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0083" ref-type="bibr">83</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0090" ref-type="bibr">90</xref>,<xref rid="cit0094" ref-type="bibr">94</xref>,<xref rid="cit0100" ref-type="bibr">100</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">15B</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0039" ref-type="bibr">39</xref>,<xref rid="cit0041" ref-type="bibr">41&#8211;43</xref>,<xref rid="cit0045" ref-type="bibr">45</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0066" ref-type="bibr">66</xref>,<xref rid="cit0069" ref-type="bibr">69&#8211;75</xref>,<xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0078" ref-type="bibr">78</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0083" ref-type="bibr">83</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0090" ref-type="bibr">90</xref>,<xref rid="cit0092" ref-type="bibr">92</xref>,<xref rid="cit0093" ref-type="bibr">93</xref>,<xref rid="cit0099" ref-type="bibr">99</xref>,<xref rid="cit0101" ref-type="bibr">101</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">15C*</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0041" ref-type="bibr">41</xref>,<xref rid="cit0045" ref-type="bibr">45</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0066" ref-type="bibr">66</xref>,<xref rid="cit0071" ref-type="bibr">71&#8211;74</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0083" ref-type="bibr">83</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0090" ref-type="bibr">90</xref>,<xref rid="cit0094" ref-type="bibr">94</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">15F</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50</xref>,<xref rid="cit0052" ref-type="bibr">52</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0069" ref-type="bibr">69</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0072" ref-type="bibr">72</xref>,<xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0078" ref-type="bibr">78</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0092" ref-type="bibr">92</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">16A</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">16C</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0052" ref-type="bibr">52</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">16F</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0043" ref-type="bibr">43&#8211;46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;54</xref>,<xref rid="cit0056" ref-type="bibr">56</xref>,<xref rid="cit0058" ref-type="bibr">58</xref>,<xref rid="cit0060" ref-type="bibr">60&#8211;65</xref>,<xref rid="cit0067" ref-type="bibr">67</xref>,<xref rid="cit0070" ref-type="bibr">70&#8211;75</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0083" ref-type="bibr">83</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0086" ref-type="bibr">86</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0090" ref-type="bibr">90</xref>,<xref rid="cit0092" ref-type="bibr">92</xref>,<xref rid="cit0093" ref-type="bibr">93</xref>,<xref rid="cit0101" ref-type="bibr">101</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">17A</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0069" ref-type="bibr">69</xref>,<xref rid="cit0073" ref-type="bibr">73</xref>,<xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0090" ref-type="bibr">90</xref>,<xref rid="cit0092" ref-type="bibr">92</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">17F*</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0039" ref-type="bibr">39</xref>,<xref rid="cit0042" ref-type="bibr">42&#8211;44</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0047" ref-type="bibr">47</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0054" ref-type="bibr">54</xref>,<xref rid="cit0056" ref-type="bibr">56</xref>,<xref rid="cit0058" ref-type="bibr">58</xref>,<xref rid="cit0061" ref-type="bibr">61&#8211;67</xref>,<xref rid="cit0069" ref-type="bibr">69&#8211;75</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0085" ref-type="bibr">85</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0090" ref-type="bibr">90</xref>,<xref rid="cit0092" ref-type="bibr">92</xref>,<xref rid="cit0093" ref-type="bibr">93</xref>,<xref rid="cit0099" ref-type="bibr">99&#8211;101</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">18A</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0041" ref-type="bibr">41&#8211;43</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0066" ref-type="bibr">66</xref>,<xref rid="cit0069" ref-type="bibr">69</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0072" ref-type="bibr">72</xref>,<xref rid="cit0078" ref-type="bibr">78</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0083" ref-type="bibr">83</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0088" ref-type="bibr">88</xref>,<xref rid="cit0100" ref-type="bibr">100</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">18B</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0045" ref-type="bibr">45</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50</xref>,<xref rid="cit0057" ref-type="bibr">57</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0069" ref-type="bibr">69&#8211;72</xref>,<xref rid="cit0084" ref-type="bibr">84</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">18F</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0069" ref-type="bibr">69</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0072" ref-type="bibr">72</xref>,<xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0093" ref-type="bibr">93</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">19B*</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0045" ref-type="bibr">45</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0066" ref-type="bibr">66</xref>,<xref rid="cit0068" ref-type="bibr">68</xref>,<xref rid="cit0070" ref-type="bibr">70&#8211;72</xref>,<xref rid="cit0074" ref-type="bibr">74</xref>,<xref rid="cit0075" ref-type="bibr">75</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0090" ref-type="bibr">90</xref>,<xref rid="cit0093" ref-type="bibr">93</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">19C</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0049" ref-type="bibr">49</xref>,<xref rid="cit0051" ref-type="bibr">51</xref>,<xref rid="cit0070" ref-type="bibr">70</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">19V</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0097" ref-type="bibr">97</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">22A</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0066" ref-type="bibr">66</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0071" ref-type="bibr">71</xref>,<xref rid="cit0074" ref-type="bibr">74</xref>,<xref rid="cit0075" ref-type="bibr">75</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0090" ref-type="bibr">90</xref>,<xref rid="cit0100" ref-type="bibr">100</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">22F</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0041" ref-type="bibr">41</xref>,<xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0044" ref-type="bibr">44</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0065" ref-type="bibr">65</xref>,<xref rid="cit0069" ref-type="bibr">69</xref>,<xref rid="cit0071" ref-type="bibr">71&#8211;73</xref>,<xref rid="cit0075" ref-type="bibr">75</xref>,<xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0090" ref-type="bibr">90</xref>,<xref rid="cit0092" ref-type="bibr">92</xref>,<xref rid="cit0101" ref-type="bibr">101</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">23A*</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0039" ref-type="bibr">39</xref>,<xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0044" ref-type="bibr">44</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;53</xref>,<xref rid="cit0056" ref-type="bibr">56</xref>,<xref rid="cit0058" ref-type="bibr">58</xref>,<xref rid="cit0061" ref-type="bibr">61&#8211;64</xref>,<xref rid="cit0066" ref-type="bibr">66</xref>,<xref rid="cit0067" ref-type="bibr">67</xref>,<xref rid="cit0070" ref-type="bibr">70&#8211;75</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0090" ref-type="bibr">90</xref>,<xref rid="cit0092" ref-type="bibr">92</xref>,<xref rid="cit0100" ref-type="bibr">100</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">23B</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0044" ref-type="bibr">44</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;54</xref>,<xref rid="cit0056" ref-type="bibr">56&#8211;63</xref>,<xref rid="cit0067" ref-type="bibr">67</xref>,<xref rid="cit0069" ref-type="bibr">69&#8211;71</xref>,<xref rid="cit0075" ref-type="bibr">75</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0083" ref-type="bibr">83</xref>,<xref rid="cit0085" ref-type="bibr">85</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0090" ref-type="bibr">90</xref>,<xref rid="cit0093" ref-type="bibr">93</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">24A</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0072" ref-type="bibr">72</xref>,<xref rid="cit0089" ref-type="bibr">89</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">24B</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0049" ref-type="bibr">49</xref>,<xref rid="cit0051" ref-type="bibr">51</xref>,<xref rid="cit0052" ref-type="bibr">52</xref>,<xref rid="cit0066" ref-type="bibr">66</xref>,<xref rid="cit0069" ref-type="bibr">69</xref>,<xref rid="cit0074" ref-type="bibr">74</xref>,<xref rid="cit0075" ref-type="bibr">75</xref>,<xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0086" ref-type="bibr">86</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0090" ref-type="bibr">90</xref>,<xref rid="cit0092" ref-type="bibr">92</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">24F</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0042" ref-type="bibr">42</xref>,<xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50</xref>,<xref rid="cit0052" ref-type="bibr">52</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0066" ref-type="bibr">66</xref>,<xref rid="cit0071" ref-type="bibr">71&#8211;74</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0092" ref-type="bibr">92&#8211;94</xref>,<xref rid="cit0100" ref-type="bibr">100</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">25A</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0050" ref-type="bibr">50</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0069" ref-type="bibr">69</xref>,<xref rid="cit0072" ref-type="bibr">72</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0084" ref-type="bibr">84</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">25F</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0051" ref-type="bibr">51</xref>,<xref rid="cit0052" ref-type="bibr">52</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0078" ref-type="bibr">78</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0100" ref-type="bibr">100</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">28A</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50</xref>,<xref rid="cit0051" ref-type="bibr">51</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0069" ref-type="bibr">69</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0073" ref-type="bibr">73</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0085" ref-type="bibr">85</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">28F</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0045" ref-type="bibr">45</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0072" ref-type="bibr">72</xref>,<xref rid="cit0075" ref-type="bibr">75</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0084" ref-type="bibr">84</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">32A</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0052" ref-type="bibr">52</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">32F</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0051" ref-type="bibr">51</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">33A</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0051" ref-type="bibr">51</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0072" ref-type="bibr">72</xref>,<xref rid="cit0073" ref-type="bibr">73</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0092" ref-type="bibr">92</xref>,<xref rid="cit0093" ref-type="bibr">93</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">33B</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0069" ref-type="bibr">69&#8211;73</xref>,<xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0084" ref-type="bibr">84&#8211;86</xref>,<xref rid="cit0093" ref-type="bibr">93</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">33C*</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0041" ref-type="bibr">41</xref>,<xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0066" ref-type="bibr">66</xref>,<xref rid="cit0069" ref-type="bibr">69&#8211;71</xref>,<xref rid="cit0074" ref-type="bibr">74</xref>,<xref rid="cit0075" ref-type="bibr">75</xref>,<xref rid="cit0096" ref-type="bibr">96</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">33D</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0041" ref-type="bibr">41</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50</xref>,<xref rid="cit0052" ref-type="bibr">52</xref>,<xref rid="cit0080" ref-type="bibr">80</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">33F</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0044" ref-type="bibr">44</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0049" ref-type="bibr">49&#8211;52</xref>,<xref rid="cit0064" ref-type="bibr">64&#8211;66</xref>,<xref rid="cit0069" ref-type="bibr">69&#8211;72</xref>,<xref rid="cit0074" ref-type="bibr">74</xref>,<xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0100" ref-type="bibr">100</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">35A</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0042" ref-type="bibr">42</xref>,<xref rid="cit0044" ref-type="bibr">44</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0070" ref-type="bibr">70&#8211;72</xref>,<xref rid="cit0075" ref-type="bibr">75</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0083" ref-type="bibr">83</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0093" ref-type="bibr">93</xref>,<xref rid="cit0100" ref-type="bibr">100</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">35B*</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0039" ref-type="bibr">39</xref>,<xref rid="cit0041" ref-type="bibr">41&#8211;47</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;54</xref>,<xref rid="cit0056" ref-type="bibr">56</xref>,<xref rid="cit0058" ref-type="bibr">58&#8211;65</xref>,<xref rid="cit0067" ref-type="bibr">67</xref>,<xref rid="cit0069" ref-type="bibr">69&#8211;73</xref>,<xref rid="cit0075" ref-type="bibr">75</xref>,<xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0083" ref-type="bibr">83</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0086" ref-type="bibr">86</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0092" ref-type="bibr">92</xref>,<xref rid="cit0093" ref-type="bibr">93</xref>,<xref rid="cit0101" ref-type="bibr">101</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">35C</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0073" ref-type="bibr">73</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0085" ref-type="bibr">85</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">35D</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0089" ref-type="bibr">89</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">35F</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0039" ref-type="bibr">39</xref>,<xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0044" ref-type="bibr">44</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0068" ref-type="bibr">68</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0072" ref-type="bibr">72</xref>,<xref rid="cit0073" ref-type="bibr">73</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0085" ref-type="bibr">85</xref>,<xref rid="cit0090" ref-type="bibr">90</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">41F</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0072" ref-type="bibr">72</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">47F</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0066" ref-type="bibr">66</xref>,<xref rid="cit0074" ref-type="bibr">74</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">6C</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0041" ref-type="bibr">41</xref>,<xref rid="cit0043" ref-type="bibr">43&#8211;47</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;53</xref>,<xref rid="cit0056" ref-type="bibr">56&#8211;58</xref>,<xref rid="cit0062" ref-type="bibr">62</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0063" ref-type="bibr">63</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0066" ref-type="bibr">66</xref>,<xref rid="cit0069" ref-type="bibr">69&#8211;75</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0082" ref-type="bibr">82</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0094" ref-type="bibr">94</xref>,<xref rid="cit0100" ref-type="bibr">100</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">6D</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0041" ref-type="bibr">41</xref>,<xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0045" ref-type="bibr">45&#8211;47</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0056" ref-type="bibr">56</xref>,<xref rid="cit0058" ref-type="bibr">58</xref>,<xref rid="cit0061" ref-type="bibr">61&#8211;63</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0084" ref-type="bibr">84</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">6F</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0046" ref-type="bibr">46</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">7A</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0050" ref-type="bibr">50</xref>,<xref rid="cit0069" ref-type="bibr">69</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0074" ref-type="bibr">74</xref>,<xref rid="cit0075" ref-type="bibr">75</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">7B</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0041" ref-type="bibr">41&#8211;43</xref>,<xref rid="cit0045" ref-type="bibr">45</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0070" ref-type="bibr">70&#8211;72</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0089" ref-type="bibr">89</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">7C*</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0044" ref-type="bibr">44</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0065" ref-type="bibr">65</xref>,<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0072" ref-type="bibr">72</xref>,<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0096" ref-type="bibr">96</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">9A</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0071" ref-type="bibr">71&#8211;73</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0093" ref-type="bibr">93</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">9B</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0075" ref-type="bibr">75</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">9L</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0045" ref-type="bibr">45</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0084" ref-type="bibr">84</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">9N</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="center" colspan="1" rowspan="1">&#10003;</td><td align="left" colspan="1" rowspan="1"><xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0066" ref-type="bibr">66</xref>,<xref rid="cit0069" ref-type="bibr">69&#8211;71</xref>,<xref rid="cit0074" ref-type="bibr">74</xref>,<xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0080" ref-type="bibr">80</xref>,<xref rid="cit0088" ref-type="bibr">88&#8211;90</xref>,<xref rid="cit0101" ref-type="bibr">101</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn0006"><p><sup>1</sup>Drug resistance refers to resistance to one or more classes of antibiotics.</p></fn><fn id="tfn0007"><p><sup>2</sup>Unspecified includes cases that have not mentioned whether the pneumococcal infection was invasive or non-invasive in nature.</p></fn><fn id="tfn0008"><p><sup>3</sup>Serogroups/serotypes marked with *in South Asia were responsible for causing deaths.<sup><xref rid="cit0039" ref-type="bibr">39</xref>,<xref rid="cit0068" ref-type="bibr">68</xref>,<xref rid="cit0074" ref-type="bibr">74</xref>,<xref rid="cit0096" ref-type="bibr">96</xref></sup></p></fn><fn id="tfn0009"><p><sup>4</sup>Mixed serotypes, as observed in <xref rid="t0001" ref-type="table">Table 1</xref>, have not been included in the analysis because of the inconsistency in how they are named and interpreted across the referenced research articles. This inconsistency limits the ability to accurately characterize mixed serotypes within the study&#8217;s framework, thus warranting their exclusion to maintain clarity and analytical appropriateness.</p></fn><fn id="tfn0010"><p>Abbreviations: NVTs: Non-vaccine serotypes; IPD: Invasive pneumococcal disease; Non-IPD: Non-invasive pneumococcal disease; NP: Nasopharyngeal.</p></fn></table-wrap-foot></table-wrap></p></sec><sec disp-level="1" id="s0003"><title>Pneumococcal vaccine landscape</title><sec disp-level="2" id="s0003-s2001"><title>Approved pneumococcal polysaccharide vaccines (PPSVs) and PCVs</title><p>There are two types of pneumococcal vaccines available that are clinically available, viz., PPSVs and PCVs, targeting multiple serotypes.<sup><xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0102" ref-type="bibr">102</xref></sup> PPSVs stimulate the B cells by cross-linking the B-cell receptors (BCR), which leads to the production of immunoglobulins.<sup><xref rid="cit0103" ref-type="bibr">103</xref></sup> This type of immune response is usually a T cell-independent response, which implies that these polysaccharides are capable of activating B cells in the absence of T helper cells.<sup><xref rid="cit0104" ref-type="bibr">104</xref>,<xref rid="cit0105" ref-type="bibr">105</xref></sup> These polysaccharides cannot be processed and presented in association with major histocompatibility complex (MHC) class II molecules and cannot be recognized by T helper cells.<sup><xref rid="cit0104" ref-type="bibr">104</xref></sup> Due to the lack of T cell collaboration, the antibodies are of low affinity and are composed mainly of immunoglobulin M (IgM) with limited isotype switching to immunoglobulin G (IgG) and immunoglobulin A (IgA).<sup><xref rid="cit0104" ref-type="bibr">104</xref></sup> It results in a lack of production of new memory B cells along with depletion of the memory B cell pool, resulting in hyporesponsiveness to future doses of vaccine.<sup><xref rid="cit0103" ref-type="bibr">103</xref></sup> PPSV23 was licensed in the United States of America (USA) in 1983.<sup><xref rid="cit0005" ref-type="bibr">5</xref></sup> It included 23 serotypes, which were responsible for 85% to 90% of IPD globally.<sup><xref rid="cit0029" ref-type="bibr">29</xref></sup> It is approved for use in individuals 50&#8201;years of age or older and persons aged &#8805;2&#8201;years who are at increased risk for pneumococcal disease.<sup><xref rid="cit0106" ref-type="bibr">106</xref></sup> PPS23&#8217;s protective efficacy has been consistently demonstrated in several studies as well as meta-analysis.<sup><xref rid="cit0107" ref-type="bibr">107&#8211;111</xref></sup> In immunocompetent individuals, the vaccine has an efficacy of 65% against pneumococcal infections with serotypes included in it.<sup><xref rid="cit0112" ref-type="bibr">112</xref></sup> The effectiveness against IPD in immunocompetent adults ranges from 56% to 81% but is lower in individuals with compromised immune status.<sup><xref rid="cit0012" ref-type="bibr">12</xref></sup> It reduces the severity of community-acquired pneumonia (CAP) but does not prevent it. It does not reduce the incidence of noninvasive pneumonia.<sup><xref rid="cit0012" ref-type="bibr">12</xref></sup> Moreover, it does not generate immunological memory in children &lt;2&#8201;years, and hence it is not effective in this population.<sup><xref rid="cit0012" ref-type="bibr">12</xref></sup> Also, it does not reduce pneumococcal carriage.<sup><xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0112" ref-type="bibr">112</xref></sup></p><p>To overcome this drawback and elicit a protective immune response in children &lt;2&#8201;years, capsular polysaccharide vaccines conjugated to a protein carrier were developed.<sup><xref rid="cit0005" ref-type="bibr">5</xref>,<xref rid="cit0112" ref-type="bibr">112</xref></sup> Conjugation of the polysaccharide to a suitable carrier protein converts it into a T cell-dependent antigen.<sup><xref rid="cit0113" ref-type="bibr">113</xref></sup> This conjugation of the capsular polysaccharide directs the processing of the carrier protein by the polysaccharide-specific B cells, followed by the presentation of the peptides to carrier-peptide specific T cells in association with MHC class II molecules.<sup><xref rid="cit0103" ref-type="bibr">103</xref></sup> When B cells receive help from T cells, they proliferate and differentiate into plasma cells, with class switching to IgG, and memory B cells. These memory B cells undergo rapid proliferation and differentiate into plasma cells upon subsequent encounter with the antigen, producing high antibody titers.<sup><xref rid="cit0103" ref-type="bibr">103</xref>,<xref rid="cit0113" ref-type="bibr">113</xref></sup> A 7-valent PCV (Prevnar, Pfizer) conjugated to cross-reactive material 197 (CRM<sub>197</sub>) was developed and licensed in the United States (U.S.) and the European Union (EU) in 2000 and 2001, respectively.<sup><xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0102" ref-type="bibr">102</xref></sup> The vaccine included serotypes, which were identified as causes of IPD in the U.S.<sup><xref rid="cit0013" ref-type="bibr">13</xref></sup> However, after the introduction of PCV7, a change in the epidemiology of pneumococcal diseases was observed, and NVTs (not included in PCV7) emerged as the most prevalent ones, a phenomenon known as &#8216;serotype replacement.<sup><xref rid="cit0005" ref-type="bibr">5</xref>,<xref rid="cit0112" ref-type="bibr">112</xref></sup> For example, serotypes 1 and 5, which were not included in PCV7, were responsible for a high burden of illness and deaths in low-income settings.<sup><xref rid="cit0013" ref-type="bibr">13</xref></sup> Another example was 19A, a problematic serotype, which exhibited antibiotic resistance.<sup><xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0013" ref-type="bibr">13</xref></sup> This serotype replacement led to the development of PCV10 (Synflorix, GlaxoSmithKline [GSK]) and PCV13 (Prevnar 13, Pfizer), which were introduced in 2009.<sup><xref rid="cit0004" ref-type="bibr">4</xref>,<xref rid="cit0012" ref-type="bibr">12</xref></sup> Surveillance data from different countries implementing PCVs in their NIPs has prevented disease not only in vaccinated individuals but also in unvaccinated adults and children through herd immunity.<sup><xref rid="cit0013" ref-type="bibr">13</xref></sup> Although PCVs were originally developed for pediatric use, clinical studies conducted in adults have shown their ability to prevent diseases in individuals of all ages through direct protection.<sup><xref rid="cit0013" ref-type="bibr">13</xref></sup> A systematic review and meta-analysis conducted to evaluate the impact of PCV10 and PCV13 in reducing the incidence of CAP in children &lt;5&#8201;years demonstrated that these vaccines showed a reduction of 17% and 31% in the hospitalization rates for clinically and radiologically confirmed pneumonia, respectively, in children &lt;24&#8201;months.<sup><xref rid="cit0114" ref-type="bibr">114</xref></sup> In children aged 24&#8211;59&#8201;months, these vaccines showed a reduction of 9% and 24% in the hospitalization rates for clinically and radiologically confirmed pneumonia, respectively.<sup><xref rid="cit0114" ref-type="bibr">114</xref></sup> A systematic review evaluating the impact of PCV10 and PCV13 on all-cause, radiologically confirmed, and severe pneumonia hospitalization rates and pneumonia mortality in children 0&#8211;9&#8201;years old across several WHO regions demonstrated reductions ranging from 7% to 60% for all-cause pneumonia hospitalization, 8% to 90% for severe pneumonia, 12% to 79% for radiologically confirmed pneumonia, and 45% to 85% for pneumococcal confirmed pneumonia.<sup><xref rid="cit0115" ref-type="bibr">115</xref></sup> Pneumonia-related mortality saw a reduction of 10% to 78% across different regions.<sup><xref rid="cit0115" ref-type="bibr">115</xref></sup> A study conducted by Bennett et al. evaluated the impact of PCV10/PCV13 on IPD incidence in children &lt;5&#8201;years and adults &#8805;65&#8201;years compared to the pre-PCV period.<sup><xref rid="cit0116" ref-type="bibr">116</xref></sup> It evaluated 275,582 cases from 47 surveillance sites in 29 countries (primarily HICs [80%]). The study demonstrated that IPD declined by 58% to 79% in children &lt;5&#8201;years and by 4% to 29% in adults.<sup><xref rid="cit0116" ref-type="bibr">116</xref></sup> The Serum Institute of India (SII) has developed an affordable 10-valent PCV (Pneumosil), which provides protection against serotypes that are responsible for causing serious illness in developing countries.<sup><xref rid="cit0012" ref-type="bibr">12</xref></sup> Walvax Biotechnology Co., Ltd. (Walvax) has developed and manufactured a 13-valent PCV (Weuphoria), which has been marketed in China, Morocco, and Thailand.<sup><xref rid="cit0117" ref-type="bibr">117</xref></sup></p><p>However, after the introduction of PCV10 and PCV13, the issue of serotype replacement continued, and newer vaccines were required to prevent pneumococcal diseases caused by serotypes 8, 12F, and 22F.<sup><xref rid="cit0005" ref-type="bibr">5</xref>,<xref rid="cit0118" ref-type="bibr">118</xref>,<xref rid="cit0119" ref-type="bibr">119</xref></sup> A systematic review of the serotype distribution of <italic toggle="yes">S. pneumoniae</italic> causing IPD in children in countries that have introduced PCV13 revealed that non-PCV13 serotypes contributed to 42.2% of the childhood IPD cases in the post-PCV era.<sup><xref rid="cit0037" ref-type="bibr">37</xref></sup> There were differences as per geography, viz., 57.8% in North America, 71.9% in Europe, 45.9% in the Western Pacific, 28.5% in Latin America, and 42.7% in South Africa. The predominant non-PCV13 serotypes were 22F, 12F, 33F, 24F, 15C, 15B, 23B, 10A, and 38.<sup><xref rid="cit0037" ref-type="bibr">37</xref></sup></p><p>In light of this grim situation, two new PCVs, viz., PCV15 (VAXNEUVANCE, Merck) and PCV20 (Prevnar 20, Pfizer), have been approved by the United States Food and Drug Administration (USFDA) in 2021.<sup><xref rid="cit0005" ref-type="bibr">5</xref>,<xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0120" ref-type="bibr">120</xref>,<xref rid="cit0121" ref-type="bibr">121</xref></sup> PCV15 is indicated for active immunization for the prevention of invasive disease in individuals 6&#8201;weeks of age and older.<sup><xref rid="cit0122" ref-type="bibr">122</xref></sup> PCV20 is approved for the prevention of invasive diseases in individuals 6&#8201;weeks of age and older; prevention of otitis media in individuals 6&#8201;weeks through 5&#8201;years of age; and active immunization for the prevention of pneumonia in individuals 18&#8201;years of age and older.<sup><xref rid="cit0123" ref-type="bibr">123</xref></sup> Prevnar 20, which was built using Prevnar 13, includes seven additional serotypes that have been associated with antibiotic resistance, heightened disease severity, invasive potential, high case fatality rates, and prevalence in pediatric pneumococcal cases.<sup><xref rid="cit0124" ref-type="bibr">124</xref>,<xref rid="cit0125" ref-type="bibr">125</xref></sup> Moreover, these seven serotypes are among the most common responsible for IPD in the pediatric population in the USA.<sup><xref rid="cit0124" ref-type="bibr">124</xref>,<xref rid="cit0125" ref-type="bibr">125</xref></sup> Biological E Ltd. has developed a 14-valent PCV, viz., PNEUBEVAX 14, which received approval from the Indian drug regulator, Drug Controller General of India (DCGI), in 2022 for manufacturing and commercialization in India.<sup><xref rid="cit0126" ref-type="bibr">126</xref></sup> It offers protection against two new serotypes, 22F and 33F.<sup><xref rid="cit0126" ref-type="bibr">126</xref></sup> A 15-valent PCV has been developed by Tergene Biotech Pvt. Ltd. and manufactured at AuroVaccines Pvt. Ltd., which is a wholly owned subsidiary of Aurobindo Pharma Ltd.<sup><xref rid="cit0127" ref-type="bibr">127</xref></sup> The Indian drug regulator has granted permission to Tergene in 2022 to manufacture and market the vaccine.<sup><xref rid="cit0127" ref-type="bibr">127</xref></sup> In 2024, the USFDA approved CAPVAXIVE (V116), a 21-valent PCV developed by Merck.<sup><xref rid="cit0128" ref-type="bibr">128</xref></sup> The vaccine is indicated for active immunization for the prevention of invasive disease and pneumonia in individuals 18&#8201;years of age and older.<sup><xref rid="cit0128" ref-type="bibr">128</xref></sup> It includes eight unique serotypes responsible for approximately 27% of IPD cases in adults 50&#8201;years of age and older and approximately 30% in adults 65&#8201;years of age and older, as per the Centre for Disease Control and Prevention (CDC) data.<sup><xref rid="cit0128" ref-type="bibr">128</xref></sup></p></sec><sec disp-level="2" id="s0003-s2002"><title>Investigational PPSVs and PCVs</title><p>Panacea Biotech has developed an 11-valent PCV, viz., NuCoVac-11, which is currently in phase 3 trial. The company has also developed a PPSV23, which is in preclinical development.<sup><xref rid="cit0129" ref-type="bibr">129</xref></sup> Techinvention Lifecare Pvt. Ltd. has developed a 16-valent PCV that is currently in preclinical studies.<sup><xref rid="cit0130" ref-type="bibr">130</xref></sup> GBP410 is a 21-valent PCV that is jointly developed by SK Bioscience and Sanofi. The vaccine has demonstrated immunogenicity and safety in phase II trials and is expected to enter phase 3 trials in H1 of 2024.<sup><xref rid="cit0131" ref-type="bibr">131</xref></sup> AFX3772, a 24-valent PCV developed by Affinivax (acquired by GSK), is currently in phase 2 development.<sup><xref rid="cit0132" ref-type="bibr">132</xref></sup> This vaccine candidate is based on the highly innovative multiple-antigen presenting system (MAPS) platform technology.<sup><xref rid="cit0132" ref-type="bibr">132</xref></sup> A 30-plus-valent pneumococcal candidate vaccine is also in preclinical development.<sup><xref rid="cit0132" ref-type="bibr">132</xref></sup> VAX-24, developed by Vaxcyte, is a 24-valent, broad-spectrum, carrier-sparing PCV that will be entering phase 3.<sup><xref rid="cit0133" ref-type="bibr">133</xref>,<xref rid="cit0134" ref-type="bibr">134</xref></sup> VAX-31, another vaccine developed by Vaxcyte, is a 31-valent PCV, which is expected to enter phase 1/2 clinical study during the fourth quarter of 2023.<sup><xref rid="cit0135" ref-type="bibr">135</xref></sup> VAX-31 and VAX-24 are designed to improve upon the standard-of-care PCVs for both children and adults by providing coverage for serotypes that are responsible for a significant portion of IPD as well as high case-fatality rates, antibiotic resistance, and meningitis.<sup><xref rid="cit0134" ref-type="bibr">134</xref></sup> Preclinical immunogenicity evaluation of a 24-valent PCV developed by Merck has been conducted in adult monkeys.<sup><xref rid="cit0136" ref-type="bibr">136</xref></sup> Inventprise Inc. has developed a 25-valent PCV that is currently in phase 2 trial.<sup><xref rid="cit0137" ref-type="bibr">137</xref></sup>
<xref rid="t0003" ref-type="table">Table 3</xref> highlights the status of PCVs in LMICs of South Asia. <xref rid="t0004" ref-type="table">Table 4</xref> gives a list of investigational and approved PPSVs and PCVs, along with their composition as well as their clinical/commercial status.<table-wrap position="float" id="t0003" orientation="portrait"><label>Table 3.</label><caption><p>PCV status in LMICs of South Asia.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Country</th><th align="center" colspan="1" rowspan="1">Introduced in NIP</th><th align="center" colspan="1" rowspan="1">Date of introduction</th><th align="center" colspan="1" rowspan="1">Type of PCV formulation</th><th align="center" colspan="1" rowspan="1">Dosing schedule<sup>1</sup></th><th align="center" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Afghanistan</td><td align="center" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1">7<sup>th</sup> December 2013</td><td align="left" colspan="1" rowspan="1">Prevnar 13</td><td align="center" colspan="1" rowspan="1">3+0</td><td rowspan="7" align="center" colspan="1"><xref rid="cit0138" ref-type="bibr">138</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Bangladesh</td><td align="center" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1">21<sup>st</sup> March 2015</td><td align="left" colspan="1" rowspan="1">Synflorix</td><td align="center" colspan="1" rowspan="1">3+0</td></tr><tr><td align="left" colspan="1" rowspan="1">Sri Lanka</td><td align="center" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="center" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1">Nepal</td><td align="center" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1">19<sup>th</sup> January 2015</td><td align="left" colspan="1" rowspan="1">Synflorix</td><td align="center" colspan="1" rowspan="1">2+1</td></tr><tr><td align="left" colspan="1" rowspan="1">Bhutan</td><td align="center" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1">1<sup>st</sup> January 2019</td><td align="left" colspan="1" rowspan="1">Prevnar 13</td><td align="center" colspan="1" rowspan="1">2+1</td></tr><tr><td align="left" colspan="1" rowspan="1">Pakistan</td><td align="center" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1">9<sup>th</sup> October 2012</td><td align="left" colspan="1" rowspan="1">Prevnar 13</td><td align="center" colspan="1" rowspan="1">3+0</td></tr><tr><td align="left" colspan="1" rowspan="1">India</td><td align="center" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1">13<sup>th</sup> May 2017</td><td align="left" colspan="1" rowspan="1">Pneumosil</td><td align="center" colspan="1" rowspan="1">2+1</td></tr></tbody></table><table-wrap-foot><fn id="tfn0011"><p><sup>1</sup>3+0: Three primary doses without a booster; 2+1: Two primary doses with one booster.<sup><xref rid="cit0139" ref-type="bibr">139</xref></sup></p></fn><fn id="tfn0012"><p>Abbreviations: NIP: National immunization program; PCV: Pneumococcal conjugate vaccine.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t0004" orientation="portrait"><label>Table 4.</label><caption><p>List of investigational and approved PPSVs and PCVs.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Sr. No.</th><th align="center" colspan="1" rowspan="1">Vaccine/<break/>Brand name</th><th align="center" colspan="1" rowspan="1">Company</th><th align="center" colspan="1" rowspan="1">Carrier protein</th><th align="center" colspan="1" rowspan="1">Serotype composition</th><th align="center" colspan="1" rowspan="1">Clinical/<break/>Commercial status</th><th align="center" colspan="1" rowspan="1">WHO prequalification</th><th align="center" colspan="1" rowspan="1">Reference</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Pneumovax</td><td align="left" colspan="1" rowspan="1">Merck</td><td align="center" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F</td><td align="left" colspan="1" rowspan="1">Approved commercially</td><td align="center" colspan="1" rowspan="1">&#8211;</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0140" ref-type="bibr">140</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">PPSV23</td><td align="left" colspan="1" rowspan="1">Sinovac Biotech Ltd.</td><td align="center" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F</td><td align="left" colspan="1" rowspan="1">Approved<break/>commercially</td><td align="center" colspan="1" rowspan="1">&#8211;</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0140" ref-type="bibr">140</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">PPSV23</td><td align="left" colspan="1" rowspan="1">Walvax<break/>Biotechnology Co. Ltd.</td><td align="center" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F</td><td align="left" colspan="1" rowspan="1">Approved<break/>commercially</td><td align="center" colspan="1" rowspan="1">&#8211;</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0141" ref-type="bibr">141</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">Prevnar</td><td align="left" colspan="1" rowspan="1">Pfizer</td><td align="left" colspan="1" rowspan="1">CRM<sub>197</sub></td><td align="left" colspan="1" rowspan="1">4, 6B, 9V, 14, 18C, 19F, and 23F</td><td align="left" colspan="1" rowspan="1">Approved<break/>commercially</td><td align="center" colspan="1" rowspan="1">&#8211;</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0140" ref-type="bibr">140</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Synflorix</td><td align="left" colspan="1" rowspan="1">GSK</td><td align="left" colspan="1" rowspan="1">Protein D for serotypes 1, 5, 6B, 7F, 9V, 14, 23F, and 4. TT for serotype 18C and DT for serotype 19.</td><td align="left" colspan="1" rowspan="1">1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F</td><td align="left" colspan="1" rowspan="1">Approved<break/>commercially</td><td align="center" colspan="1" rowspan="1">Yes</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0140" ref-type="bibr">140</xref>,<xref rid="cit0142" ref-type="bibr">142</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Pneumosil</td><td align="left" colspan="1" rowspan="1">SII</td><td align="left" colspan="1" rowspan="1">CRM<sub>197</sub></td><td align="left" colspan="1" rowspan="1">1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F, and 23F</td><td align="left" colspan="1" rowspan="1">Approved<break/>commercially</td><td align="center" colspan="1" rowspan="1">Yes</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0140" ref-type="bibr">140</xref>,<xref rid="cit0142" ref-type="bibr">142</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Prevnar 13</td><td align="left" colspan="1" rowspan="1">Pfizer</td><td align="left" colspan="1" rowspan="1">CRM<sub>197</sub></td><td align="left" colspan="1" rowspan="1">1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F</td><td align="left" colspan="1" rowspan="1">Approved commercially</td><td align="center" colspan="1" rowspan="1">Yes</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0140" ref-type="bibr">140</xref>,<xref rid="cit0142" ref-type="bibr">142</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">Weuphoria</td><td align="left" colspan="1" rowspan="1">Walvax Biotechnology Co., Ltd.</td><td align="left" colspan="1" rowspan="1">TT</td><td align="left" colspan="1" rowspan="1">1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F</td><td align="left" colspan="1" rowspan="1">Approved commercially</td><td align="center" colspan="1" rowspan="1">&#8211;</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0012" ref-type="bibr">12</xref>, <xref rid="cit0117" ref-type="bibr">117</xref>, <xref rid="cit0140" ref-type="bibr">140</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">PNEUBEVAX 14</td><td align="left" colspan="1" rowspan="1">Biological E Ltd.</td><td align="left" colspan="1" rowspan="1">CRM<sub>197</sub></td><td align="left" colspan="1" rowspan="1">1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F</td><td align="left" colspan="1" rowspan="1">Approved commercially</td><td align="center" colspan="1" rowspan="1">&#8211;</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0126" ref-type="bibr">126</xref>,<xref rid="cit0143" ref-type="bibr">143</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">VAXNEUVANCE</td><td align="left" colspan="1" rowspan="1">Merck</td><td align="left" colspan="1" rowspan="1">CRM<sub>197</sub></td><td align="left" colspan="1" rowspan="1">1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F</td><td align="left" colspan="1" rowspan="1">Approved commercially</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0140" ref-type="bibr">140</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">PCV15</td><td align="left" colspan="1" rowspan="1">Tergene Biotech Pvt. Ltd. and AuroVaccines Pvt. Ltd.</td><td align="left" colspan="1" rowspan="1">CRM<sub>197</sub></td><td align="left" colspan="1" rowspan="1">1, 2, 3, 4, 5, 6A, 6B, 7F, 9V, 12F,<break/>14, 18C, 19A, 19F, and 23F</td><td align="left" colspan="1" rowspan="1">Permission granted by Indian drug regulator to manufacture and market</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0127" ref-type="bibr">127</xref>,<xref rid="cit0144" ref-type="bibr">144</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">Prevnar 20</td><td align="left" colspan="1" rowspan="1">Pfizer</td><td align="left" colspan="1" rowspan="1">CRM<sub>197</sub></td><td align="left" colspan="1" rowspan="1">1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F</td><td align="left" colspan="1" rowspan="1">Approved commercially</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0140" ref-type="bibr">140</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">CAPVAXIVE</td><td align="left" colspan="1" rowspan="1">Merck</td><td align="left" colspan="1" rowspan="1">CRM<sub>197</sub></td><td align="left" colspan="1" rowspan="1">3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B</td><td align="left" colspan="1" rowspan="1">Approved commercially</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0128" ref-type="bibr">128</xref>,<xref rid="cit0145" ref-type="bibr">145</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">NuCoVac-11</td><td align="left" colspan="1" rowspan="1">Panacea Biotec</td><td align="left" colspan="1" rowspan="1">CRM<sub>197</sub></td><td align="left" colspan="1" rowspan="1">1, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F</td><td align="left" colspan="1" rowspan="1">Phase 3</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0129" ref-type="bibr">129</xref>,<xref rid="cit0146" ref-type="bibr">146</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">NuVac-23</td><td align="left" colspan="1" rowspan="1">Panacea Biotec</td><td align="center" colspan="1" rowspan="1">-</td><td align="center" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Preclinical</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0129" ref-type="bibr">129</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">PneumoWin</td><td align="left" colspan="1" rowspan="1">Techinvention Lifecare Pvt. Ltd.</td><td align="left" colspan="1" rowspan="1">rCRM<sub>197</sub></td><td align="left" colspan="1" rowspan="1">1, 3, 4, 5, 6A, 6B, 7F, 9V, 12F, 14, 15A, 18C, 19A, 19F, 22F, and 23F</td><td align="left" colspan="1" rowspan="1">Preclinical</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0130" ref-type="bibr">130</xref>,<xref rid="cit0147" ref-type="bibr">147</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">17</td><td align="left" colspan="1" rowspan="1">GBP410</td><td align="left" colspan="1" rowspan="1">SK Bioscience and Sanofi</td><td align="left" colspan="1" rowspan="1">Serotypes 1, 3 and 5 conjugated to TT.<break/>Serotypes 4, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F conjugated to CRM<sub>197</sub></td><td align="left" colspan="1" rowspan="1">1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F</td><td align="left" colspan="1" rowspan="1">Completed phase 2</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0131" ref-type="bibr">131</xref>,<xref rid="cit0148" ref-type="bibr">148</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">AFX3772</td><td align="left" colspan="1" rowspan="1">GSK</td><td align="left" colspan="1" rowspan="1">Rhizavidin-fused<break/>carrier proteins</td><td align="left" colspan="1" rowspan="1">1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20B, 22F, and 33F</td><td align="left" colspan="1" rowspan="1">Currently in phase 2 development</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0132" ref-type="bibr">132</xref>,<xref rid="cit0140" ref-type="bibr">140</xref>,<xref rid="cit0149" ref-type="bibr">149</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">VAX-24</td><td align="left" colspan="1" rowspan="1">Vaxcyte</td><td align="left" colspan="1" rowspan="1">eCRM</td><td align="left" colspan="1" rowspan="1">1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20B, 22F, 23F, and 33F</td><td align="left" colspan="1" rowspan="1">Will be entering phase 3</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0133" ref-type="bibr">133</xref>,<xref rid="cit0134" ref-type="bibr">134</xref>,<xref rid="cit0140" ref-type="bibr">140</xref>,<xref rid="cit0150" ref-type="bibr">150</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">PCV24</td><td align="left" colspan="1" rowspan="1">Merck</td><td align="left" colspan="1" rowspan="1">CRM<sub>197</sub></td><td align="left" colspan="1" rowspan="1">1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F</td><td align="left" colspan="1" rowspan="1">Preclinical development</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0136" ref-type="bibr">136</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">21</td><td align="left" colspan="1" rowspan="1">PCV25</td><td align="left" colspan="1" rowspan="1">Inventprise Inc.</td><td align="left" colspan="1" rowspan="1">CRM<sub>197</sub></td><td align="left" colspan="1" rowspan="1">1, 2, 3, 4, 5, 6B, 6C, 7F, 8, 9N, 9V, 10A, 12F, 14, 15A, 15B, 16F, 18C, 19A, 19F, 22F, 23F, 24F, 33F, and 35B</td><td align="left" colspan="1" rowspan="1">Phase 2</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0151" ref-type="bibr">151</xref>,<xref rid="cit0152" ref-type="bibr">152</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">22</td><td align="left" colspan="1" rowspan="1">VAX-31</td><td align="left" colspan="1" rowspan="1">Vaxcyte</td><td align="left" colspan="1" rowspan="1">eCRM</td><td align="left" colspan="1" rowspan="1">1, 2, 3, 4, 5, 6A, 6B, 7C, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 16F, 17F, 18C, 19A, 19F, 20B, 22F, 23A, 23B, 23F, 31, 33F, and 35B</td><td align="left" colspan="1" rowspan="1">Expected to enter phase 1/2 clinical trial</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0135" ref-type="bibr">135</xref>,<xref rid="cit0153" ref-type="bibr">153</xref>,<xref rid="cit0154" ref-type="bibr">154</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">23</td><td align="left" colspan="1" rowspan="1">30-plus valent PCV</td><td align="left" colspan="1" rowspan="1">GSK</td><td align="center" colspan="1" rowspan="1">-</td><td align="center" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Preclinical development</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0132" ref-type="bibr">132</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn0013"><p>Abbreviations: WHO: World Health Organization; PPSV: Pneumococcal polysaccharide vaccine; CRM<sub>197</sub>: Cross-reactive material 197; GSK: GlaxoSmithKline; TT: Tetanus toxoid; DT: Diphtheria toxoid; SII: Serum Institute of India; rCRM<sub>197</sub>: Recombinant cross-reactive material 197; eCRM: Enhanced carrier protein.</p></fn></table-wrap-foot></table-wrap></p><p>In light of recent findings, it has become increasingly evident that a decline in immunogenicity against shared serotypes has been noted with the adoption of higher-valency PCVs.<sup><xref rid="cit0155" ref-type="bibr">155</xref></sup> This observed trend, while pointing toward a potential decrease in immune response, poses uncertainties regarding its clinical implications.<sup><xref rid="cit0155" ref-type="bibr">155</xref></sup> While reduced immunogenicity has been observed among higher- vs. lower-valency PCVs, the trend is inconsistent.<sup><xref rid="cit0155" ref-type="bibr">155</xref></sup> Different vaccine components, platforms, technologies, and manufacturing processes can affect serotype-specific immunogenicity.<sup><xref rid="cit0155" ref-type="bibr">155</xref></sup> Consequently, further exploration through additional research is needed to fully comprehend the impact and effectiveness of these new vaccines.<sup><xref rid="cit0155" ref-type="bibr">155</xref></sup></p><p>Exploring various avenues to enhance immunogenicity and overall vaccine efficacy is key in this scenario.<sup><xref rid="cit0155" ref-type="bibr">155</xref></sup> Innovative conjugation processes, diverse carriers, strategic use of adjuvants, and advancements in vaccine platforms represent promising approaches that could potentially offset any reduction in immunogenicity.<sup><xref rid="cit0155" ref-type="bibr">155</xref></sup> Some of these strategies include choosing appropriate carrier proteins to prevent carrier-induced suppression, such as utilizing single or multiple conserved <italic toggle="yes">S. pneumoniae</italic> proteins or employing enhanced carrier protein (eCRM) to facilitate conjugation reactions outside the primary T cell epitope region.<sup><xref rid="cit0155" ref-type="bibr">155</xref></sup> Techniques like preserving the structural integrity of capsular polysaccharides through polysaccharide activation or using specific linker moieties between polysaccharides and proteins are also being explored.<sup><xref rid="cit0155" ref-type="bibr">155</xref></sup> Novel vaccine platforms, like MAPS, in vivo bioconjugation, virus-like particle (VLP) technology, and messenger ribonucleic acid (mRNA) technology are being investigated to enhance overall B cell and T cell responses while generating enhanced serotype-specific IgG levels without the need for adjuvants.<sup><xref rid="cit0155" ref-type="bibr">155</xref></sup> By striving to maintain or elevate immunogenicity levels and subsequently boost vaccine effectiveness, it&#8217;s possible to extend the coverage and protection offered by PCVs, especially as their valency increases.<sup><xref rid="cit0155" ref-type="bibr">155</xref></sup></p><p>VAX-24 contains eCRM, a proprietary carrier protein with non-native amino acids (para-azidomethyl-L-phenylalanine) that undergo site-specific conjugation to pneumococcal polysaccharides activated with a small-molecule linker (dibenzocyclooctyne).<sup><xref rid="cit0156" ref-type="bibr">156</xref></sup> Site-specific conjugation utilizing click chemistry allows consistent exposure of T cell epitopes, reduction in carrier protein to pneumococcal polysaccharide ratio, and augments manufacturing process consistency to improve PCVs by increasing the coverage of serotypes and minimizing carrier suppression.<sup><xref rid="cit0156" ref-type="bibr">156</xref></sup> VAX-24 has demonstrated promising results in a phase 1/2 trial by targeting a wide array of pneumococcal serotypes without compromising the immunogenicity.<sup><xref rid="cit0157" ref-type="bibr">157</xref></sup></p><p>Despite the widespread use of PCVs in vaccination programs and continuous advancements in serotype coverage, the underlying reasons for decreased antibody responses, particularly in infants and the elderly, remain incompletely understood.<sup><xref rid="cit0158" ref-type="bibr">158</xref></sup> Deeper insights into the molecular and cellular mechanisms governing protective antibody responses against <italic toggle="yes">S. pneumoniae</italic> could potentially inform the development of adjuvants that enhance these responses.<sup><xref rid="cit0158" ref-type="bibr">158</xref></sup></p><p>Moreover, in alignment with the guidelines set forth by the WHO, the evaluation of noninferiority between higher- and lower-valency PCVs relies on specific criteria related to IgG response rates and IgG geometric mean concentrations (GMCs).<sup><xref rid="cit0159" ref-type="bibr">159</xref></sup> Each serotype is individually assessed to determine noninferiority, with the WHO underscoring that meeting the predefined criteria for either IgG response rates or GMCs should suffice for regulatory approval.<sup><xref rid="cit0159" ref-type="bibr">159</xref></sup> The correlate of protection for IPD is typically measured by noting the levels of vaccine-induced, serotype-specific IgG, with a protective threshold set at 0.35&#8201;&#181;g/ml.<sup><xref rid="cit0159" ref-type="bibr">159</xref></sup> In 2008, the WHO reviewed data on PCVs, including effectiveness studies in Canada, the United Kingdom (UK), and the USA.<sup><xref rid="cit0159" ref-type="bibr">159</xref></sup> The data indicated variability in IgG concentrations and thresholds, with some suggesting alternative thresholds and the correlation of opsonophagocytic activity (OPA) titers for a few serotypes for vaccine effectiveness.<sup><xref rid="cit0159" ref-type="bibr">159</xref></sup></p></sec><sec disp-level="2" id="s0003-s2003"><title>Drawbacks</title><p>Administration of additional pneumococcal vaccines may be required in adults due to waning immunity. For example, the effectiveness of PPSV23 wanes over several years, and high-risk individuals may require revaccination every 5&#8211;10&#8201;years.<sup><xref rid="cit0111" ref-type="bibr">111</xref></sup> As mentioned earlier, serotype replacement has been observed with the implementation of PCVs, where niches occupied earlier by VTs have now been colonized by NVTs.<sup><xref rid="cit0029" ref-type="bibr">29</xref>,<xref rid="cit0038" ref-type="bibr">38</xref>,<xref rid="cit0160" ref-type="bibr">160</xref>,<xref rid="cit0161" ref-type="bibr">161</xref></sup> Both PPSVs and PCVs are serotype-based vaccines and therefore elicit a serotype-specific immune response.<sup><xref rid="cit0162" ref-type="bibr">162</xref></sup> Geographical differences with respect to serotype distribution have led to reduced vaccine effectiveness when they were implemented in geographies where the serotypes were not covered by the vaccines.<sup><xref rid="cit0029" ref-type="bibr">29</xref></sup> PCVs have weak efficacy at mucosal sites, such as for pneumonia and otitis media.<sup><xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0038" ref-type="bibr">38</xref></sup>
<italic toggle="yes">S. pneumoniae</italic> undergoes phase variation, wherein the capsule shifts stochastically from high to low expression levels.<sup><xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0038" ref-type="bibr">38</xref></sup> This is a result of anatomical-site-specific selective pressures in the host environment.<sup><xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0038" ref-type="bibr">38</xref></sup> The pathogens present on mucosal surfaces are less encapsulated as compared to those present in the blood, thereby exposing surface adhesins.<sup><xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0038" ref-type="bibr">38</xref></sup> Therefore, the antibodies directed at the capsule are not efficient in opsonophagocytosis at the mucosal level.<sup><xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0038" ref-type="bibr">38</xref></sup> Serotype coverage by PCVs in developed countries is substantially higher compared to developing countries, where pneumococcal diseases are caused by a wider spectrum of serotypes.<sup><xref rid="cit0162" ref-type="bibr">162</xref></sup> Vaccine failures have been reported following immunization with PCV10 and PCV13.<sup><xref rid="cit0162" ref-type="bibr">162</xref>,<xref rid="cit0163" ref-type="bibr">163</xref></sup> A systematic review published by Oligbu et al. identified serotypes 19B, 6B, and 4 associated with vaccine failure in countries with established PCV programs.<sup><xref rid="cit0164" ref-type="bibr">164</xref></sup> PCVs cannot offer protection against the emergence of <italic toggle="yes">S. pneumoniae</italic> strains, which are found among non-typeable isolates.<sup><xref rid="cit0165" ref-type="bibr">165</xref></sup> Capsular switching has been observed post the introduction of PCVs.<sup><xref rid="cit0029" ref-type="bibr">29</xref></sup> Although PCVs provide protection from infection, but not all serotypes are covered with equal potency.<sup><xref rid="cit0012" ref-type="bibr">12</xref></sup> For some serotypes, viz., 1, 3, and 5, the levels of functional antibodies against capsular polysaccharides induced by the vaccines and detected by opsonophagocytic killing are not ideal.<sup><xref rid="cit0012" ref-type="bibr">12</xref></sup> PCV manufacturing is an extremely complex and expensive process, making it unaffordable for the developing countries, which can lead to low vaccination coverage.<sup><xref rid="cit0102" ref-type="bibr">102</xref>,<xref rid="cit0162" ref-type="bibr">162</xref></sup> One of the glaring examples is the sub-Saharan countries, which still have the highest mortality rates in children &lt;5&#8201;years, even after 10 years post-PCV licensure.<sup><xref rid="cit0102" ref-type="bibr">102</xref></sup> Increasing the valency of PCV also poses challenges with respect to conjugation.<sup><xref rid="cit0102" ref-type="bibr">102</xref></sup> A crucial issue of PCV is the binding of the carrier protein to the capsular polysaccharide to elicit a robust immune response as compared to the capsular polysaccharide alone.<sup><xref rid="cit0102" ref-type="bibr">102</xref></sup> Adding additional serotypes to the formulation results in blunting of the immune response to individual serotypes due to carrier suppression.<sup><xref rid="cit0012" ref-type="bibr">12</xref></sup> An increase in valency as well as the dosage of the carrier protein in the formulation can lead to immune response interference, both in the vaccine itself and other vaccines that are administered previously, jointly, or subsequently.<sup><xref rid="cit0102" ref-type="bibr">102</xref>,<xref rid="cit0166" ref-type="bibr">166</xref></sup> These interferences result in an imbalance in several arms of the immune response and hence require readjustment in each new vaccine formulation.<sup><xref rid="cit0102" ref-type="bibr">102</xref></sup></p></sec><sec disp-level="2" id="s0003-s2004"><title>Alternative approaches</title><p>In light of the above-mentioned drawbacks, novel vaccines based on a non-serotype-independent approach targeting conserved antigens are warranted and have been extensively investigated.<sup><xref rid="cit0010" ref-type="bibr">10</xref>,<xref rid="cit0038" ref-type="bibr">38</xref>,<xref rid="cit0102" ref-type="bibr">102</xref>,<xref rid="cit0112" ref-type="bibr">112</xref>,<xref rid="cit0140" ref-type="bibr">140</xref>,<xref rid="cit0162" ref-type="bibr">162</xref>,<xref rid="cit0165" ref-type="bibr">165</xref></sup> An ideal pneumococcal vaccine with broader coverage, the ability to induce mucosal and systemic immunity, and the ability to prevent primary intranasal colonization and invasive disease is highly desirable.<sup><xref rid="cit0012" ref-type="bibr">12</xref></sup> Several protein-based vaccines and whole-cell (live-attenuated and inactivated) vaccines are being evaluated in preclinical and clinical studies.<sup><xref rid="cit0010" ref-type="bibr">10</xref></sup> Protein vaccines targeting the highly conserved virulence proteins can confer broad serotype coverage.<sup><xref rid="cit0029" ref-type="bibr">29</xref></sup> Different types of protein vaccines that are investigated include recombinant proteins (individual or in combination), fusion or hybrid proteins, nanoparticle-packaged fusion or hybrid proteins, recombinant protein-boosted PCVs, and capsular polysaccharide-conjugated recombinant protein carrier.<sup><xref rid="cit0162" ref-type="bibr">162</xref>,<xref rid="cit0167" ref-type="bibr">167</xref></sup> Protein-based vaccines offer several advantages, such as the production of opsonophagocytic antibodies, providing respiratory tract protection, preventing invasion of the pathogen in different organs, neutralizing pneumolysin cytotoxicity, cross-protection against additional childhood pathogens, and blunting complications arising out of disseminated bacterial infections.<sup><xref rid="cit0038" ref-type="bibr">38</xref>,<xref rid="cit0162" ref-type="bibr">162</xref></sup> It can also serve as a cheaper option for children in developing countries, provide coverage for a wide range of serotypes responsible for IPD, and offer an alternative option to prevent recurrent infections.<sup><xref rid="cit0140" ref-type="bibr">140</xref></sup> With respect to manufacturing, there are less hindrances associated with structural differences and variations, a drawback that is commonly observed with conjugate vaccines.<sup><xref rid="cit0140" ref-type="bibr">140</xref></sup> On the flip side, protein antigens have numerous limitations. They contain non-repeating conformational epitopes for antibody binding as compared to capsular polysaccharides that have repeating and conformationally less-restricted antigenic determinants.<sup><xref rid="cit0140" ref-type="bibr">140</xref></sup> This poses challenges to mounting a protective antibody-mediated immune response as well as explains the difficulty in developing protein-based vaccines.<sup><xref rid="cit0140" ref-type="bibr">140</xref></sup> Also, they may not be present in all clinical isolates and may be poorly conserved due to significant sequence heterogeneity.<sup><xref rid="cit0140" ref-type="bibr">140</xref></sup> Another drawback of protein antigens is their accessibility to opsonic antibodies.<sup><xref rid="cit0140" ref-type="bibr">140</xref></sup> WCVs present a wide range of antigens in their native form and can confer broader protection against <italic toggle="yes">S. pneumoniae</italic>.<sup><xref rid="cit0029" ref-type="bibr">29</xref>,<xref rid="cit0102" ref-type="bibr">102</xref></sup> These vaccines can serve as an economical alternative to PCVs in developing countries because of their low manufacturing costs.<sup><xref rid="cit0029" ref-type="bibr">29</xref>,<xref rid="cit0102" ref-type="bibr">102</xref></sup> WCVs can be developed from killed or live-attenuated whole-cell or by using genetically modified strains of pneumococcus for ensuring safety and retaining immunogenicity.<sup><xref rid="cit0009" ref-type="bibr">9</xref></sup> Inactivated WCVs offer the advantage of carrying several types of antigens, which are common to all serotypes.<sup><xref rid="cit0010" ref-type="bibr">10</xref></sup> These vaccines are relatively safe as the organism is completely inactivated.<sup><xref rid="cit0010" ref-type="bibr">10</xref></sup> Live-attenuated vaccines enhance humoral and mucosal immune responses after a single-dose, as compared to inactivated ones.<sup><xref rid="cit0168" ref-type="bibr">168</xref></sup> Other merits and demerits of these vaccine technologies are described in detail by Kumraj et al.<sup><xref rid="cit0169" ref-type="bibr">169</xref></sup>
<xref rid="t0005" ref-type="table">Table 5</xref> highlights the properties of <italic toggle="yes">S. pneumoniae</italic> proteins that are investigated as vaccine candidates. <xref rid="t0006 t0007" ref-type="table">Tables 6 and 7</xref> highlight the results of protein-based vaccines and WCVs (inactivated and live-attenuated) investigated in suitable animal models, respectively. <xref rid="t0008" ref-type="table">Table 8</xref> highlights the results of protein-based vaccines and WCVs (inactivated and live-attenuated) evaluated in clinical trials.<table-wrap position="float" id="t0005" orientation="portrait"><label>Table 5.</label><caption><p>Properties of different <italic toggle="yes">S. pneumoniae</italic> proteins investigated as vaccine candidates.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/></colgroup><thead><tr><th colspan="2" align="left" rowspan="1">Protein</th><th align="center" colspan="1" rowspan="1">Properties</th><th align="center" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td colspan="2" align="left" rowspan="1">Ply</td><td align="left" colspan="1" rowspan="1"><list list-type="order" id="list_0003"><list-item><p>Highly conserved</p></list-item><list-item><p>Immune evasion</p></list-item><list-item><p>Triggers inflammation</p></list-item><list-item><p>Cell death</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><xref rid="cit0009" ref-type="bibr">9</xref>,<xref rid="cit0029" ref-type="bibr">29</xref>,<xref rid="cit0170" ref-type="bibr">170</xref>,<xref rid="cit0171" ref-type="bibr">171</xref></td></tr><tr><td rowspan="7" align="left" colspan="1">CBPs</td><td align="left" colspan="1" rowspan="1">PspA</td><td align="left" colspan="1" rowspan="1"><list list-type="order" id="list_0004"><list-item><p>Highly conserved</p></list-item><list-item><p>Immune evasion</p></list-item><list-item><p>Pneumococcal adhesion</p></list-item><list-item><p>Binds lactoferrin for critical iron uptake</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><xref rid="cit0029" ref-type="bibr">29</xref>,<xref rid="cit0165" ref-type="bibr">165</xref>,<xref rid="cit0172" ref-type="bibr">172</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">PspC</td><td align="left" colspan="1" rowspan="1"><list list-type="order" id="list_0005"><list-item><p>Highly immunogenic</p></list-item><list-item><p>Highly conserved</p></list-item><list-item><p>Immune evasion</p></list-item><list-item><p>Pneumococcal adhesion</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><xref rid="cit0009" ref-type="bibr">9</xref>,<xref rid="cit0029" ref-type="bibr">29</xref>,<xref rid="cit0173" ref-type="bibr">173</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">PcpA</td><td align="left" colspan="1" rowspan="1"><list list-type="order" id="list_0006"><list-item><p>Pneumococcal adhesion</p></list-item><list-item><p>Biofilm formation</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><xref rid="cit0165" ref-type="bibr">165</xref>,<xref rid="cit0174" ref-type="bibr">174</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">LytA</td><td align="left" colspan="1" rowspan="1"><list list-type="order" id="list_0007"><list-item><p>Immunogenic</p></list-item><list-item><p>Highly conserved</p></list-item><list-item><p>Facilitates the release of cytotoxin Ply</p></list-item><list-item><p>Inhibits complement</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><xref rid="cit0165" ref-type="bibr">165</xref>,<xref rid="cit0175" ref-type="bibr">175</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">LytB</td><td align="left" colspan="1" rowspan="1"><list list-type="order" id="list_0008"><list-item><p>Biofilm formation</p></list-item><list-item><p>Attachment to host epithelial cells</p></list-item><list-item><p>Immune evasion</p></list-item><list-item><p>Well-conserved</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><xref rid="cit0165" ref-type="bibr">165</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">CbpG</td><td align="left" colspan="1" rowspan="1"><list list-type="order" id="list_0009"><list-item><p>Pneumococcal adhesion</p></list-item><list-item><p>Secreted form can cleave host ECM</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><xref rid="cit0165" ref-type="bibr">165</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">CbpM</td><td align="left" colspan="1" rowspan="1"><list list-type="order" id="list_0010"><list-item><p>Binds fibronectin</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><xref rid="cit0165" ref-type="bibr">165</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">PsaA</td><td align="left" colspan="1" rowspan="1"><list list-type="order" id="list_0011"><list-item><p>Oxidative stress resistance</p></list-item><list-item><p>Bacterial adhesion</p></list-item><list-item><p>Manganese and zinc acquisition</p></list-item><list-item><p>Highly conserved</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><xref rid="cit0009" ref-type="bibr">9</xref>,<xref rid="cit0176" ref-type="bibr">176</xref></td></tr><tr><td rowspan="4" align="left" colspan="1">PHTs</td><td align="left" colspan="1" rowspan="1">PhtA</td><td align="left" colspan="1" rowspan="1"><list list-type="order" id="list_0012"><list-item><p>Highly conserved</p></list-item><list-item><p>Immune system evasion</p></list-item><list-item><p>Bacterial dissemination in the lungs</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><xref rid="cit0177" ref-type="bibr">177</xref>,<xref rid="cit0178" ref-type="bibr">178</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">PhtB</td><td align="left" colspan="1" rowspan="1"><list list-type="order" id="list_0013"><list-item><p>Conserved protein</p></list-item><list-item><p>Immunogenic</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><xref rid="cit0179" ref-type="bibr">179</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">PhtD</td><td align="left" colspan="1" rowspan="1"><list list-type="order" id="list_0014"><list-item><p>Highly conserved</p></list-item><list-item><p>Adherence to nasopharyngeal and epithelial cell lines</p></list-item><list-item><p>Inhibits complement</p></list-item><list-item><p>Zinc acquisition</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><xref rid="cit0165" ref-type="bibr">165</xref>,<xref rid="cit0179" ref-type="bibr">179&#8211;183</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">PhtE</td><td align="left" colspan="1" rowspan="1"><list list-type="order" id="list_0015"><list-item><p>Highly conserved protein</p></list-item><list-item><p>Adherence to nasopharyngeal and epithelial cell lines</p></list-item><list-item><p>Inhibits complement</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><xref rid="cit0165" ref-type="bibr">165</xref>,<xref rid="cit0179" ref-type="bibr">179</xref>,<xref rid="cit0180" ref-type="bibr">180</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">PiuA and PiaA</td><td align="left" colspan="1" rowspan="1"><list list-type="order" id="list_0016"><list-item><p>Iron uptake</p></list-item><list-item><p>Highly conserved</p></list-item><list-item><p>Highly immunogenic</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><xref rid="cit0009" ref-type="bibr">9</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">PsrP</td><td align="left" colspan="1" rowspan="1"><list list-type="order" id="list_0017"><list-item><p>Biofilm formation</p></list-item><list-item><p>Lung adhesion and infection</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><xref rid="cit0165" ref-type="bibr">165</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">Ef-Tu</td><td align="left" colspan="1" rowspan="1"><list list-type="order" id="list_0018"><list-item><p>Highly conserved protein</p></list-item><list-item><p>Enhances pathogenicity through complement inhibition and degradation of ECM</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><xref rid="cit0184" ref-type="bibr">184</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn0014"><p>Abbreviations: Ply: Pneumolysin; CBPs: Choline-binding proteins; PspA: Pneumococcal surface protein A; PspC: Pneumococcal surface protein C; PcpA: Pneumococcal choline binding protein A; LytA: N-acetylmuramoyl-L-alanine amidase; LytB: N-acetylglucosaminidase; CbpG: Choline-binding protein G; ECM: Extracellular matrix; CbpM: Choline-binding protein M; PsaA: Pneumococcal surface antigen A; PHTs: Pneumococcal histidine triad proteins; PhtA: Pneumococcal histidine triad protein A; PhtB: Pneumococcal histidine triad protein B; PhtD: Pneumococcal histidine triad protein D; PhtE: Pneumococcal histidine triad protein E; PiuA: Pneumococcal iron uptake A; PiaA: Pneumococcal iron acquisition A; PsrP: Pneumococcal serine-rich repeat protein; Ef-Tu: Elongation factor Tu.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t0006" orientation="portrait"><label>Table 6.</label><caption><p>Results of protein-based vaccines investigated in animal models.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/></colgroup><thead><tr><th colspan="2" align="left" rowspan="1">Protein</th><th align="center" colspan="1" rowspan="1">Results</th><th align="center" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td rowspan="7" colspan="2" align="left">Ply</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0019"><list-item><p>Intramuscular immunization with recombinant PlyD1 protected mice against lethal intranasal challenge with pneumococci and lung injury mediated through Ply challenge. Protection was associated with PlyD1-specific IgG titers and <italic toggle="yes">in vitro</italic> neutralization titers.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0185" ref-type="bibr">185</xref></td></tr><tr><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0020"><list-item><p>CaP-&#916;A146PLY<sup>1</sup> nanoparticles induced efficient humoral and cellular immune responses in mice that protected them from both pneumonia and sepsis.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0186" ref-type="bibr">186</xref></td></tr><tr><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0021"><list-item><p>Intramuscular immunization with dPly protected mice against lethal intranasal challenge with Ply. Also, intranasal immunization in mice inhibited nasopharyngeal colonization after intranasal challenge with homologous or heterologous pneumococcal strain.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0187" ref-type="bibr">187</xref></td></tr><tr><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0022"><list-item><p>Mice immunized subcutaneously with &#916;A146Ply-SP0148<sup>2</sup> elicited high levels of anti-&#916;A146Ply and anti-SP0148 IgG antibodies. Mice had a high survival rate when challenged with a lethal dose of <italic toggle="yes">S. pneumoniae</italic>.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0188" ref-type="bibr">188</xref></td></tr><tr><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0023"><list-item><p>Subcutaneous immunization of mice with &#916;A146 Ply<sup>3</sup> generated high titers of anti-Ply IgGs and protected them from intraperitoneal challenge with TIGR4 <italic toggle="yes">S. pneumoniae</italic>.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0189" ref-type="bibr">189</xref></td></tr><tr><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0024"><list-item><p>Intramuscular immunization of mice with PLY-D<sup>4</sup> conferred significant protection post-intranasal challenge with different <italic toggle="yes">S. pneumoniae</italic> serotypes and strains.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0190" ref-type="bibr">190</xref></td></tr><tr><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0025"><list-item><p>Vaccination with a monovalent formulation of recombinant PlyD1 led to bacterial reductions in both infant and adult mice after a lethal-dose intranasal challenge with serotype 6A.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0191" ref-type="bibr">191</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">CBPs</td><td rowspan="2" align="left" colspan="1">CbpG</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0026"><list-item><p>Intramuscular immunization of mice with recombinant CbpG provided significant protection against colonization and substantial protection against systemic infection by wild-type TIGR4 cells.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0192" ref-type="bibr">192</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0027"><list-item><p>Subcutaneous immunization with recombinant CbpG protected mice against intraperitoneal challenge with serotype 19F pneumococcal strain.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0193" ref-type="bibr">193</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">CbpM</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0028"><list-item><p>Subcutaneous immunization with recombinant CbpM protected mice against intraperitoneal challenge with serotype 19F pneumococcal strain.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0193" ref-type="bibr">193</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">LytA</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0029"><list-item><p>Purified recombinant LytA administered intranasally elicited IgG and IgA antibodies in mice. These mice also showed significantly higher survival rates and lower bacterial carriage in response to <italic toggle="yes">S. pneumoniae</italic> infection.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0194" ref-type="bibr">194</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">LytB</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0030"><list-item><p>Intraperitoneal immunization with LytB enhanced <italic toggle="yes">S. pneumoniae</italic> recognition by complement components C1q and C3b, demonstrating that anti-LytB antibodies activated the classical pathway. Vaccination with LytB protected mice against pneumococcal sepsis and invasive pneumonia caused by clinical isolates of serotypes 3 or 23F.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0195" ref-type="bibr">195</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td rowspan="6" align="left" colspan="1">PspC/<break/>CbpA</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0031"><list-item><p>Intranasal immunization with PspC using cholera toxin subunit B as an adjuvant protected mice against intranasal challenge with pneumolysin mutant of D39 or serotype 6B strain BG7322.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0196" ref-type="bibr">196</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0032"><list-item><p>Intraperitoneal immunization of PspC protected mice from intraperitoneal challenge with virulent capsular type 2 pneumococcal strain D39.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0197" ref-type="bibr">197</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0033"><list-item><p>Intranasal immunization with PspC induced high levels of anti-PspC antibodies in mice. The hyperimmune sera significantly inhibited the adhesion of <italic toggle="yes">S. pneumoniae</italic> to A549 cells.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0198" ref-type="bibr">198</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0034"><list-item><p>Nasal immunization with <italic toggle="yes">L. casei</italic> expressing PspC primed the immune system of mice that prompted faster immune responses, resulting in a decrease in pneumococcal colonization.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0199" ref-type="bibr">199</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0035"><list-item><p>Subcutaneous immunization with purified PspC protected mice against sepsis. The protection was mediated by antibodies cross-reactive with PspA.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0200" ref-type="bibr">200</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0036"><list-item><p>Subcutaneous or intranasal immunization of PspC vaccines did not protect mice against an invasive intranasal challenge with pneumococcal strain ATCC 6303.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0201" ref-type="bibr">201</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">PcpA</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0037"><list-item><p>Vaccination with a monovalent formulation of recombinant PcpA led to bacterial reductions in both infant and adult mice after a lethal-dose intranasal challenge with serotype 6A.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0191" ref-type="bibr">191</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">PspA</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0038"><list-item><p>Antibodies generated post-immunization with recombinant family 1 PspA in humans in a phase 1 trial offered passive protection in mice against a pneumococcal challenge from serotypes 3, 6A, or 6B.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0202" ref-type="bibr">202</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0039"><list-item><p>Transcutaneous immunization with PspA + cholera toxin B induced antigen-specific mucosal and systemic immune responses in mice. It significantly reduced the CFU numbers in nasal washes and passages when they were challenged with <italic toggle="yes">S. pneumoniae</italic> strain EF3030 via the nasal route.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0203" ref-type="bibr">203</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0040"><list-item><p>Intranasal immunization with a nanogel-based PspA nasal vaccine provided protective immunity in mice against intranasal lethal challenge with <italic toggle="yes">S. pneumoniae</italic> Xen10. It reduced the bacterial colonization and invasion and induced high levels of PspA-specific IgG and nasal and bronchial IgA responses.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0204" ref-type="bibr">204</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0041"><list-item><p>Mucosal immunization with various nanoparticle PspA formulations protected mice against lethal intranasal challenge <italic toggle="yes">S. pneumoniae</italic> strain ATCC6303.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0205" ref-type="bibr">205</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0042"><list-item><p>Intranasal immunization with PspA delivered by BLPs enhanced PspA-specific antibody responses in mice and provided significant protection against intranasal challenge with pneumococci of two different clades of both homologous and heterologous PspA families.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0206" ref-type="bibr">206</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0043"><list-item><p>Intranasal immunization with PspA-BLP vaccine<sup>5</sup> conferred protection in mice against fatal intranasal challenge with both PspA family 1 and 2 pneumococcal strains regardless of serotype.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0207" ref-type="bibr">207</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0044"><list-item><p>Intramuscular immunization with polymer particles entrapping PspA elicited robust IgG responses both in mice and in rats. Antigen load in microparticles correlated with the antibody titers.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0208" ref-type="bibr">208</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0045"><list-item><p>Mucosal immunization with NP/NCMP PspA4Pro<sup>6</sup> provided partial protection against intranasal lethal pneumococcal challenge with a serotype 3 strain expressing PspA from clade 5.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0209" ref-type="bibr">209</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0046"><list-item><p>Intranasal vaccination with PspA and cationic liposomes conferred protective immunity against lethal <italic toggle="yes">S. pneumoniae</italic> inhalation and improved the survival rate of infected mice. It also induced the production of PspA-specific IgA and IgG by both mucosal and systemic compartments as well as elicited PspA-specific Th17 responses.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0210" ref-type="bibr">210</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0047"><list-item><p>Subcutaneous immunization of mice with PspA-based polyanhydride nanovaccine had significantly higher survival rates upon intravenous challenge with <italic toggle="yes">S. pneumoniae</italic> strain A66.1 clad 2 of family 1.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0211" ref-type="bibr">211</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0048"><list-item><p>Nasal vaccination with PspA-nanogel<sup>7</sup> effectively induced PspA-specific serum IgG with protective activity and mucosal SIgA antibody responses in cynomolgus macaques.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0212" ref-type="bibr">212</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0049"><list-item><p>Mice vaccinated orally with a RASV strain delivering PspA decreased pulmonary inflammation. It provided effective protection against secondary pneumococcal pneumonia that was established in mice by intratracheal challenge with influenza PR8 and <italic toggle="yes">S. pneumoniae</italic> WU2 strains.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0213" ref-type="bibr">213</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0050"><list-item><p>Subcutaneous immunization of mice with fusion proteins containing family 1 and family 2 PspA fragments increased complement deposition and provided protection against pneumococcal infection with strains bearing PspA fragments from both families.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0214" ref-type="bibr">214</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0051"><list-item><p>Nasal vaccination of macaques with cCHP-trivalent PspA generated PspA-specific IgGs that protected from pneumococcal intratracheal challenge through inhibition of lung inflammation and a reduction in the numbers of bacteria in the lungs.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0215" ref-type="bibr">215</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0052"><list-item><p>Subcutaneous immunization with PspA3+2<sup>8</sup> provided significant protection against intranasal challenge by five pneumococcal strains with different clades in mice.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0216" ref-type="bibr">216</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0053"><list-item><p>Nasal immunization of mice with a combination of PspA5 and wP<sup>9</sup> or wP<sub>low</sub><sup>10</sup> conferred protection against intranasal respiratory lethal challenge with <italic toggle="yes">S. pneumoniae</italic> ATCC6303 or A66.1 strain. Both PspA5-wP and PspA5-wP<sub>low</sub> vaccines induced high levels of systemic and mucosal antibodies against PspA5.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0217" ref-type="bibr">217</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">PsaA</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0054"><list-item><p>Subcutaneous immunization of mice with PsaA using either complete Freund&#8217;s or TiterMax adjuvants significantly protected against challenge from type 3 pneumococcal strain WU2.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0218" ref-type="bibr">218</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0055"><list-item><p>Intranasal or oral administration of full-length PsaA in mice demonstrated significant reduction in colonization of nasopharyngeal tissues after intranasal challenge with <italic toggle="yes">S. pneumoniae</italic> strains compared to controls.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0219" ref-type="bibr">219</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0056"><list-item><p>Intraperitoneal immunization with PsaA admixed with BlyS exhibited only modest elevations in PsaA-specific responses. Mice sera obtained post-immunization exhibited high titers of IgG1, IgG2a, IgG2b, and IgG3, but no IgA.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0220" ref-type="bibr">220</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0057"><list-item><p>Intranasal immunization with chitosan-PsaA<sup>11</sup> generated mucosal and systemic immune responses in mice, and fewer pneumococci were recovered from the immunized mice following intranasal challenge with ATCC 6303 (serotype 3).</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0221" ref-type="bibr">221</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0058"><list-item><p>Intranasal immunization with chitosan-PsaA generated mucosal and systemic immune responses in mice. Immunized mice had increased protection against AOM following middle ear challenge with pneumococcus serotype 14 and improved survival following intraperitoneal challenge with pneumococcus serotype 3 or serotype 14.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0222" ref-type="bibr">222</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">PHTs</td><td align="left" colspan="1" rowspan="1">PhtA</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0059"><list-item><p>Subcutaneous immunization with full-length PhtA generated antibodies that protected mice against lethal sepsis challenge with serotype 6A or 6B.</p></list-item><list-item><p>Immunization with either N-terminal or C-terminal portion of PhtA also protected mice against serotype 6B challenge.</p></list-item><list-item><p>N-terminal half of PhtA induced a protective response against serotype 6A challenge.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0178" ref-type="bibr">178</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">PhtB</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0060"><list-item><p>Subcutaneous immunization with full-length PhtB generated high levels of antibody titers and protected mice against challenge with serotype 6B.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0178" ref-type="bibr">178</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td rowspan="5" align="left" colspan="1">PhtD</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0061"><list-item><p>Subcutaneous immunization with recombinant PhtD induced antibodies that protected mice against sepsis challenge with serotype 6A and 6B and highly virulent capsular type 4 strain or with the capsular type 3 strain WU2.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0178" ref-type="bibr">178</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0062"><list-item><p>Subcutaneous immunization of PhtD and its C-terminal fragment provided protection against pneumococcal sepsis in mice.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0223" ref-type="bibr">223</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0063"><list-item><p>Mice immunized intraperitoneally with PhtD and its C-terminal with OMVs and alum as adjuvants survived after intraperitoneal challenge with <italic toggle="yes">S. pneumoniae</italic> ATCC6303.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0224" ref-type="bibr">224</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0064"><list-item><p>Vaccination with a monovalent formulation of recombinant PhtD led to bacterial reductions in both infant and adult mice after a lethal-dose intranasal challenge with serotype 6A.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0191" ref-type="bibr">191</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0065"><list-item><p>Intranasal administration of PhtD in mice conferred protection against pneumococcal colonization through robust serum antibodies and CD4 Th1-biased immune memory.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0225" ref-type="bibr">225</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td rowspan="2" align="left" colspan="1">PhtE</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0066"><list-item><p>Intranasal administration of PhtE in mice conferred protection against pneumococcal colonization through robust serum antibodies and CD4 Th1-biased immune memory.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0225" ref-type="bibr">225</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0067"><list-item><p>Subcutaneous immunization of mice with recombinant PhtE elicits protective immunity against experimental sepsis and pneumonia.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0226" ref-type="bibr">226</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">PsrP</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0068"><list-item><p>Antibodies directed against SRR1 and BR regions of recombinant PsrP neutralized bacterial adhesion to lung cells <italic toggle="yes">in vitro</italic>.</p></list-item><list-item><p>Passive immunization of mice with PsrP antiserum conferred protection against pneumococcal challenge.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0227" ref-type="bibr">227</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">Ef-Tu</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0069"><list-item><p>Subcutaneous immunization with recombinant EF-Tu induced the production of inflammatory cytokines and IgG1 and IgG2a antibodies in mice.</p></list-item><list-item><p>Significantly and non-specifically protected mice against lethal intraperitoneal challenge with <italic toggle="yes">S. pneumoniae</italic> serotypes 2 and 15A.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0184" ref-type="bibr">184</xref></td></tr><tr><td colspan="4" align="left" rowspan="1"><bold>Pneumococcal proteins explored as carrier proteins</bold></td></tr><tr><td colspan="2" align="left" rowspan="1">PLD<sup>12</sup></td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0070"><list-item><p>Mice immunized subcutaneously with 19F polysaccharide conjugated with PLD as a carrier protein elicited high antibody titers against the polysaccharide and the carrier protein. Immunized mice effectively cleared the bacteria and had a significantly better survival rate when they were challenged intraperitoneally with type 19F pneumococci.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0228" ref-type="bibr">228</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">PLD</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0071"><list-item><p>Subcutaneous immunization of mice with both monovalent and tetravalent conjugate formulations (serotypes 6B, 14, 19F, and 23F) conjugated to PLD as a carrier protein generated high levels of polysaccharide-specific IgGs that demonstrated opsonophagocytic activity for serotypes tested, viz., 6B, 14, 19F, and 23F.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0229" ref-type="bibr">229</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">Ply</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0072"><list-item><p>Intraperitoneal immunization of 18C polysaccharide conjugated to recombinant Ply conferred significant protection in mice challenged with type 18C pneumococci.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0230" ref-type="bibr">230</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">PsaA</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0073"><list-item><p>Intraperitoneal immunization with Hib polysaccharide vaccine conjugated with recombinant PsaA protein carrier in mice generated anti-PsaA and anti-Hib immune responses. It was able to offer effective protection against AOM caused by pneumococcus.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0231" ref-type="bibr">231</xref></td></tr><tr><td colspan="4" align="left" rowspan="1"><bold>Proteins explored in combination</bold></td></tr><tr><td colspan="2" align="left" rowspan="1">PhtD-dPly</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0074"><list-item><p>Intranasal immunization with PhtD-dPly vaccine protected rhesus macaques from mortality induced by <italic toggle="yes">S. pneumoniae</italic> challenge.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0232" ref-type="bibr">232</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">PlyD6<sup>13</sup>, PspA, PsaA, PiuA, RrgB, RrgA, Hsp 60, and Hsp 70</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0075"><list-item><p>Intramuscular vaccination of rabbits with a multiantigen vaccine comprising PlyD6, PspA, PsaA, PiuA, RrgB, RrgA, Hsp 60, and Hsp 70 demonstrated the killing of vaccine strain TIGR4 in an opsonophagocytic killing assay and heterologous strains 6B, 19F, and 15B.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0233" ref-type="bibr">233</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">Ply, PspC, and PspA</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0076"><list-item><p>In the intraperitoneal infection sepsis model, mice immunized intraperitoneally or subcutaneously with H70+YLN<sup>14</sup> provided significant protection against challenge with three different strains (serotypes 1, 2, and 6A).</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0234" ref-type="bibr">234</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">PspA and PsaA</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0077"><list-item><p>Intranasal immunization with a combination of PspA and PsaA offered the best protection against nasopharyngeal carriage.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0235" ref-type="bibr">235</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">PsaA and PspA</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0078"><list-item><p>Subcutaneous immunization of mice with a vaccine containing the fusion protein PsaA-PspA23 and a single protein, PspA4, significantly increased anti-PspA IgG levels. Mice challenged intranasally with <italic toggle="yes">S. pneumoniae</italic> from PspA clades 1 to 5 were protected as demonstrated by a decrease in the bacterial load in the lungs and blood along with an increase in survival rates.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0236" ref-type="bibr">236</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">PspA and PdT</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0079"><list-item><p>Subcutaneous immunization with rPspA-FL-PdT<sup>15</sup> and rPspA-RL-PdT<sup>16</sup> protected mice against intranasal challenge with <italic toggle="yes">S. pneumoniae</italic> strain A66.1.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0237" ref-type="bibr">237</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">CbpA and Pneumolysoid</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0080"><list-item><p>Passive and active immunization with CbpA peptide&#8211;L460D fusion protein<sup>17</sup> protected mice from pneumococcal carriage, otitis media, pneumonia, bacteremia, meningitis, and meningococcal sepsis.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0238" ref-type="bibr">238</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">PdB, PspA, and PspC</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0081"><list-item><p>Intraperitoneal immunization of mice with a combination of PdB, PspA, and PspC offered the best protection after they were challenged intraperitoneally with virulent type 2 and 6A.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0239" ref-type="bibr">239</xref></td></tr><tr><td rowspan="4" colspan="2" align="left">PcpA, PhtD, and PlyD1</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0082"><list-item><p>Immunization with trivalent PPrV containing PcpA, PhtD, and PlyD1 conferred protection in infant mice from lethal pneumonia challenge using serotypes 6A and 3.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0240" ref-type="bibr">240</xref></td></tr><tr><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0083"><list-item><p>Intramuscular vaccination with trivalent PPrV containing PcpA, PhtD, and PlyD1 enhanced the serum and lung antibody levels to the three components, reduced <italic toggle="yes">S. pneumoniae</italic> lethality, enhanced the clearance of the pathogen via phagocytosis, and reduced lung inflammation and tissue damage.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0241" ref-type="bibr">241</xref></td></tr><tr><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0084"><list-item><p>Intramuscular immunization with trivalent PPrV containing PcpA, PhtD, and PlyD1 protected mice against AOM caused by <italic toggle="yes">S. pneumoniae</italic>. It reduced the bacterial burden and cytokine inflammatory response in middle ears during AOM induced by <italic toggle="yes">S. pneumoniae</italic>.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0242" ref-type="bibr">242</xref></td></tr><tr><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0085"><list-item><p>Immunization with PPrV comprising PhtD, PcpA, and PlyD1 induced anti-PhtD and anti-PcpA antibodies in mice that protected against <italic toggle="yes">S. pneumoniae</italic> through complement- and macrophage-dependent opsonophagocytosis.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0243" ref-type="bibr">243</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">PsaA and PspA</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0086"><list-item><p>Subcutaneous immunization of mice with PsaA-PspA fusion protein reduced <italic toggle="yes">S. pneumoniae</italic> levels in the blood and lungs after intranasal infection. It also protected mice against a fatal challenge with pneumococcal strains expressing different PspAs irrespective of the challenge route.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0244" ref-type="bibr">244</xref></td></tr><tr><td colspan="2" align="left" rowspan="1">PcsB, StkP, PsaA, and PspA</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0087"><list-item><p>Subcutaneous immunization of mice with a quadrivalent vaccine formulation containing PcsB, StkP, PsaA, and PspA with adjuvant significantly reduced bacteremia and lung infection when challenged intranasally with <italic toggle="yes">S. pneumoniae</italic> serotype 1.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0245" ref-type="bibr">245</xref></td></tr><tr><td rowspan="3" colspan="2" align="left">PiuA and PiaA</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0088"><list-item><p>Two booster vaccinations consisting of recombinant PiuA and PiaA administered intraperitoneally induced stronger antibody responses (majorly IgG1) in mice than a single or no booster vaccinations.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0246" ref-type="bibr">246</xref></td></tr><tr><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0089"><list-item><p>Intraperitoneal immunization of mice with purified recombinant PiuA and PiaA proteins elicited antibody responses. It also provided a high degree of protection against intraperitoneal challenge with <italic toggle="yes">S. pneumoniae</italic>.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0247" ref-type="bibr">247</xref></td></tr><tr><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0090"><list-item><p>Intranasal vaccination of mice with PiuA and PiaA generated specific antibody responses in serum and respiratory secretions and protected against intranasal challenge with <italic toggle="yes">S. pneumoniae</italic>.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0248" ref-type="bibr">248</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn0015"><p><sup>1</sup>CaP-&#916;A146PLY: Calcium phosphate binding domains fused with attenuated pneumolysin mutant, viz., &#916;A146PLY.</p></fn><fn id="tfn0016"><p><sup>2</sup>&#916;A146Ply-SP0148: Fusion protein composed of noncytotoxic mutant of Ply, viz., &#916;A146Ply and conserved lipoprotein with high immunogenicity produced by <italic toggle="yes">S. pneumoniae</italic>, viz., SP0148.</p></fn><fn id="tfn0017"><p><sup>3</sup>&#916;A146 Ply: Ply mutant with one single-amino acid deletion.</p></fn><fn id="tfn0018"><p><sup>4</sup>PLY-D: Genetic toxoid constructed with two amino acid changes to attenuate PLY toxicity.</p></fn><fn id="tfn0019"><p><sup>5</sup>PspA-BLP vaccine: PspA proteins from two different families, PspA2 from family 1 and PspA4 from family 2, and formulated with a BLP adjuvant also acting as a carrier.</p></fn><fn id="tfn0020"><p><sup>6</sup>NP/NCMP PspA4Pro: Poly(glycerol adipate-co-&#969;-pentadecalactone) polymeric nanoparticles adsorbed with PspA from clade 4 within L-leucine microcarriers.</p></fn><fn id="tfn0021"><p><sup>7</sup>PspA-nanogel: cCHP nanogel containing PspA.</p></fn><fn id="tfn0022"><p><sup>8</sup>PspA3+2: Recombinant PspA protein comprising PspA families 1 and 2.</p></fn><fn id="tfn0023"><p><sup>9</sup>wP: <italic toggle="yes">B. pertussis</italic> vaccine.</p></fn><fn id="tfn0024"><p><sup>10</sup>wP<sub>low</sub>: Vaccine containing low levels of <italic toggle="yes">B. pertussis</italic> LPS.</p></fn><fn id="tfn0025"><p><sup>11</sup>Chitosan-PsaA: Chitosan-DNA nanoparticles expressing PsaA.</p></fn><fn id="tfn0026"><p><sup>12</sup>PLD: Genetic derivative of Ply.</p></fn><fn id="tfn0027"><p><sup>13</sup>PlyD6: Nontoxic Ply.</p></fn><fn id="tfn0028"><p><sup>14</sup>H70+YLN: L460D [Ply toxoid with the L460D substitution] fused with protective peptide epitopes from PspC + PspA proline-rich region and SM1 region.</p></fn><fn id="tfn0029"><p><sup>15</sup>rPspA-FL-PdT: Proteins joined by flexible linker.</p></fn><fn id="tfn0030"><p><sup>16</sup>rPspA-RL-PdT: Proteins joined by rigid helix-forming linker.</p></fn><fn id="tfn0031"><p><sup>17</sup>CbpA peptide&#8211;L460D fusion protein: Biologically active peptides derived from CbpA of pneumococcus genetically fused to L460D pneumolysoid.</p></fn><fn id="tfn0032"><p>Abbreviations: Ply: Pneumolysin; PlyD1/dPly/PdT: Detoxified pneumolysin; <italic toggle="yes">S. pneumoniae</italic>: <italic toggle="yes">Streptococcus pneumoniae</italic>; IgG: Immunoglobulin G; CBPs: Choline-binding proteins; CbpG: Choline-binding protein G; CbpM: Choline-binding protein M; LytA: N-acetylmuramoyl-L-alanine amidase; LytB: N-acetylglucosaminidase; PspC/CbpA: Pneumococcal surface protein C/Choline-binding protein A; <italic toggle="yes">L. casei</italic>: <italic toggle="yes">Lactobacillus casei</italic>; PspA: Pneumococcal surface protein A; PcpA: Pneumococcal choline binding protein A; CFU: Colony-forming unit; IgA: Immunoglobulin A; BLPs: Bacterium-like particles; SIgA: Secretory immunoglobulin A; RASV: Recombinant attenuated Salmonella vaccine; cCHP: Cationic cholesteryl pullulan; <italic toggle="yes">B. pertussis</italic>: <italic toggle="yes">Bordetella pertussis</italic>; LPS: Lipopolysaccharide; PsaA: Pneumococcal surface antigen A; BlyS: B lymphocyte stimulator; IgG1: Immunoglobulin G1; IgG2a: Immunoglobulin G2a; IgG2b: Immunoglobulin G2b; IgG3: Immunoglobulin G3; AOM: Acute otitis media; PHTs: Pneumococcal histidine triad proteins; PhtA: Pneumococcal histidine triad protein A; PhtB: Pneumococcal histidine triad protein B; PhtD: Pneumococcal histidine triad protein D; OMVs: Outer membrane vesicles; PhtE: Pneumococcal histidine triad protein E; PsrP: Pneumococcal serine-rich repeat protein; SRR1: Short serine-rich repeat region; BR: Basic region; Ef-Tu: Elongation factor Tu; PLD: Pneumolysoid; HiB: <italic toggle="yes">Haemophilus influenzae</italic> type b; PiuA: Pneumococcal iron uptake A; Hsp 60: Heat shock protein 60; Hsp 70: Heat shock protein 70;PdB: Pneumolysin toxoid; PPrV: Pneumococcal protein vaccine; PcsB: Putative murine hydrolase; StkP: Serine/threonine kinase protein; PiaA: Pneumococcal iron acquisition A.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t0007" orientation="portrait"><label>Table 7.</label><caption><p>Results of WCVs investigated in animal models.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Sr. No.</th><th align="center" colspan="1" rowspan="1">Vaccine candidate</th><th align="center" colspan="1" rowspan="1">Results</th><th align="center" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td colspan="4" align="left" rowspan="1"><bold>Inactivated WCVs</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">1.</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">S. pneumoniae</italic> strain RX1mutated by deletingLytA and killed using ethanol</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0091"><list-item><p>Intranasal administration using cholera toxin as an adjuvant conferred protection against nasopharyngeal colonization by serotype 6B in mice as well as conferred protection against illness and death in rats with serotype 3 strains.</p></list-item><list-item><p>In murine models, intranasal administration significantly decreased nasopharyngeal and middle ear colonization by serotypes 6B, 14, and 23F.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0249" ref-type="bibr">249</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">2.</td><td align="left" colspan="1" rowspan="1">RM200 (Rx1E PdT &#916;<italic toggle="yes">lytA</italic>): Constructed by replacing the entire LytA gene with a kanamycin resistance gene in strain RX1E and inactivated using beta-propiolactone</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0092"><list-item><p>Intramuscular immunization in mice offered strong protection against nasopharyngeal colonization with serotype 6B and activated IL-17A priming.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0250" ref-type="bibr">250</xref>,<xref rid="cit0251" ref-type="bibr">251</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">3.</td><td align="left" colspan="1" rowspan="1">SPY1: Developed from strain D39 and killed using ethanol</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0093"><list-item><p>Intranasal immunization with killed SPY1 using cholera toxin as an adjuvant elicited effective protection against colonization with pneumococcal strains 19F and 4 as well as lethal infection with pneumococcal serotypes 2, 3, 14, and 6B.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0252" ref-type="bibr">252</xref></td></tr><tr><td colspan="4" align="left" rowspan="1"><bold>Live-attenuated WCVs</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">1.</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">S. pneumoniae</italic> D39 attenuated by removing pep27 gene</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0094"><list-item><p>Intranasal immunization in mice exhibited high levels of IgG and serotype-independent protection against lethal intranasal challenge.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0253" ref-type="bibr">253</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">2.</td><td align="left" colspan="1" rowspan="1">&#916;pep27&#916;comD: Constructed by deleting comD gene</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0095"><list-item><p>Immunization in mice significantly increased survival time after heterologous challenge and diminished colonization levels independent of serotype.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0254" ref-type="bibr">254</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">3.</td><td align="left" colspan="1" rowspan="1">TIGR4&#916;<italic toggle="yes">lgt</italic>: Constructed by removing Lgt gene in the encapsulated pneumococcal strain TIGR4</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0096"><list-item><p>Colonized mouse nasopharynx long enough to induce strong mucosal IgA and IgG2b-dominant systemic antibody responses, exhibiting cross-reactivity to heterologous pneumococcal serotypes.</p></list-item><list-item><p>Intranasal immunization in mice demonstrated serotype-independent protection against pneumococcal challenge.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0168" ref-type="bibr">168</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">4.</td><td align="left" colspan="1" rowspan="1">cpsE-endA double mutant strain: Constructed by knocking out cpsE and endA genes in <italic toggle="yes">S. pneumoniae</italic> D39</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0097"><list-item><p>Intranasal immunization in mice showed the highest survival rate and longest survival time after a lethal dose intranasal challenge with wild-type <italic toggle="yes">S. pneumoniae</italic> D39 infection compared to the single-gene knockout strains.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0255" ref-type="bibr">255</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">5.</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">&#8710;</italic>cps/piaA and <italic toggle="yes">&#8710;</italic>cps/proABC: Strains containing cps locus deletions along with <italic toggle="yes">S. pneumoniae</italic> virulence factors PsaA or proABC</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0098"><list-item><p>Previous colonization with these strains in mice protected them against septicemic pneumonia but could not prevent recolonization with the wild-type strain.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0256" ref-type="bibr">256</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn0033"><p>Abbreviations: WCVs: Whole-cell vaccines; LytA: N-acetylmuramoyl-L-alanine amidase; IL-17A: Interleukin-17A; IgG: Immunoglobulin G; Lgt: Prolipoprotein diacylglyceryl transferase; IgA: Immunoglobulin A; IgG2b: Immunoglobulin G2b; PsaA: Pneumococcal surface antigen A.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t0008" orientation="portrait"><label>Table 8.</label><caption><p>Results of protein-based vaccines and WCVs (inactivated and live-attenuated) evaluated in clinical trials.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Proteins</th><th align="center" char="." colspan="1" rowspan="1">Phase</th><th align="center" colspan="1" rowspan="1">Identifier</th><th align="center" colspan="1" rowspan="1">Status</th><th align="center" colspan="1" rowspan="1">Results</th><th align="center" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td colspan="6" align="left" rowspan="1"><bold>Protein-based candidates in clinical trials</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">PlyD1<sup>1</sup></td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01444352">NCT01444352</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0099"><list-item><p>Vaccine was immunogenic and safe.</p></list-item><list-item><p>Anti-PlyD1 antibodies produced were shown to be functional in an <italic toggle="yes">in vitro</italic> assay by neutralizing wild-type Ply activity.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0257" ref-type="bibr">257</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">PnuBioVax<break/>(PlyD6<sup>2</sup>&#8201;+&#8201;PspA&#8201;+&#8201;PsaA&#8201;+&#8201;PiuA&#8201;+&#8201;RrgB&#8201;+&#8201;RrgA&#8201;+&#8201;Hsp60&#8201;+&#8201;Hsp70)</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02572635">NCT02572635</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0100"><list-item><p>The vaccine was safe and immunogenic.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0233" ref-type="bibr">233</xref>,<xref rid="cit0258" ref-type="bibr">258</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">dPly-PhtD&#8201;&#177;&#8201;PHiD-CV<sup>3</sup></td><td align="char" char="." colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00985751">NCT00985751</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0101"><list-item><p>The vaccine formulations were safe and immunogenic.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0259" ref-type="bibr">259</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">PhtD</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01444001">NCT01444001</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0102"><list-item><p>The vaccine was safe and immunogenic at various doses evaluated.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0260" ref-type="bibr">260</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">PhtD, PhtD&#8201;+&#8201;PcpA</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01444339">NCT01444339</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0103"><list-item><p>The vaccine candidates were immunogenic and had promising safety profiles.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0261" ref-type="bibr">261</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">PcpA&#8201;+&#8201;PhtD&#8201;+&#8201;PlyD1</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">U1111&#8211;1117&#8211;7316</td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0104"><list-item><p>The vaccine was safe and immunogenic.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0262" ref-type="bibr">262</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">PcpA&#8201;+&#8201;PhtD&#8201;+&#8201;PlyD1</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01446926">NCT01446926</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">NA</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0263" ref-type="bibr">263</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">PhtD</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01767402">NCT01767402</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0105"><list-item><p>The formulations had an acceptable reactogenicity profile, without safety concerns.</p></list-item><list-item><p>Vaccination with PhtD elicited both CD4 T cell and memory B cell responses in adults.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0264" ref-type="bibr">264</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">dPly, PhtD-dPly&#8201;&#177;&#8201;PHiD-CV</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00707798">NCT00707798</ext-link><sup>4</sup></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0106"><list-item><p>Vaccine formulations were well-tolerated and immunogenic when given as standalone proteins or combined with PhiD-CV conjugates.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0265" ref-type="bibr">265</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">PhtD-dPly&#8201;&#177;&#8201;PCV 8</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00756067">NCT00756067</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0107"><list-item><p>Vaccine formulations containing free or conjugated PhtD and dPly had acceptable reactogenicity and safety profiles.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0266" ref-type="bibr">266</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">PhtD-dPly&#8201;+&#8201;PhiD</td><td align="char" char="." colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0108"><list-item><p>The vaccine was well-tolerated and immunogenic.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0267" ref-type="bibr">267</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">PhtD-dPly&#8201;+&#8201;PHiD</td><td align="char" char="." colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01262872">NCT01262872</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0109"><list-item><p>PhtD-dPly&#8201;+&#8201;PHiD had no impact on pneumococcal nasopharyngeal carriage.</p></list-item><list-item><p>dPly and PhtD proteins did not alter the immune response to PHiD-CV antigens.</p></list-item><list-item><p>PhtD-dPly&#8201;+&#8201;PHiD did not alter the immunogenicity of co-administered routine vaccines.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0268" ref-type="bibr">268</xref>,<xref rid="cit0269" ref-type="bibr">269</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">PhtD- dPly&#8201;+&#8201;PCV13<sup>5</sup></td><td align="char" char="." colspan="1" rowspan="1">2b</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01545375">NCT01545375</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0110"><list-item><p>The dPly-PhtD vaccine was immunogenic and well-tolerated.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0270" ref-type="bibr">270</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">dPLY+PsaA +24CPS<sup>6</sup></td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04525599">NCT04525599</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0111"><list-item><p>The vaccine had an acceptable safety and tolerability profile.</p></list-item><list-item><p>Immune responses were elicited (IgG concentrations and OPA titers) against 13 common and 10 of the 11 unique <italic toggle="yes">S. pneumoniae</italic> serotypes.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0271" ref-type="bibr">271</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">dPLY+PsaA +24CPS</td><td align="char" char="." colspan="1" rowspan="1">1/2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03803202">NCT03803202</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0112"><list-item><p>The vaccine was immunogenic, well-tolerated, and had a safety profile comparable to PCV13.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0272" ref-type="bibr">272</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">PspA</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01033409">NCT01033409</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="center" colspan="1" rowspan="1">NA</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0273" ref-type="bibr">273</xref>,<xref rid="cit0274" ref-type="bibr">274</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">PsaA&#8201;+&#8201;StkP&#8201;+&#8201;PcsB</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00873431">NCT00873431</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0113"><list-item><p>The vaccine was safe and immunogenic.</p></list-item><list-item><p>It induced protective antibodies against all three proteins.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0275" ref-type="bibr">275</xref>,<xref rid="cit0276" ref-type="bibr">276</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">SP_2108&#8201;+&#8201;SP_0148&#8201;+&#8201;SP_1912<break/>(GEN-004)</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01995617">NCT01995617</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0114"><list-item><p>The vaccine was safe and immunogenic.</p></list-item><list-item><p>Rise in antigen- specific IgG response was observed.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0263" ref-type="bibr">263</xref>,<xref rid="cit0277" ref-type="bibr">277</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">SP_2108&#8201;+&#8201;SP_0148&#8201;+&#8201;SP_1912<break/>(GEN-004)</td><td align="char" char="." colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02116998">NCT02116998</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0115"><list-item><p>Reduced colonization rate by 22&#8211;25%.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0263" ref-type="bibr">263</xref>,<xref rid="cit0277" ref-type="bibr">277</xref></td></tr><tr><td colspan="6" align="left" rowspan="1"><bold>WCVs in clinical trials</bold></td></tr><tr><td colspan="6" align="left" rowspan="1"><bold>Inactivated</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">SPWCV developed from strain RM200 (RX1E PdT &#916;lytA) using alum as an adjuvant</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01537185">NCT01537185</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1"><list list-type="bullet" id="list_0116"><list-item><p>The vaccine was safe, well-tolerated, and elicited a significant rise in IgG responses to PspA and Ply.</p></list-item><list-item><p>An increase in T cell cytokine responses, including IL-17A, was also observed.</p></list-item></list></td><td align="center" colspan="1" rowspan="1"><xref rid="cit0278" ref-type="bibr">278</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">SPWCV developed from strain RM200 (RX1E PdT &#916;lytA) using alum as an adjuvant</td><td align="char" char="." colspan="1" rowspan="1">1/2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02097472">NCT02097472</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="center" colspan="1" rowspan="1">NA</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0029" ref-type="bibr">29</xref>,<xref rid="cit0279" ref-type="bibr">279</xref>,<xref rid="cit0280" ref-type="bibr">280</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">SPWCV developed from strain RM200 (RX1E PdT &#916;lytA) using alum as an adjuvant</td><td align="char" char="." colspan="1" rowspan="1">1/2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02543892">NCT02543892</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="center" colspan="1" rowspan="1">NA</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0281" ref-type="bibr">281</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn0034"><p><sup>1</sup>PlyD1: Detoxified form of Ply.</p></fn><fn id="tfn0035"><p><sup>2</sup>PlyD6: Non-toxic Ply.</p></fn><fn id="tfn0036"><p><sup>3</sup>PHiD-CV: 10-valent pneumococcal non-typeable <italic toggle="yes">H. influenzae</italic> protein D conjugate vaccine, viz., Synflorix (GSK).</p></fn><fn id="tfn0037"><p><sup>4</sup>Two groups primed with a formulation containing dPly and PhtD (10 or 30&#8201;&#956;g each) continued to the follow-up phase II study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00896064">NCT00896064</ext-link>), in which they received a booster dose at 5&#8211;9&#8201;months after primary vaccination. The study has been completed.<sup><xref rid="cit0282" ref-type="bibr">282</xref></sup></p></fn><fn id="tfn0038"><p><sup>5</sup>PCV13 refers to Pfizer&#8217;s Prevnar 13.</p></fn><fn id="tfn0039"><p><sup>6</sup>dPLY+PsaA +24CPS refers to AFX3772.</p></fn><fn id="tfn0040"><p>Abbreviations: Ply: Pneumolysin; PspA: Pneumococcal surface protein A; PsaA: Pneumococcal surface antigen A; PiuA: Pneumococcal iron uptake A; Hsp 60: Heat shock protein 60; Hsp 70: Heat shock protein 70; dPly: Pneumolysin toxoid; PhtD: Pneumococcal histidine triad protein D; PcpA: Pneumococcal choline binding protein A; CPS: Capsular polysaccharides; IgG: Immunoglobulin G; OPA: Opsonophagocytic activity; <italic toggle="yes">S. pneumoniae</italic>: <italic toggle="yes">Streptococcus pneumoniae</italic>; StkP: Serine/threonine kinase protein; PcsB: Putative murine hydrolase; WCVs: Whole-cell vaccines; SPWCV: <italic toggle="yes">S. pneumoniae</italic> whole-cell vaccine; IL-17A: Interleukin-17A; <italic toggle="yes">H. influenzae</italic>: <italic toggle="yes">Haemophilus influenzae</italic>; GSK: GlaxoSmithKline.</p></fn></table-wrap-foot></table-wrap></p><p>From <xref rid="t0006 t0007 t0008" ref-type="table">Tables 6&#8211;8</xref>, it is evident that there are numerous <italic toggle="yes">S. pneumoniae</italic> proteins, such as pneumolysin (Ply), pneumococcal surface protein A (PspA), pneumococcal surface protein C (PspC), pneumococcal histidine triad protein D (PhtD), pneumococcal surface antigen A (PsaA), etc. that are investigated as vaccine candidates either alone or in combination with other proteins using suitable adjuvants and delivery systems. Some of these proteins have also been explored as carrier proteins to conjugate vaccines. Many of these candidates have shown promising results in animal studies, while some have demonstrated their safety and efficacy in clinical trials. Similarly, many WCVs (inactivated and live-attenuated) have shown promising results in animal studies and clinical trials. However, further studies are warranted to demonstrate the efficacy and safety of these protein vaccines and WCVs.</p><p>Some of the vaccine technologies, such as mRNA vaccines, deoxyribonucleic acid (DNA) vaccines, non-replicating viral vaccines, etc., grabbed the limelight during the coronavirus disease 2019 (COVID-19) pandemic. There exists a possibility that the next generation of pneumococcal vaccines may be developed using such technologies.<sup><xref rid="cit0102" ref-type="bibr">102</xref></sup></p></sec></sec><sec disp-level="1" id="s0004"><title>Recommendations for future vaccine design and development for LMICs of South Asia</title><p>
<list list-type="order" id="list_0117"><list-item><p>LMICs should have a robust surveillance system to monitor the pneumococcal serotype prevalence and distribution, the emergence of NVTs, the burden of IPD, and the impact of PCVs. This will give a better and in-depth understanding of the evolving epidemiology of <italic toggle="yes">S. pneumoniae</italic>, aid in formulating and implementing vaccination policies, and guide the development of next-generation pneumococcal vaccines.</p></list-item><list-item><p>These countries should have access to high-end and quality diagnostics to understand the AMR pattern of <italic toggle="yes">S. pneumoniae</italic>. Antibiotic stewardship programs and national AMR plans should be religiously implemented. Data from the AMR pattern can play a decisive role in selecting the appropriate serotypes for PCV development.</p></list-item><list-item><p>Pharmaceutical/Biotech companies should customize or tailor PCVs as per the region-specific prevalence and disease-causing potential of pneumococcal serotypes based on robust surveillance data as well as taking into consideration the pros and cons of adding additional serotypes. For example, companies can develop or modify the existing PCV formulations and incorporate serotypes as shown in <xref rid="t0009" ref-type="table">Table 9</xref>.<table-wrap position="float" id="t0009" orientation="portrait"><label>Table 9.</label><caption><p>Plausible serotypes that can be incorporated in the existing PCV formulations.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Region</th><th align="center" colspan="1" rowspan="1">*Plausible serotypes</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">South Asia</td><td align="left" colspan="1" rowspan="1">2, 8, 13, 20, 29, 31, 34, 38, 39, 45, 10A, 10F, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 18B, 19B, 22F, 23B, 28A, 28F, 33F, 35B, 35F, 6C, 6D, 7B, 9&#8201;L, 9N</td></tr></tbody></table><table-wrap-foot><fn id="tfn0041"><p>1) *These serotypes have been implicated in IPD, non-IPD, and drug resistance as shown in <xref rid="t0002" ref-type="table">Table 2</xref>.</p></fn><fn id="tfn0042"><p>Abbreviations: IPD: Invasive pneumococcal disease; Non-IPD: Non-invasive pneumococcal disease.</p></fn></table-wrap-foot></table-wrap></p></list-item><list-item><p>Serotype replacement due to PCVs and regional differences in the dominant serotypes warrant the inclusion of additional serotypes in the existing vaccines. Adding a new serotype will increase the complexity and the cost. This in turn can affect affordability and accessibility in countries with high pneumococcal disease burden and lack of robust healthcare infrastructure. To mitigate this risk, a non-serotype-based approach, such as a protein-based vaccine, a live-attenuated vaccine, or an inactivated vaccine, would be an ideal one. Such vaccines target the highly conserved proteins across all <italic toggle="yes">S. pneumoniae</italic> serotypes and can provide broader protection as compared to the existing PCVs. However, large, robust studies in different geographies are warranted to demonstrate its efficacy and safety in clinical trials as well as the real-world effectiveness of these vaccine candidates.</p></list-item></list></p></sec></body><back><bio id="b0001"><p><bold><italic toggle="yes">Syed Ahmed</italic></bold> is the director and chief executive officer of TechInvention Lifecare Private Limited, an innovation-driven biotech company focused on vaccines, diagnostics, and biotherapeutics for infectious diseases. He is also the board member and vice president of Emerging Biopharmaceutical Manufacturers Network (EBPMN), a not-for-profit pan global association supporting access and manufacturing of biopharmaceuticals across low- and middle-income countries (LMICs). Syed is also the co-founder of another not-for-profit organization in its inception stage, namely Association for Veterinary Vaccine Manufacturers (AVVM), with a focus on enabling access and equity of veterinary vaccines in LMICs. Syed is the co-inventor and has 15+ patents filed in the field of discovery and development of immunobiologicals. He&#8217;s also the corresponding author of four manuscripts in the arena of vaccines and biotherapeutics published in global journals of repute. He&#8217;s also leading quite a few &#8216;One Health&#8217; initiatives and focused on interventions in the domain of infectious diseases that can impact climate change and sustainability.</p></bio><sec sec-type="COI-statement" disp-level="1" id="s0005"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><sec disp-level="1" id="s0006"><title>Author contributions</title><p>Conceptualization, P.D., S.S., K.S., and S.A.; writing &#8211; original draft preparation, P.D., S.S., K.S., V.K., A.B., S.D., P.S. S.A.; writing &#8211; review and editing, P.D., S.S., D.S., and S.A. All authors have read and agreed to the published version of the manuscript.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Leonard</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>M&#246;hlis</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Schl&#252;ter</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Taylor</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lalk</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Methling</surname><given-names>K.</given-names></string-name></person-group><article-title>Exploring metabolic adaptation of Streptococcus pneumoniae to antibiotics</article-title>. <source>J Antibiot (Tokyo)</source>. <year>2020</year>;<volume>73</volume>(<issue>7</issue>):<fpage>441</fpage>&#8211;<lpage>25</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41429-020-0296-3</pub-id>.<pub-id pub-id-type="pmid">32210362</pub-id><pub-id pub-id-type="pmcid">PMC7292801</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Plainvert</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Varon</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Viriot</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kempf</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Plainvert</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Alauzet</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Auger</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Batah</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Brieu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Cattoir</surname><given-names>V</given-names></string-name>, et al</person-group>. <article-title>Invasive pneumococcal infections in France: changes from 2009 to 2021 in antibiotic resistance and serotype distribution of Streptococcus pneumoniae based on data from the French Regional Pneumococcal Observatories network</article-title>. <source>Infect Dis Now</source>. <year>2023</year>;<volume>53</volume>(<issue>1</issue>):<fpage>104632</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.idnow.2022.11.001</pub-id>.<pub-id pub-id-type="pmid">36375765</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Deloria Knoll</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Garcia Quesada</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kagucia</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Peterson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Feikin</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hetrich</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sinkevitch</surname><given-names>J</given-names></string-name>, et al</person-group>. <article-title>Global landscape review of serotype-specific invasive
pneumococcal disease surveillance among countries using PCV10/13: the pneumococcal serotype replacement and
distribution estimation (PSERENADE) project</article-title>. <source>Microorganisms</source>. <year>2021</year>;<volume>9</volume>(<issue>4</issue>):<fpage>742</fpage>. doi:<pub-id pub-id-type="doi">10.3390/microorganisms9040742</pub-id>.<pub-id pub-id-type="pmid">33918127</pub-id><pub-id pub-id-type="pmcid">PMC8066045</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cui</surname><given-names>YA</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wm</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Saddier</surname><given-names>P</given-names></string-name></person-group>. <article-title>Pneumococcal serotype distribution: a snapshot of recent data in pediatric and adult populations around the world</article-title>. <source>Hum Vaccines Immunother</source>. <year>2017</year>;<volume>13</volume>(<issue>6</issue>):<fpage>1229</fpage>&#8211;<lpage>1241</lpage>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2016.1277300</pub-id>.<pub-id pub-id-type="pmcid">PMC5489298</pub-id><pub-id pub-id-type="pmid">28125317</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Teixeira</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kossyvaki</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Galvez</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>M&#233;ndez</surname><given-names>C</given-names></string-name></person-group>. <article-title>Pneumococcal serotype evolution and burden in European adults in the last decade: a systematic review</article-title>. <source>Microorganisms</source>. <year>2023</year>;<volume>11</volume>(<issue>6</issue>):<fpage>1376</fpage>. doi:<pub-id pub-id-type="doi">10.3390/microorganisms11061376</pub-id>.<pub-id pub-id-type="pmid">37374878</pub-id><pub-id pub-id-type="pmcid">PMC10303156</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Chung</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>J-H</given-names></string-name>, <string-name name-style="western"><surname>Baek</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Thamlikitkul</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Carlos</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ahmad</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Arushothy</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>SH</given-names></string-name>, et al</person-group>. <article-title>Changes in serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates from adult patients in Asia: emergence of drug-resistant non-vaccine serotypes</article-title>. <source>Vaccine</source>. <year>2020</year>;<volume>38</volume>(<issue>38</issue>):<fpage>6065</fpage>&#8211;<lpage>6073</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2019.09.065</pub-id>.<pub-id pub-id-type="pmid">31590932</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="webpage"><article-title>Pneumococcal Disease Surveillance and Trends</article-title>. [<date-in-citation>accessed 2024 <month>Jul</month><day>3</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/pneumococcal/php/surveillance/index.html" ext-link-type="uri">https://www.cdc.gov/pneumococcal/php/surveillance/index.html</ext-link>.</mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Cill&#243;niz</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Garcia-Vidal</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ceccato</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Torres</surname><given-names>A</given-names></string-name></person-group>. <part-title>Antimicrobial resistance among Streptococcus pneumoniae</part-title>. In: <person-group person-group-type="editor"><string-name name-style="western"><surname>Fong</surname><given-names>I</given-names></string-name>; <string-name name-style="western"><surname>Shlaes</surname><given-names>D</given-names></string-name><string-name name-style="western"><surname>Drlica</surname><given-names>K</given-names></string-name></person-group>, editors. <source>Antimicrobial Resistance in the 21st Century</source>. <publisher-loc>Cham</publisher-loc>: <publisher-name>Springer International Publishing</publisher-name>; <year>2018</year>. p. <fpage>13</fpage>&#8211;<lpage>38</lpage>.</mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>S-H</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X-Y</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Recent progress in pneumococcal protein vaccines</article-title>. <source>Front Immunol</source>. <year>2023</year>;<volume>14</volume>:<fpage>1278346</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2023.1278346</pub-id>.<pub-id pub-id-type="pmid">37818378</pub-id><pub-id pub-id-type="pmcid">PMC10560988</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Silva</surname><given-names>PH</given-names></string-name>, <string-name name-style="western"><surname>V&#225;zquez</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Campusano</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Retamal-D&#237;az</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lay</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Mu&#241;oz</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Gonz&#225;lez</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Kalergis</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Bueno</surname><given-names>SM</given-names></string-name></person-group>. <article-title>Non-capsular based immunization approaches to prevent Streptococcus pneumoniae infection</article-title>. <source>Front Cell Infect Microbiol</source>. <year>2022</year>;<volume>12</volume>:<fpage>949469</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fcimb.2022.949469</pub-id>.<pub-id pub-id-type="pmid">36225231</pub-id><pub-id pub-id-type="pmcid">PMC9548657</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weiser</surname><given-names>JN</given-names></string-name>, <string-name name-style="western"><surname>Ferreira</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Paton</surname><given-names>JC</given-names></string-name></person-group>. <article-title>Streptococcus pneumoniae: transmission, colonization and invasion</article-title>. <source>Nat Rev Microbiol</source>. <year>2018</year>;<volume>16</volume>(<issue>6</issue>):<fpage>355</fpage>&#8211;<lpage>367</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41579-018-0001-8</pub-id>.<pub-id pub-id-type="pmid">29599457</pub-id><pub-id pub-id-type="pmcid">PMC5949087</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Micoli</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Romano</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Carboni</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Adamo</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Berti</surname><given-names>F</given-names></string-name></person-group>. <article-title>Strengths and weaknesses of pneumococcal conjugate vaccines</article-title>. <source>Glycoconj J</source>. <year>2023</year>;<volume>40</volume>(<issue>2</issue>):<fpage>135</fpage>&#8211;<lpage>148</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10719-023-10100-3</pub-id>.<pub-id pub-id-type="pmid">36652051</pub-id><pub-id pub-id-type="pmcid">PMC10027807</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rodgers</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Whitney</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Klugman</surname><given-names>KP</given-names></string-name></person-group>. <article-title>Triumph of pneumococcal conjugate vaccines: overcoming a common foe</article-title>. <source>J Infect Dis</source>. <year>2021</year>;<volume>224</volume>(<issue>Supplement_4</issue>):<fpage>S352</fpage>&#8211;<lpage>9</lpage>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jiaa535</pub-id>.<pub-id pub-id-type="pmid">34590137</pub-id><pub-id pub-id-type="pmcid">PMC8482025</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kartasasmita</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Rezeki Hadinegoro</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kurniati</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Triasih</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Halim</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Gamil</surname><given-names>G</given-names></string-name></person-group>. <article-title>Triumph of pneumococcal conjugate vaccines: overcoming a common foe</article-title>. <source>Infect Dis Ther</source>. <year>2020</year>;<volume>9</volume>(<issue>4</issue>):<fpage>723</fpage>&#8211;<lpage>736</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40121-020-00330-5</pub-id>.<pub-id pub-id-type="pmid">32864725</pub-id><pub-id pub-id-type="pmcid">PMC7680475</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>L&#248;chen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Croucher</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>RM</given-names></string-name></person-group>. <article-title>Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency</article-title>. <source>Sci Rep</source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>18977</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-020-75691-5</pub-id>.<pub-id pub-id-type="pmid">33149149</pub-id><pub-id pub-id-type="pmcid">PMC7643077</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Song</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Nahm</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Moseley</surname><given-names>MA</given-names></string-name></person-group>. <article-title>Clinical implications of
pneumococcal serotypes: invasive disease potential, clinical
presentations, and antibiotic resistance</article-title>. <source>J Korean Med Sci</source>. <year>2013</year>;<volume>28</volume>(<issue>1</issue>):<fpage>4</fpage>. doi:<pub-id pub-id-type="doi">10.3346/jkms.2013.28.1.4</pub-id>.<pub-id pub-id-type="pmid">23341706</pub-id><pub-id pub-id-type="pmcid">PMC3546102</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wattal</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Goel</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Byotra</surname><given-names>SP</given-names></string-name></person-group>. <article-title>pneumococcal serotypes in adults &#8805;50 years of age</article-title>. <source>Indian J Med Microbiol</source>. <year>2017</year>;<volume>35</volume>(<issue>1</issue>):<fpage>95</fpage>&#8211;<lpage>100</lpage>. doi:<pub-id pub-id-type="doi">10.4103/ijmm.IJMM_16_132</pub-id>.<pub-id pub-id-type="pmid">28303826</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Du</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>K</given-names></string-name></person-group>. <article-title>Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines</article-title>. <source>Hum Vaccines Immunother</source>. <year>2024</year>;<volume>17</volume>(<issue>12</issue>):<fpage>5628</fpage>&#8211;<lpage>5637</lpage>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2021.1985353</pub-id>.<pub-id pub-id-type="pmcid">PMC8903918</pub-id><pub-id pub-id-type="pmid">34726580</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Grant</surname><given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Slack</surname><given-names>MPE</given-names></string-name>, <string-name name-style="western"><surname>Theilacker</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Vojicic</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dion</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Reinert</surname><given-names>R-R</given-names></string-name>, <string-name name-style="western"><surname>Jodar</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gessner</surname><given-names>BD</given-names></string-name></person-group>. <article-title>Distribution of serotypes causing invasive pneumococcal disease in children from high-income countries and the impact of pediatric pneumococcal vaccination</article-title>. <source>Clin Infect Dis</source>. <year>2023</year>;<volume>76</volume>(<issue>3</issue>):<fpage>e1062</fpage>&#8211;<lpage>70</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciac475</pub-id>.<pub-id pub-id-type="pmid">35789262</pub-id><pub-id pub-id-type="pmcid">PMC9907512</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lister</surname><given-names>AJJ</given-names></string-name>, <string-name name-style="western"><surname>Le</surname><given-names>CF</given-names></string-name>, <string-name name-style="western"><surname>Cheah</surname><given-names>ESG</given-names></string-name>, <string-name name-style="western"><surname>Desa</surname><given-names>MNM</given-names></string-name>, <string-name name-style="western"><surname>Cleary</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Clarke</surname><given-names>SC</given-names></string-name></person-group>. <article-title>Serotype distribution of invasive, non-invasive and carried Streptococcus pneumoniae in Malaysia: a meta-analysis</article-title>. <source>Pneumonia</source>. <year>2021</year>;<volume>13</volume>(<issue>1</issue>):<fpage>9</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s41479-021-00086-7</pub-id>.<pub-id pub-id-type="pmid">34030731</pub-id><pub-id pub-id-type="pmcid">PMC8147341</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>El-Beleidy</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>El-Saied</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fasseeh</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>El Saie</surname><given-names>RZ</given-names></string-name>, <string-name name-style="western"><surname>Haridy</surname><given-names>H</given-names></string-name></person-group>. <article-title>A Systematic review of pneumococcal carriage, disease, antimicrobial resistance, and vaccination in Egyptian children aged 18 years and younger</article-title>. <source>Infect Dis Ther</source>. <year>2021</year>;<volume>10</volume>(<issue>4</issue>):<fpage>2119</fpage>&#8211;<lpage>2155</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40121-021-00523-6</pub-id>.<pub-id pub-id-type="pmid">34468962</pub-id><pub-id pub-id-type="pmcid">PMC8408359</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Abebaw</surname><given-names>T-A</given-names></string-name>, <string-name name-style="western"><surname>Aregay</surname><given-names>WK</given-names></string-name>, <string-name name-style="western"><surname>Ashami</surname><given-names>MT</given-names></string-name></person-group>. <article-title>Risk factors for childhood pneumonia at Adama Hospital Medical College, Adama, Ethiopia: a case-control study</article-title>. <source>Pneumonia Nathan Qld</source>. <year>2022</year>;<volume>14</volume>(<issue>1</issue>):<fpage>9</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s41479-022-00102-4</pub-id>.<pub-id pub-id-type="pmid">36471452</pub-id><pub-id pub-id-type="pmcid">PMC9721024</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jaiswal</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Thumburu</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Bharti</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Agarwal</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kaur</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chadha</surname><given-names>N</given-names></string-name></person-group>. <article-title>Burden of invasive pneumococcal disease in children aged 1 month to 12 years living in South Asia: A Systematic Review</article-title>. <source>PLOS ONE</source>. <year>2014</year>;<volume>9</volume>(<issue>5</issue>):<fpage>e96282</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0096282</pub-id>.<pub-id pub-id-type="pmid">24798424</pub-id><pub-id pub-id-type="pmcid">PMC4010478</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wasserman</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Perdrizet</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Grant</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hayford</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Saharia</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Horn</surname><given-names>EK</given-names></string-name>, <string-name name-style="western"><surname>Farkouh</surname><given-names>RA</given-names></string-name></person-group>. <article-title>Clinical and economic burden of pneumococcal disease due to serotypes contained in current and investigational pneumococcal conjugate vaccines in children under five years of age</article-title>. <source>Infect Dis Ther</source>. <year>2021</year>;<volume>10</volume>(<issue>4</issue>):<fpage>2701</fpage>&#8211;<lpage>2720</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40121-021-00544-1</pub-id>.<pub-id pub-id-type="pmid">34633639</pub-id><pub-id pub-id-type="pmcid">PMC8503717</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lai</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Von Mollendorf</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Blyth</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dance</surname><given-names>DAB</given-names></string-name>, <string-name name-style="western"><surname>Datta</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dunne</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Ford</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Fox</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hinds</surname><given-names>J</given-names></string-name>, et al</person-group>. <article-title>Determining the pneumococcal conjugate vaccine coverage required for indirect protection within Asia and the Pacific: a prospective observational study</article-title>. <source>Lancet Glob Health</source>. <year>2019</year>;<volume>7</volume>:<fpage>S15</fpage>. doi:<pub-id pub-id-type="doi">10.1016/S2214-109X(19)30100-7</pub-id>.</mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="report"><article-title>View-hub Report: Global Vaccine Introduction and Implementation</article-title>. [<date-in-citation>accessed 2025 <month>Jan</month><day>18</day>]</date-in-citation>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://view-hub.org/sites/default/files/2024-09/VIEW-hub_Report_August2024.pdf" ext-link-type="uri">https://view-hub.org/sites/default/files/2024-09/VIEW-hub_Report_August2024.pdf</ext-link>.</mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Syeed</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Ghule</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Le</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Veettil</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Horn</surname><given-names>EK</given-names></string-name>, <string-name name-style="western"><surname>Perdrizet</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wasserman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Thakkinstian</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chaiyakunapruk</surname><given-names>N</given-names></string-name></person-group>. <article-title>Pneumococcal vaccination in children: a systematic review and meta-analysis of cost-effectiveness studies</article-title>. <source>Value Health</source>. <year>2023</year>;<volume>26</volume>(<issue>4</issue>):<fpage>598</fpage>&#8211;<lpage>611</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jval.2022.10.006</pub-id>.<pub-id pub-id-type="pmid">36328324</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Nguyen</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Dunne</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Kim Mulholland</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mungun</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Pomat</surname><given-names>WS</given-names></string-name>, <string-name name-style="western"><surname>Rafai</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Satzke</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Weinberger</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Russell</surname><given-names>FM</given-names></string-name></person-group>. <article-title>Using pneumococcal carriage studies to monitor vaccine impact in low- and middle-income countries</article-title>. <source>Vaccine</source>. <year>2019</year>;<volume>37</volume>(<issue>43</issue>):<fpage>6299</fpage>&#8211;<lpage>6309</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2019.08.073</pub-id>.<pub-id pub-id-type="pmid">31500968</pub-id></mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Masomian</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ahmad</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Ti Gew</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Poh</surname><given-names>CL</given-names></string-name></person-group>. <article-title>Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection</article-title>. <source>Vaccines</source>. <year>2020</year>;<volume>8</volume>(<issue>1</issue>):<fpage>132</fpage>. doi:<pub-id pub-id-type="doi">10.3390/vaccines8010132</pub-id>.<pub-id pub-id-type="pmid">32192117</pub-id><pub-id pub-id-type="pmcid">PMC7157650</pub-id></mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Van Tonder</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Gladstone</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Lo</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Nahm</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>du Plessis</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cornick</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kwambana-Adams</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Hawkins</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Benisty</surname><given-names>R</given-names></string-name>, et al</person-group>. <article-title>Putative novel cps loci in a large global collection of pneumococci</article-title>. <source>Microb Genomics</source>. <year>2019</year>;<volume>5</volume>(<issue>7</issue>). doi:<pub-id pub-id-type="doi">10.1099/mgen.0.000274</pub-id>.<pub-id pub-id-type="pmcid">PMC6700660</pub-id><pub-id pub-id-type="pmid">31184299</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Manzanal</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vicente</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Alonso</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Azkue</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ercibengoa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Marim&#243;n</surname><given-names>JM</given-names></string-name></person-group>. <article-title>Impact of the progressive uptake of pneumococcal conjugate vaccines on the epidemiology and antimicrobial resistance of invasive pneumococcal disease in Gipuzkoa, northern Spain, 1998&#8211;2022</article-title>. <source>Front Public Health</source>. <year>2023</year>;<volume>11</volume>:<fpage>1238502</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fpubh.2023.1238502</pub-id>.<pub-id pub-id-type="pmid">37719737</pub-id><pub-id pub-id-type="pmcid">PMC10501722</pub-id></mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weinberger</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Warren</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Dalby</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Shapiro</surname><given-names>ED</given-names></string-name>, <string-name name-style="western"><surname>Valentiner-Branth</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Slotved</surname><given-names>H-C</given-names></string-name>, <string-name name-style="western"><surname>Harboe</surname><given-names>ZB</given-names></string-name></person-group>. <article-title>Differences in the impact of pneumococcal serotype replacement in individuals with and pneumococcal serotype replacement in individuals with and without underlying medical conditions</article-title>.<source>Clin Infect Dis Off Publ Infect Dis Soc Am</source>. <year>2019</year>;<volume>69</volume>(<issue>1</issue>):<fpage>100</fpage>&#8211;<lpage>106</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciy875</pub-id>.<pub-id pub-id-type="pmcid">PMC6579958</pub-id><pub-id pub-id-type="pmid">30321313</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lewnard</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Hanage</surname><given-names>WP</given-names></string-name></person-group>. <article-title>Making sense of differences in pneumococcal serotype replacement</article-title>. <source>Lancet Infect Dis</source>. <year>2019</year>;<volume>19</volume>(<issue>6</issue>):<fpage>e213</fpage>&#8211;<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(18)30660-1</pub-id>.<pub-id pub-id-type="pmid">30709666</pub-id></mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wambugu</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Shah</surname><given-names>M-M</given-names></string-name>, <string-name name-style="western"><surname>Nguyen</surname><given-names>H-A</given-names></string-name>, <string-name name-style="western"><surname>Le</surname><given-names>K-A</given-names></string-name>, <string-name name-style="western"><surname>Le</surname><given-names>H-H</given-names></string-name>, <string-name name-style="western"><surname>Vo</surname><given-names>H-M</given-names></string-name>, <string-name name-style="western"><surname>Toizumi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bui</surname><given-names>M-X</given-names></string-name>, <string-name name-style="western"><surname>Dang</surname><given-names>D-A</given-names></string-name>, <string-name name-style="western"><surname>Yoshida</surname><given-names>L-M</given-names></string-name></person-group>. <article-title>Molecular epidemiology of streptococcus pneumoniae detected in hospitalized pediatric acute respiratory infection cases in Central Vietnam</article-title>. <source>Pathogens</source>. <year>2023</year>;<volume>12</volume>(<issue>7</issue>):<fpage>943</fpage>. doi:<pub-id pub-id-type="doi">10.3390/pathogens12070943</pub-id>.<pub-id pub-id-type="pmid">37513790</pub-id><pub-id pub-id-type="pmcid">PMC10385502</pub-id></mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sabbar</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Mahraoui</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bast&#236;as Garci&#224;</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jroundi</surname><given-names>I</given-names></string-name></person-group>. <article-title>Streptococcus pneumoniae vaccination strategies and its expected impact on penicillin non-susceptibility in children under the age of five: let&#8217;s recap!</article-title><source>Vaccine X</source>. <year>2022</year>;<volume>11</volume>:<fpage>100170</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jvacx.2022.100170</pub-id>.<pub-id pub-id-type="pmid">35620569</pub-id><pub-id pub-id-type="pmcid">PMC9127579</pub-id></mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lo</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Gladstone</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Van Tonder</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Lees</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>du Plessis</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Benisty</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Givon-Lavi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Hawkins</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Cornick</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Kwambana-Adams</surname><given-names>B</given-names></string-name>, et al</person-group>. <article-title>Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study</article-title>. <source>Lancet Infect Dis</source>. <year>2019</year>;<volume>19</volume>(<issue>7</issue>):<fpage>759</fpage>&#8211;<lpage>769</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(19)30297-X</pub-id>.<pub-id pub-id-type="pmid">31196809</pub-id><pub-id pub-id-type="pmcid">PMC7641901</pub-id></mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Balsells</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Guillot</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Nair</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kyaw</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Borrow</surname><given-names>R</given-names></string-name></person-group>. <article-title>Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-pcv era: a systematic review and meta-analysis</article-title>. <source>PLOS ONE</source>. <year>2017</year>;<volume>12</volume>(<issue>5</issue>):<fpage>e0177113</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0177113</pub-id>.<pub-id pub-id-type="pmid">28486544</pub-id><pub-id pub-id-type="pmcid">PMC5423631</pub-id></mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Scott</surname><given-names>NR</given-names></string-name>, <string-name name-style="western"><surname>Mann</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Tuomanen</surname><given-names>EI</given-names></string-name>, <string-name name-style="western"><surname>Orihuela</surname><given-names>CJ</given-names></string-name></person-group>. <article-title>Multi-valent protein hybrid pneumococcal vaccines: a strategy for the next</article-title>. <source>Vaccines</source>. <year>2021</year>;<volume>9</volume>(<issue>3</issue>):<fpage>209</fpage>. doi:<pub-id pub-id-type="doi">10.3390/vaccines9030209</pub-id>.<pub-id pub-id-type="pmid">33801372</pub-id><pub-id pub-id-type="pmcid">PMC8002124</pub-id></mixed-citation></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zabihullah</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Dhoubhadel</surname><given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Rauf</surname><given-names>FA</given-names></string-name>, <string-name name-style="western"><surname>Shafiq</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Suzuki</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Watanabe</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Yoshida</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Yasunami</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zabihullah</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Parry</surname><given-names>CM</given-names></string-name>, et al</person-group>. <article-title>Risk for death among children with pneumonia, Afghanistan</article-title>. <source>Emerg Infect Dis</source>. <year>2017</year>;<volume>23</volume>(<issue>8</issue>):<fpage>1404</fpage>&#8211;<lpage>1408</lpage>. doi:<pub-id pub-id-type="doi">10.3201/eid2308.151550</pub-id>.<pub-id pub-id-type="pmid">28726625</pub-id><pub-id pub-id-type="pmcid">PMC5547795</pub-id></mixed-citation></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pichichero</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Malley</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kaur</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zagursky</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>P</given-names></string-name></person-group>. <article-title>Acute otitis media pneumococcal disease burden and nasopharyngeal colonization in children due to serotypes included and not included in current and new pneumococcal conjugate vaccines</article-title>. <source>Expert Rev Vaccines</source>. <year>2023</year>;<volume>22</volume>(<issue>1</issue>):<fpage>118</fpage>&#8211;<lpage>138</lpage>. doi:<pub-id pub-id-type="doi">10.1080/14760584.2023.2162506</pub-id>.<pub-id pub-id-type="pmid">36565291</pub-id></mixed-citation></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Malaker</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Saha</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hanif</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Saha</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hasanuzzaman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Khondakar</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Islam</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Baqui</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Santosham</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Invasive pneumococcal infections in children with nephrotic syndrome in Bangladesh</article-title>. <source>Pediatr Infect Dis J</source>. <year>2019</year>;<volume>38</volume>(<issue>8</issue>):<fpage>798</fpage>&#8211;<lpage>803</lpage>. doi:<pub-id pub-id-type="doi">10.1097/INF.0000000000002386</pub-id>.<pub-id pub-id-type="pmid">31220048</pub-id></mixed-citation></ref><ref id="cit0042"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baqui</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>McCollum</surname><given-names>ED</given-names></string-name>, <string-name name-style="western"><surname>Mahmud</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Roy</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chowdhury</surname><given-names>NH</given-names></string-name>, <string-name name-style="western"><surname>Rafiqullah</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Rizvi</surname><given-names>SJR</given-names></string-name>, <string-name name-style="western"><surname>Begum</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Mitra</surname><given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Khanam</surname><given-names>R</given-names></string-name>, et al</person-group>. <article-title>Population-based incidence and serotype distribution of invasive pneumococcal disease prior to introduction of conjugate pneumococcal vaccine in Bangladesh</article-title>. <source>PLOS ONE</source>. <year>2020</year>;<volume>15</volume>(<issue>2</issue>):<fpage>e0228799</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0228799</pub-id>.<pub-id pub-id-type="pmid">32053640</pub-id><pub-id pub-id-type="pmcid">PMC7018078</pub-id></mixed-citation></ref><ref id="cit0043"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Saha</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Hossain</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Islam</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hasanuzzaman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Saha</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hasan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Darmstadt</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Chowdury</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Arifeen</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Baqui</surname><given-names>AH</given-names></string-name>, et al</person-group>. <article-title>Epidemiology of invasive pneumococcal disease in Bangladeshi children before introduction of pneumococcal conjugate vaccine</article-title>. <source>Pediatr Infect Dis J</source>. <year>2016</year>;<volume>35</volume>(<issue>6</issue>):<fpage>655</fpage>&#8211;<lpage>661</lpage>. doi:<pub-id pub-id-type="doi">10.1097/INF.0000000000001037</pub-id>.<pub-id pub-id-type="pmid">26658530</pub-id></mixed-citation></ref><ref id="cit0044"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Siddik</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Tanvir</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>Bhuyan</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Alam</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Islam</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Bulbul</surname><given-names>MRH</given-names></string-name>, <string-name name-style="western"><surname>Moniruzzaman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Halder</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Rahman</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Endtz</surname><given-names>H</given-names></string-name>, et al</person-group>. <article-title>Bacterial and viral etiology of acute respiratory infection among the Forcibly Displaced Myanmar Nationals (FDMNs) in fragile settings in Cox&#8217;s Bazar- a prospective case-control study</article-title>. <source>PloS Negl Trop Dis</source>. <year>2023</year>;<volume>17</volume>(<issue>4</issue>):<fpage>e0011189</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pntd.0011189</pub-id>.<pub-id pub-id-type="pmid">37036845</pub-id><pub-id pub-id-type="pmcid">PMC10085056</pub-id></mixed-citation></ref><ref id="cit0045"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Naziat</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Saha</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Islam</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Saha</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Uddin</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Hussain</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Luby</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Darmstadt</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Whitney</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Gessner</surname><given-names>BD</given-names></string-name>, et al</person-group>. <article-title>Epidemiology of Otitis media with Otorrhea among Bangladeshi children: Baseline study for future assessment of pneumococcal conjugate vaccine impact</article-title>. <source>Pediatr Infect Dis J</source>. <year>2018</year>;<volume>37</volume>(<issue>7</issue>):<fpage>715</fpage>&#8211;<lpage>721</lpage>. doi:<pub-id pub-id-type="doi">10.1097/INF.0000000000002077</pub-id>.<pub-id pub-id-type="pmid">29634626</pub-id></mixed-citation></ref><ref id="cit0046"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Apte</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dayma</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Naziat</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sanghavi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Uddin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kawade</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Islam</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, et al</person-group>. <article-title>Nasopharyngeal pneumococcal carriage in South Asian infants: results of observational cohort studies in vaccinated and unvaccinated populations</article-title>. <source>J Glob Health</source>. <year>2021</year>;<volume>11</volume>:<fpage>04054</fpage>. doi:<pub-id pub-id-type="doi">10.7189/jogh.11.04054</pub-id>.<pub-id pub-id-type="pmid">34552723</pub-id><pub-id pub-id-type="pmcid">PMC8442578</pub-id></mixed-citation></ref><ref id="cit0047"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vidanapathirana</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Angulmaduwa</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Munasinghe</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ekanayake</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kudagammana</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Dissanayaka</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Liyanapathirana</surname><given-names>V</given-names></string-name></person-group>. <article-title>Pneumococcal colonization among healthy and hospitalized vaccine-naive Sri Lankan children</article-title>. <source>Vaccine</source>. <year>2020</year>;<volume>38</volume>(<issue>46</issue>):<fpage>7308</fpage>&#8211;<lpage>7315</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2020.09.040</pub-id>.<pub-id pub-id-type="pmid">32981783</pub-id></mixed-citation></ref><ref id="cit0048"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vidanapathirana</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Angulmaduwa</surname><given-names>ALSK</given-names></string-name>, <string-name name-style="western"><surname>Munasinghe</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Ekanayake</surname><given-names>EWMA</given-names></string-name>, <string-name name-style="western"><surname>Harasgama</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kudagammana</surname><given-names>ST</given-names></string-name>, <string-name name-style="western"><surname>Dissanayake</surname><given-names>BN</given-names></string-name>, <string-name name-style="western"><surname>Liyanapathirana</surname><given-names>LVC</given-names></string-name></person-group>. <article-title>Comparison of pneumococcal colonization density among healthy children and children with respiratory symptoms using real time PCR (RT-PCR)</article-title>. <source>BMC Microbiol</source>. <year>2022</year>;<volume>22</volume>(<issue>1</issue>):<fpage>31</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12866-022-02442-z</pub-id>.<pub-id pub-id-type="pmid">35057744</pub-id><pub-id pub-id-type="pmcid">PMC8772066</pub-id></mixed-citation></ref><ref id="cit0049"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carter</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Gurung</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pokhrel</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bijukchhe</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Karmacharya</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Khadka</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Maharjan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bhattarai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shrestha</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Khadka</surname><given-names>B</given-names></string-name>, et al</person-group>. <article-title>Childhood invasive bacterial disease in Kathmandu, Nepal (2005&#8211;2013)</article-title>. <source>Pediatr Infect Dis J</source>. <year>2022</year>;<volume>41</volume>(<issue>3</issue>):<fpage>192</fpage>&#8211;<lpage>198</lpage>. doi:<pub-id pub-id-type="doi">10.1097/INF.0000000000003421</pub-id>.<pub-id pub-id-type="pmid">34955523</pub-id></mixed-citation></ref><ref id="cit0050"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shrestha</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gurung</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Amatya</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bijukchhe</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bose</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Carter</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Gautam</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Gurung</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hinds</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kandasamy</surname><given-names>R</given-names></string-name>, et al</person-group>. <article-title>Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study</article-title>. <source>Lancet Glob Health</source>. <year>2022</year>;<volume>10</volume>(<issue>10</issue>):<fpage>e1494</fpage>&#8211;<lpage>504</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2214-109X(22)00281-9</pub-id>.<pub-id pub-id-type="pmid">36113533</pub-id></mixed-citation></ref><ref id="cit0051"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kandasamy</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Gurung</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Thapa</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ndimah</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Adhikari</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Murdoch</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Kelly</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Waldron</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Gould</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Thorson</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Multi-serotype pneumococcal nasopharyngeal carriage prevalence in vaccine na&#239;ve Nepalese children, assessed using molecular serotyping</article-title>. <source>PLOS ONE</source>. <year>2015</year>;<volume>10</volume>(<issue>2</issue>):<fpage>e0114286</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0114286</pub-id>.<pub-id pub-id-type="pmid">25643355</pub-id><pub-id pub-id-type="pmcid">PMC4313945</pub-id></mixed-citation></ref><ref id="cit0052"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kandasamy</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gurung</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Carter</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Gladstone</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lees</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shrestha</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Thorson</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bijukchhe</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gautam</surname><given-names>MC</given-names></string-name>, et al</person-group>. <article-title>Effect of childhood vaccination and antibiotic use on pneumococcal populations and genome-wide associations with disease among children in Nepal: an observational study</article-title>. <source>The Lancet Microbe</source>. <year>2022</year>;<volume>3</volume>(<issue>7</issue>):<fpage>e503</fpage>&#8211;<lpage>11</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2666-5247(22)00066-0</pub-id>.<pub-id pub-id-type="pmid">35779566</pub-id><pub-id pub-id-type="pmcid">PMC9242864</pub-id></mixed-citation></ref><ref id="cit0053"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jullien</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lhamu Mynak</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Henares</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mu&#241;oz-Almagro</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bassat</surname><given-names>Q</given-names></string-name></person-group>. <article-title>Pneumococcal nasopharyngeal carriage among Bhutanese children hospitalized with clinical pneumonia: serotypes and viral co-infection</article-title>. <source>BMC Infect Dis</source>. <year>2020</year>;<volume>20</volume>(<issue>1</issue>):<fpage>940</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12879-020-05674-4</pub-id>.<pub-id pub-id-type="pmid">33297987</pub-id><pub-id pub-id-type="pmcid">PMC7725031</pub-id></mixed-citation></ref><ref id="cit0054"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shahid</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nisar</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Jehan</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kabir</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hotwani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Muneer</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Qazi</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Muhammad</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ali</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>Co-carriage of Staphylococcus aureus and Streptococcus pneumoniae among children younger than 2 years of age in a rural population in Pakistan</article-title>. <source>Clin Epidemiol Glob Health</source>. <year>2023</year>;<volume>21</volume>:<fpage>101293</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cegh.2023.101293</pub-id>.<pub-id pub-id-type="pmcid">PMC10276771</pub-id><pub-id pub-id-type="pmid">37337613</pub-id></mixed-citation></ref><ref id="cit0055"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Riaz</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mohiuddin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Husain</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yousafzai</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Sajid</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kabir</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Rehman</surname><given-names>NU</given-names></string-name>, <string-name name-style="western"><surname>Mirza</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Salam</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Nadeem</surname><given-names>N</given-names></string-name>, et al</person-group>. <article-title>Effectiveness of 10-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in Pakistan</article-title>. <source>Int J Infect Dis</source>. <year>2019</year>;<volume>80</volume>:<fpage>28</fpage>&#8211;<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijid.2018.12.007</pub-id>.<pub-id pub-id-type="pmid">30576865</pub-id></mixed-citation></ref><ref id="cit0056"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nisar</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Nayani</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Akhund</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Riaz</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Irfan</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Shakoor</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Muneer</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Muslim</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hotwani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kabir</surname><given-names>F</given-names></string-name>, et al</person-group>. <article-title>Nasopharyngeal carriage of Streptococcus pneumoniae in children under 5 years of age before introduction of pneumococcal vaccine (PCV10) in urban and rural districts in Pakistan</article-title>. <source>BMC Infect Dis</source>. <year>2018</year>;<volume>18</volume>(<issue>1</issue>):<fpage>672</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12879-018-3608-5</pub-id>.<pub-id pub-id-type="pmid">30563483</pub-id><pub-id pub-id-type="pmcid">PMC6299586</pub-id></mixed-citation></ref><ref id="cit0057"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khan</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bashir</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Taahir</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zafar</surname><given-names>AU</given-names></string-name></person-group>. <article-title>Molecular Characterization of Pneumococcal Surface Protein A (PspA), Serotype Distribution and Antibiotic Susceptibility of Streptococcus pneumoniae Strains Isolated from Pakistan</article-title>. <source>Infect Dis Ther</source>. <year>2018</year> Jun;<volume>7</volume>(<issue>2</issue>):<fpage>291</fpage>. doi:<pub-id pub-id-type="doi">10.1007/s40121-018-0199-9</pub-id>.<pub-id pub-id-type="pmid">29524198</pub-id><pub-id pub-id-type="pmcid">PMC5986679</pub-id></mixed-citation></ref><ref id="cit0058"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nisar</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Jehan</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Shahid</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shakoor</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kabir</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hotwani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Muneer</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Khalid</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Muhammad</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Serotype-specific effectiveness against pneumococcal carriage and serotype replacement after ten-valent Pneumococcal Conjugate Vaccine (PCV10) introduction in Pakistan</article-title>. <source>PLOS ONE</source>. <year>2022</year>;<volume>17</volume>(<issue>1</issue>):<fpage>e0262466</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0262466</pub-id>.<pub-id pub-id-type="pmid">35061793</pub-id><pub-id pub-id-type="pmcid">PMC8782386</pub-id></mixed-citation></ref><ref id="cit0059"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shakoor</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kabir</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Khowaja</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Qureshi</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Jehan</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Qamar</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Whitney</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Zaidi</surname><given-names>AKM</given-names></string-name></person-group>. <article-title>Pneumococcal serotypes and serogroups causing invasive disease in Pakistan, 2005&#8211;2013</article-title>. <source>PLOS ONE</source>. <year>2014</year>;<volume>9</volume>(<issue>6</issue>):<fpage>e98796</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0098796</pub-id>.<pub-id pub-id-type="pmid">24892937</pub-id><pub-id pub-id-type="pmcid">PMC4043782</pub-id></mixed-citation></ref><ref id="cit0060"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nisar</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Shahid</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jehan</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shakoor</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kabir</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hotwani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Munir</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Khalid</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Muhammad</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Antimicrobial resistance in pneumococcal carriage isolates from children under 2 years of age in rural Pakistan</article-title>. <source>Microbiol Spectr</source>. <year>2021</year>;<volume>9</volume>(<issue>3</issue>):<fpage>e01019</fpage>&#8211;<lpage>21</lpage>. doi:<pub-id pub-id-type="doi">10.1128/Spectrum.01019-21</pub-id>.<pub-id pub-id-type="pmid">34935431</pub-id><pub-id pub-id-type="pmcid">PMC8693922</pub-id></mixed-citation></ref><ref id="cit0061"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Javaid</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lo</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Nisar</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Basharat</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jaleel</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Rasool</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sultana</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Kabir</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hotwani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Breiman</surname><given-names>RF</given-names></string-name>, et al</person-group>. <article-title>Strain features of pneumococcal isolates in the pre- and post-PCV10 era in Pakistan</article-title>. <source>Microb Genomics</source>. <year>2024</year>;<volume>10</volume>(<issue>1</issue>). doi:<pub-id pub-id-type="doi">10.1099/mgen.0.001163</pub-id>.<pub-id pub-id-type="pmcid">PMC10868622</pub-id><pub-id pub-id-type="pmid">38270581</pub-id></mixed-citation></ref><ref id="cit0062"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shahid</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nisar</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Khalid</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Qazi</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kabir</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hotwani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Muneer</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ali</surname><given-names>SA</given-names></string-name>, et al</person-group>. <article-title>Pneumococcal carriage in infants post-PCV10 introduction in Pakistan: results from serial cross-sectional surveys</article-title>. <source>Vaccines</source>. <year>2022</year>;<volume>10</volume>(<issue>6</issue>):<fpage>971</fpage>. doi:<pub-id pub-id-type="doi">10.3390/vaccines10060971</pub-id>.<pub-id pub-id-type="pmid">35746579</pub-id><pub-id pub-id-type="pmcid">PMC9230137</pub-id></mixed-citation></ref><ref id="cit0063"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nisar</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jehan</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Shahid</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shakoor</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kabir</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hotwani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Munir</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Muhammad</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Khalid</surname><given-names>F</given-names></string-name>, et al</person-group>. <article-title>Direct and indirect effect of 10 valent pneumococcal vaccine on nasopharyngeal carriage in children under 2 years of age in Matiari, Pakistan</article-title>. <source>Vaccine</source>. <year>2021</year>;<volume>39</volume>(<issue>8</issue>):<fpage>1319</fpage>&#8211;<lpage>1327</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2020.12.066</pub-id>.<pub-id pub-id-type="pmid">33422379</pub-id><pub-id pub-id-type="pmcid">PMC7910277</pub-id></mixed-citation></ref><ref id="cit0064"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jaiswal</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Das</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Jindal</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Agarwal</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Thumburu</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chauhan</surname><given-names>A</given-names></string-name></person-group>. <article-title>Distribution of serotypes, vaccine coverage, and antimicrobial susceptibility pattern of streptococcus pneumoniae in children living in SAARC countries: A systematic review</article-title>. <source>PLOS ONE</source>. <year>2014</year>;<volume>9</volume>(<issue>9</issue>):<fpage>e108617</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0108617</pub-id>.<pub-id pub-id-type="pmid">25268974</pub-id><pub-id pub-id-type="pmcid">PMC4182530</pub-id></mixed-citation></ref><ref id="cit0065"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dananch&#233;</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Paranhos-Baccal&#224;</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Messaoudi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sylla</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Awasthi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bavdekar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sanghavi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Diallo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pape</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Rouzier</surname><given-names>V</given-names></string-name>, et al</person-group>. <article-title>Serotypes of Streptococcus pneumoniae in Children Aged &lt;5 Years Hospitalized With or Without Pneumonia in Developing and Emerging Countries: A Descriptive, Multicenter Study</article-title>. <source>Clin Infect Dis</source>. <year>2020</year>;<volume>70</volume>(<issue>5</issue>):<fpage>875</fpage>&#8211;<lpage>883</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciz277</pub-id>.<pub-id pub-id-type="pmid">31556939</pub-id></mixed-citation></ref><ref id="cit0066"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Balaji</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Jayaraman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Verghese</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Baliga</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kurien</surname><given-names>T</given-names></string-name></person-group>. <article-title>Pneumococcal serotypes associated with invasive disease in under five children in India &amp; implications for vaccine policy</article-title>. <source>Indian J Med Res</source>. <year>2015</year>;<volume>142</volume>(<issue>3</issue>):<fpage>286</fpage>. doi:<pub-id pub-id-type="doi">10.4103/0971-5916.166588</pub-id>.<pub-id pub-id-type="pmid">26458344</pub-id><pub-id pub-id-type="pmcid">PMC4669863</pub-id></mixed-citation></ref><ref id="cit0067"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Veeraraghavan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Jayaraman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>John</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Varghese</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Neeravi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Verghese</surname><given-names>VP</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>K</given-names></string-name></person-group>. <article-title>Customized sequential multiplex PCR for accurate and early determination of invasive pneumococcal serotypes found in India</article-title>. <source>J Microbiol Methods</source>. <year>2016</year>;<volume>130</volume>:<fpage>133</fpage>&#8211;<lpage>135</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.mimet.2016.09.007</pub-id>.<pub-id pub-id-type="pmid">27623479</pub-id></mixed-citation></ref><ref id="cit0068"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nagaraj</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kalal</surname><given-names>BS</given-names></string-name>, <string-name name-style="western"><surname>Manoharan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shet</surname><given-names>A</given-names></string-name></person-group>. <article-title>Streptococcus pneumoniae serotype prevalence and antibiotic resistance among young children with invasive pneumococcal disease: experience from a tertiary care center in South India</article-title>. <source>GERMS</source>. <year>2017</year>;<volume>7</volume>(<issue>2</issue>):<fpage>78</fpage>&#8211;<lpage>85</lpage>. doi:<pub-id pub-id-type="doi">10.18683/germs.2017.1112</pub-id>.<pub-id pub-id-type="pmid">28626738</pub-id><pub-id pub-id-type="pmcid">PMC5466826</pub-id></mixed-citation></ref><ref id="cit0069"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Singh</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sundaresan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Manoharan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shet</surname><given-names>A</given-names></string-name></person-group>. <article-title>Serotype distribution and antimicrobial susceptibility pattern in children &#8804; 5 years with invasive pneumococcal disease in India &#8211; a systematic review</article-title>. <source>Vaccine</source>. <year>2017</year>;<volume>35</volume>(<issue>35</issue>):<fpage>4501</fpage>&#8211;<lpage>4509</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2017.06.079</pub-id>.<pub-id pub-id-type="pmid">28711387</pub-id></mixed-citation></ref><ref id="cit0070"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jayaraman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Varghese</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Neeravi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shanmugasundaram</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ralph</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Veeraraghavan</surname><given-names>B</given-names></string-name></person-group>. <article-title>Invasive pneumococcal disease in Indian adults: 11 years&#8217; experience</article-title>. <source>J Microbiol Immunol Infect</source>. <year>2019</year>;<volume>52</volume>(<issue>5</issue>):<fpage>736</fpage>&#8211;<lpage>742</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jmii.2018.03.004</pub-id>.<pub-id pub-id-type="pmid">29884448</pub-id></mixed-citation></ref><ref id="cit0071"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sutcliffe</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Shet</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Varghese</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Veeraraghavan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Manoharan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wahl</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Chandy</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sternal</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>RK</given-names></string-name>, et al</person-group>. <article-title>Nasopharyngeal carriage of Streptococcus pneumoniae serotypes among children in India prior to the introduction of pneumococcal conjugate vaccines: a cross-sectional study</article-title>. <source>BMC Infect Dis</source>. <year>2019</year>;<volume>19</volume>(<issue>1</issue>):<fpage>605</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12879-019-4254-2</pub-id>.<pub-id pub-id-type="pmid">31291902</pub-id><pub-id pub-id-type="pmcid">PMC6621985</pub-id></mixed-citation></ref><ref id="cit0072"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Manoharan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Manchanda</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Balasubramanian</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lalwani</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Modak</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Vijayan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shet</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nagaraj</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Karande</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Invasive pneumococcal disease in children aged younger than 5 years in India: a surveillance study</article-title>. <source>Lancet Infect Dis</source>. <year>2017</year>;<volume>17</volume>(<issue>3</issue>):<fpage>305</fpage>&#8211;<lpage>312</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(16)30466-2</pub-id>.<pub-id pub-id-type="pmid">27956163</pub-id></mixed-citation></ref><ref id="cit0073"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gupta</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Awasthi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Verma</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Rastogi</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Pandey</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Naziat</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Rahman</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Islam</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Saha</surname><given-names>S</given-names></string-name></person-group>. <article-title>Nasopharyngeal carriage of streptococcus pneumoniae serotypes among healthy children in Northern India</article-title>. <source>Curr Microbiol</source>. <year>2023</year>;<volume>80</volume>(<issue>1</issue>):<fpage>41</fpage>. doi:<pub-id pub-id-type="doi">10.1007/s00284-022-03114-x</pub-id>.<pub-id pub-id-type="pmcid">PMC9763132</pub-id><pub-id pub-id-type="pmid">36534266</pub-id></mixed-citation></ref><ref id="cit0074"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>John</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Varghese</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lionell</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Neeravi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Veeraraghavan</surname><given-names>B</given-names></string-name></person-group>. <article-title>Nonvaccine pneumococcal serotypes among children with invasive pneumococcal disease</article-title>. <source>Indian Pediatr</source>. <year>2018</year>;<volume>55</volume>(<issue>10</issue>):<fpage>874</fpage>&#8211;<lpage>876</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13312-018-1398-x</pub-id>.<pub-id pub-id-type="pmid">30426954</pub-id></mixed-citation></ref><ref id="cit0075"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Verghese</surname><given-names>VP</given-names></string-name>, <string-name name-style="western"><surname>Veeraraghavan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Jayaraman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Varghese</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Neeravi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jayaraman</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Mehendale</surname><given-names>SM</given-names></string-name></person-group>. <article-title>Increasing incidence of penicillin- and cefotaxime-resistant streptococcus pneumoniae causing meningitis in India: time for revision of treatment guidelines?</article-title><source>Indian J Med Microbiol</source>. <year>2017</year>;<volume>35</volume>(<issue>2</issue>):<fpage>228</fpage>&#8211;<lpage>236</lpage>. doi:<pub-id pub-id-type="doi">10.4103/ijmm.IJMM_17_124</pub-id>.<pub-id pub-id-type="pmid">28681811</pub-id></mixed-citation></ref><ref id="cit0076"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sharma</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ray</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Chakraborti</surname><given-names>A</given-names></string-name></person-group>. <article-title>Antimicrobial susceptibility pattern and serotype distribution of streptococcus pneumoniae isolates from a hospital-based study in Chandigarh, North India</article-title>. <source>Cureus</source>. <year>2022</year>; <comment>published online Jan 19</comment>. DOI:<pub-id pub-id-type="doi">10.7759/cureus.21437</pub-id>.<pub-id pub-id-type="pmcid">PMC8860682</pub-id><pub-id pub-id-type="pmid">35223224</pub-id></mixed-citation></ref><ref id="cit0077"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vandana</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Feroze</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Geetha</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Avid</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ravi Kumar</surname><given-names>KL</given-names></string-name></person-group>. <article-title>Pan India distribution of pneumococcal serotypes (PIDOPS) causing invasive pneumococcal disease and pneumonia in children between 6 weeks and 5 years and their antimicrobial resistance &#8211; Phase I</article-title>. <source>Pediatr Infect Dis</source>. <year>2016</year>;<volume>8</volume>(<issue>2</issue>):<fpage>47</fpage>&#8211;<lpage>51</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pid.2016.06.004</pub-id>.</mixed-citation></ref><ref id="cit0078"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Balasubramanian</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Dhanalakshmi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Putlibai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Varghese</surname><given-names>R</given-names></string-name></person-group>. <article-title>Clinico-microbiological profile of invasive pneumococcal disease amongst hospitalised children in South India</article-title>. <source>Indian J Med Microbiol</source>. <year>2019</year>;<volume>37</volume>(<issue>4</issue>):<fpage>598</fpage>&#8211;<lpage>599</lpage>. doi:<pub-id pub-id-type="doi">10.4103/ijmm.IJMM_20_135</pub-id>.<pub-id pub-id-type="pmid">32436889</pub-id></mixed-citation></ref><ref id="cit0079"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jayaraman</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Veeraraghavan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Girish Kumar</surname><given-names>CP</given-names></string-name>, <string-name name-style="western"><surname>Sukumar</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Rajkumar</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kangusamy</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Verghese</surname><given-names>VP</given-names></string-name>, <string-name name-style="western"><surname>Varghese</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Jayaraman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kapoor</surname><given-names>AN</given-names></string-name>, et al</person-group>. <article-title>Hospital-based sentinel surveillance for bacterial meningitis in under-five children prior to the introduction of the PCV13 in India</article-title>. <source>Vaccine</source>. <year>2021</year>;<volume>39</volume>(<issue>28</issue>):<fpage>3737</fpage>&#8211;<lpage>3744</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2021.05.041</pub-id>.<pub-id pub-id-type="pmid">34074545</pub-id></mixed-citation></ref><ref id="cit0080"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Verma</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Pandey</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Awasthi</surname><given-names>S</given-names></string-name></person-group>. <article-title>Nasopharyngeal carriage of Streptococcus pneumoniae serotypes among sick and healthy children in Northern India: a case-control study</article-title>. <source>Vaccine</source>. <year>2023</year>;<volume>41</volume>(<issue>44</issue>):<fpage>6619</fpage>&#8211;<lpage>6624</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2023.09.029</pub-id>.<pub-id pub-id-type="pmid">37758571</pub-id><pub-id pub-id-type="pmcid">PMC10663590</pub-id></mixed-citation></ref><ref id="cit0081"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Manoharan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jayaraman</surname><given-names>R</given-names></string-name></person-group>. <article-title>Pneumococcal aaccines</article-title>. <source>Indian J Med Microbiol</source>. <year>2018</year>;<volume>36</volume>(<issue>4</issue>):<fpage>465</fpage>&#8211;<lpage>474</lpage>. doi:<pub-id pub-id-type="doi">10.4103/ijmm.IJMM_18_442</pub-id>.<pub-id pub-id-type="pmid">30880692</pub-id></mixed-citation></ref><ref id="cit0082"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mazumdar</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sarma</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Medhi</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Dutta</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kataki</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Baishya</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Dutta</surname><given-names>BS</given-names></string-name>, <string-name name-style="western"><surname>Saikia</surname><given-names>L</given-names></string-name></person-group>. <article-title>Capsular typing of Streptococcus pneumoniae isolated from clinical specimens in Gauhati Medical College and hospital, Assam, India</article-title>. <source>Indian J Med Microbiol</source>. <year>2023</year>;<volume>44</volume>:<fpage>100350</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijmmb.2023.01.008</pub-id>.<pub-id pub-id-type="pmid">37356826</pub-id></mixed-citation></ref><ref id="cit0083"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Varghese</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Neeravi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Subramanian</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Pavithra</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kavipriya</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>CPG</given-names></string-name>, <string-name name-style="western"><surname>Jeyraman</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Karthik</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Verghese</surname><given-names>VP</given-names></string-name>, et al</person-group>. <article-title>Clonal similarities and sequence-Type diversity of invasive and carriage Streptococcus pneumoniae in India among children under 5 years</article-title>. <source>Indian J Med Microbiol</source>. <year>2019</year>;<volume>37</volume>(<issue>3</issue>):<fpage>358</fpage>&#8211;<lpage>361</lpage>. doi:<pub-id pub-id-type="doi">10.4103/ijmm.IJMM_19_348</pub-id>.<pub-id pub-id-type="pmid">32003333</pub-id></mixed-citation></ref><ref id="cit0084"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nagaraj</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Govindan</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Ganaie</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Venkatesha</surname><given-names>VT</given-names></string-name>, <string-name name-style="western"><surname>Hawkins</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Gladstone</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>McGee</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Breiman</surname><given-names>RF</given-names></string-name>, <string-name name-style="western"><surname>Bentley</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Klugman</surname><given-names>KP</given-names></string-name>, et al</person-group>. <article-title>Streptococcus pneumoniae genomic datasets from an Indian population describing pre-vaccine evolutionary epidemiology using a whole genome sequencing approach</article-title>. <source>Microb Genomics</source>. <year>2021</year>;<volume>7</volume>(<issue>9</issue>). doi:<pub-id pub-id-type="doi">10.1099/mgen.0.000645</pub-id>.<pub-id pub-id-type="pmcid">PMC8715438</pub-id><pub-id pub-id-type="pmid">34494953</pub-id></mixed-citation></ref><ref id="cit0085"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Napolean</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rosemol</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>John</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Varghese</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Periyasamy</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Balaji</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Naina</surname><given-names>P</given-names></string-name></person-group>. <article-title>Nasopharyngeal colonization of otopathogens in South Indian children with acute otitis media &#8211; a case control pilot study</article-title>. <source>J Otol</source>. <year>2021</year>;<volume>16</volume>(<issue>4</issue>):<fpage>220</fpage>&#8211;<lpage>224</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.joto.2021.02.004</pub-id>.<pub-id pub-id-type="pmid">34548867</pub-id><pub-id pub-id-type="pmcid">PMC8438633</pub-id></mixed-citation></ref><ref id="cit0086"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jain</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Das</surname><given-names>BK</given-names></string-name>, <string-name name-style="western"><surname>Mahajan</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kapil</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chaudhry</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sood</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kabra</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Dwivedi</surname><given-names>SN</given-names></string-name></person-group>. <article-title>Molecular capsular typing and multi locus sequence typing of invasive, non-invasive and commensal Streptococcus pneumoniae isolates from North India</article-title>. <source>Indian J Med Microbiol</source>. <year>2020</year>;<volume>38</volume>(<issue>1</issue>):<fpage>78</fpage>&#8211;<lpage>86</lpage>. doi:<pub-id pub-id-type="doi">10.4103/ijmm.IJMM_20_111</pub-id>.<pub-id pub-id-type="pmid">32719213</pub-id></mixed-citation></ref><ref id="cit0087"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Varghese</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Neeravi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jacob</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Vasudevan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Subramanian</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Veeraraghavan</surname><given-names>B</given-names></string-name></person-group>. <article-title>Comparative genomics of invasive Streptococcus pneumoniae CC320/271 serotype 19F/19A before the introduction of pneumococcal vaccine in India</article-title>. <source>Mol Biol Rep</source>. <year>2021</year>;<volume>48</volume>(<issue>4</issue>):<fpage>3265</fpage>&#8211;<lpage>3276</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11033-021-06353-6</pub-id>.<pub-id pub-id-type="pmid">33876375</pub-id></mixed-citation></ref><ref id="cit0088"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jayaraman</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Veeraraghavan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Chethrapilly Purushothaman</surname><given-names>GK</given-names></string-name>, <string-name name-style="western"><surname>Sukumar</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kangusamy</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Nair Kapoor</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Mehendale</surname><given-names>SM</given-names></string-name></person-group>. <article-title>Burden of bacterial meningitis in India: Preliminary data from a hospital based sentinel surveillance network</article-title>. <source>PLOS ONE</source>. <year>2018</year>;<volume>13</volume>(<issue>5</issue>):<fpage>e0197198</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0197198</pub-id>.<pub-id pub-id-type="pmid">29768458</pub-id><pub-id pub-id-type="pmcid">PMC5955554</pub-id></mixed-citation></ref><ref id="cit0089"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rafiqullah</surname><given-names>IM</given-names></string-name>, <string-name name-style="western"><surname>Varghese</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hellmann</surname><given-names>KT</given-names></string-name>, <string-name name-style="western"><surname>Velmurugan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Neeravi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kumar Daniel</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Vidal</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Kompithra</surname><given-names>RZ</given-names></string-name>, <string-name name-style="western"><surname>Verghese</surname><given-names>VP</given-names></string-name>, <string-name name-style="western"><surname>Veeraraghavan</surname><given-names>B</given-names></string-name>, et al</person-group>. <article-title>Pneumococcal population genomics changes during the early time period of conjugate vaccine uptake in southern India</article-title>. <source>Microb Genomics</source>. <year>2024</year>;<volume>10</volume>(<issue>2</issue>). doi:<pub-id pub-id-type="doi">10.1099/mgen.0.001191</pub-id>.<pub-id pub-id-type="pmcid">PMC10926699</pub-id><pub-id pub-id-type="pmid">38315173</pub-id></mixed-citation></ref><ref id="cit0090"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kumar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Purakayastha</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Kapil</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Saha</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dawood</surname><given-names>FS</given-names></string-name>, <string-name name-style="western"><surname>Das</surname><given-names>BK</given-names></string-name>, <string-name name-style="western"><surname>Amarchand</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lafond</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Jain</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Carriage rates and antimicrobial sensitivity of pneumococci in the upper respiratory tract of children less than ten years old, in a North Indian rural community</article-title>. <source>PLOS ONE</source>. <year>2021</year>;<volume>16</volume>(<issue>2</issue>):<fpage>e0246522</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0246522</pub-id>.<pub-id pub-id-type="pmid">33539406</pub-id><pub-id pub-id-type="pmcid">PMC7861412</pub-id></mixed-citation></ref><ref id="cit0091"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Arya</surname><given-names>BK</given-names></string-name>, <string-name name-style="western"><surname>Bhattacharya</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Sutcliffe</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Ganaie</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bhaskar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bhattacharyya</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Niyogi</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Moss</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Panda</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ravikumar</surname><given-names>KL</given-names></string-name>, et al</person-group>. <article-title>Nasopharyngeal pneumococcal colonization and impact of a single dose of 13-valent pneumococcal conjugate vaccine in Indian children with HIV and their unvaccinated parents</article-title>. <source>Pediatr Infect Dis J</source>. <year>2018</year>;<volume>37</volume>(<issue>5</issue>):<fpage>451</fpage>&#8211;<lpage>458</lpage>. doi:<pub-id pub-id-type="doi">10.1097/INF.0000000000001800</pub-id>.<pub-id pub-id-type="pmid">28961675</pub-id></mixed-citation></ref><ref id="cit0092"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ganaie</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Nagaraj</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Govindan</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Basha</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hussain</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ashraf</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ravi Kumar</surname><given-names>KL</given-names></string-name></person-group>. <article-title>Impact of Hajj on the S. pneumoniae carriage among Indian pilgrims during 2016- a longitudinal molecular surveillance study</article-title>. <source>Travel Med Infect Dis</source>. <year>2018</year>;<volume>23</volume>:<fpage>64</fpage>&#8211;<lpage>71</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tmaid.2018.04.002</pub-id>.<pub-id pub-id-type="pmid">29625178</pub-id></mixed-citation></ref><ref id="cit0093"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Samson</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rupa</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Veeraraghavan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Varghese</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Isaac</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>J</surname><given-names>L</given-names></string-name></person-group>. <article-title>Follow up of a birth cohort to identify prevalence and risk factors for otitis media among Indian children in the eighth year of life</article-title>. <source>Int J Pediatr Otorhinolaryngol</source>. <year>2020</year>;<volume>137</volume>:<fpage>110201</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijporl.2020.110201</pub-id>.<pub-id pub-id-type="pmid">32658800</pub-id></mixed-citation></ref><ref id="cit0094"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Arya</surname><given-names>BK</given-names></string-name>, <string-name name-style="western"><surname>Bhattacharya</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Harigovind</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Das</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ganaie</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Niyogi</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Ravikumar</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Manoharan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bhattacharyya</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Streptococcus pneumoniae acquisition and carriage in vaccine Na&#239;ve Indian children with HIV and their parents: a longitudinal
household study</article-title>. <source>Indian J Pediatr</source>. <year>2019</year>;<volume>86</volume>(<issue>11</issue>):<fpage>1002</fpage>&#8211;<lpage>1010</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12098-019-02995-4</pub-id>.<pub-id pub-id-type="pmid">31222554</pub-id></mixed-citation></ref><ref id="cit0095"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Veeraraghavan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Varghese</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Saigal</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Balasubramanian</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bai</surname><given-names>PSP</given-names></string-name>, <string-name name-style="western"><surname>Lal Y</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Neeravi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Baskar</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Anandhan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>CPG</given-names></string-name>, et al</person-group>. <article-title>Activity of novel lactone ketolide nafithromycin against multicentric invasive and non-invasive pneumococcal isolates collected in India</article-title>. <source>JAC-Antimicrob Resist</source>. <year>2021</year>;<volume>3</volume>(<issue>2</issue>):<fpage>dlab066</fpage>. doi:<pub-id pub-id-type="doi">10.1093/jacamr/dlab066</pub-id>.<pub-id pub-id-type="pmid">34223128</pub-id><pub-id pub-id-type="pmcid">PMC8210042</pub-id></mixed-citation></ref><ref id="cit0096"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kanungo</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Anandhalakshmi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sheeladevi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sudhagar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>John</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Prashanth</surname><given-names>K</given-names></string-name></person-group>. <article-title>Fatal infection in adults by pneumolysin &amp; autolysin producing, non-vaccine serotype Streptococcus pneumonia</article-title>. <source>Indian J Med Res</source>. <year>2016</year>;<volume>143</volume>(<issue>4</issue>):<fpage>514</fpage>. doi:<pub-id pub-id-type="doi">10.4103/0971-5916.184307</pub-id>.<pub-id pub-id-type="pmid">27377510</pub-id><pub-id pub-id-type="pmcid">PMC4928560</pub-id></mixed-citation></ref><ref id="cit0097"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sankar</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Putlibai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Raghavan</surname><given-names>V</given-names></string-name></person-group>. <article-title>Demographic profile of healthy children with Nasopharyngeal colonisation of Streptococcus pneumoniae: a research paper</article-title>. <source>Indian J Med Microbiol</source>. <year>2017</year>;<volume>35</volume>(<issue>4</issue>):<fpage>607</fpage>&#8211;<lpage>609</lpage>. doi:<pub-id pub-id-type="doi">10.4103/ijmm.IJMM_15_347</pub-id>.<pub-id pub-id-type="pmid">29405160</pub-id></mixed-citation></ref><ref id="cit0098"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Amritha</surname><given-names>GN</given-names></string-name>, <string-name name-style="western"><surname>M</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>R</surname><given-names>APS</given-names></string-name>, <string-name name-style="western"><surname>Shanmugam</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Jayaraman</surname><given-names>P</given-names></string-name></person-group>. <article-title>A comparative profile of Oropharyngeal colonization of Streptococcus pneumoniae and Hemophilus influenzae among HealthCare Workers (HCW) in a tertiary care hospital and non-healthcare individuals</article-title>. <source>J Prev Med Hyg</source>. <year>2020</year>;<volume>61</volume>(<issue>3</issue>):<fpage>E 379</fpage>. doi:<pub-id pub-id-type="doi">10.15167/2421-4248/jpmh2020.61.3.1479</pub-id>.<pub-id pub-id-type="pmcid">PMC7595066</pub-id><pub-id pub-id-type="pmid">33150226</pub-id></mixed-citation></ref><ref id="cit0099"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Arjun</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ratheesh</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Mohan</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Uduman</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jalaludeen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Prabhakaran</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sasidharan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Niyas</surname><given-names>VKM</given-names></string-name></person-group>. <article-title>Susceptibility and serotypes of Streptococcus pneumoniae isolates in invasive pneumococcal disease: a study from Kerala, South India</article-title>. <source>Infez Med</source>. <year>2020</year>;<volume>28</volume>(<issue>4</issue>):<fpage>558</fpage>&#8211;<lpage>564</lpage>.<pub-id pub-id-type="pmid">33257631</pub-id></mixed-citation></ref><ref id="cit0100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Varghese</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Daniel</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Neeravi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Baskar</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Manoharan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sundaram</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Manchanda</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Saigal</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Yesudhasan</surname><given-names>BL</given-names></string-name>, <string-name name-style="western"><surname>Veeraraghavan</surname><given-names>B</given-names></string-name></person-group>. <article-title>Multicentric analysis of Erythromycin resistance determinants in invasive Streptococcus pneumoniae; associated serotypes and sequence types in India</article-title>. <source>Curr Microbiol</source>. <year>2021</year>;<volume>78</volume>(<issue>8</issue>):<fpage>3239</fpage>&#8211;<lpage>3245</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00284-021-02594-7</pub-id>.<pub-id pub-id-type="pmid">34223923</pub-id></mixed-citation></ref><ref id="cit0101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Varghese</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yesudhason</surname><given-names>BL</given-names></string-name>, <string-name name-style="western"><surname>Vimala</surname><given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Neeravi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Anandhan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Baskar</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Elangovan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Manesh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>James</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>R</given-names></string-name>, et al</person-group>. <article-title>Pneumococcal serotypes causing non-invasive pneumonia in adults from a South Indian tertiary care hospital and the impact of the newer conjugate vaccines</article-title>. <source>Access Microbiol</source>. <year>2021</year>;<volume>3</volume>(<issue>12</issue>). doi:<pub-id pub-id-type="doi">10.1099/acmi.0.000258</pub-id>.<pub-id pub-id-type="pmcid">PMC8749137</pub-id><pub-id pub-id-type="pmid">35024548</pub-id></mixed-citation></ref><ref id="cit0102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Oliveira</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Oliveira</surname><given-names>MLS</given-names></string-name>, <string-name name-style="western"><surname>Miyaji</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Rodrigues</surname><given-names>TC</given-names></string-name></person-group>. <article-title>Pneumococcal vaccines: past findings, present work, and future strategies</article-title>. <source>Vaccines</source>. <year>2021</year>;<volume>9</volume>(<issue>11</issue>):<fpage>1338</fpage>. doi:<pub-id pub-id-type="doi">10.3390/vaccines9111338</pub-id>.<pub-id pub-id-type="pmid">34835269</pub-id><pub-id pub-id-type="pmcid">PMC8620834</pub-id></mixed-citation></ref><ref id="cit0103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pollard</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Perrett</surname><given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Beverley</surname><given-names>PC</given-names></string-name></person-group>. <article-title>Maintaining protection against invasive bacteria with protein&#8211;polysaccharide conjugate vaccines</article-title>. <source>Nat Rev Immunol</source>. <year>2009</year>;<volume>9</volume>(<issue>3</issue>):<fpage>213</fpage>&#8211;<lpage>220</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nri2494</pub-id>.<pub-id pub-id-type="pmid">19214194</pub-id></mixed-citation></ref><ref id="cit0104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morais</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Suarez</surname><given-names>N</given-names></string-name></person-group>. <article-title>Conjugation mechanism for pneumococcal glycoconjugate vaccines: classic and emerging methods</article-title>. <source>Bioengineering</source>. <year>2022</year>;<volume>9</volume>(<issue>12</issue>):<fpage>774</fpage>. doi:<pub-id pub-id-type="doi">10.3390/bioengineering9120774</pub-id>.<pub-id pub-id-type="pmid">36550980</pub-id><pub-id pub-id-type="pmcid">PMC9774679</pub-id></mixed-citation></ref><ref id="cit0105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Perera</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Sokaribo</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>AP</given-names></string-name></person-group>. <article-title>Polysaccharide vaccines: a perspective on non-typhoidal Salmonella</article-title>. <source>Polysaccharides</source>. <year>2021</year>;<volume>2</volume>(<issue>3</issue>):<fpage>691</fpage>&#8211;<lpage>714</lpage>. doi:<pub-id pub-id-type="doi">10.3390/polysaccharides2030042</pub-id>.</mixed-citation></ref><ref id="cit0106"><label>106.</label><mixed-citation publication-type="webpage"><article-title>PNEUMOVAX 23 dosage and administration</article-title>. [<date-in-citation>accessed 2024 <month>Aug</month><day>7</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.merckvaccines.com/vaxneuvancepneumovax23/p23-dosage-and-administration/" ext-link-type="uri">https://www.merckvaccines.com/vaxneuvancepneumovax23/p23-dosage-and-administration/</ext-link>.</mixed-citation></ref><ref id="cit0107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shapiro</surname><given-names>ED</given-names></string-name>, <string-name name-style="western"><surname>Berg</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Austrian</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Schroeder</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Parcells</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Margolis</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Adair</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Clemens</surname><given-names>JD</given-names></string-name></person-group>. <article-title>The protective efficacy of polyvalent pneumococcal polysaccharide vaccine</article-title>. <source>N Engl J Med</source>. <year>1991</year>;<volume>325</volume>(<issue>21</issue>):<fpage>1453</fpage>&#8211;<lpage>1460</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJM199111213252101</pub-id>.<pub-id pub-id-type="pmid">1944423</pub-id></mixed-citation></ref><ref id="cit0108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jackson</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Neuzil</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Benson</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Barlow</surname><given-names>WE</given-names></string-name>, <string-name name-style="western"><surname>Adams</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Hanson</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Mahoney</surname><given-names>LD</given-names></string-name>, <string-name name-style="western"><surname>Shay</surname><given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Thompson</surname><given-names>WW</given-names></string-name></person-group>. <article-title>Effectiveness of pneumococcal polysaccharide vaccine in older adults</article-title>. <source>N Engl J Med</source>. <year>2003</year>;<volume>348</volume>(<issue>18</issue>):<fpage>1747</fpage>&#8211;<lpage>1755</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa022678</pub-id>.<pub-id pub-id-type="pmid">12724480</pub-id></mixed-citation></ref><ref id="cit0109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maruyama</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Taguchi</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Niederman</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Morser</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kobayashi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kobayashi</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>D&#8217;Alessandro-Gabazza</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Nakayama</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nishikubo</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Noguchi</surname><given-names>T</given-names></string-name>, et al</person-group>. <article-title>Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial</article-title>. <source>BMJ</source>. <year>2010</year>;<volume>340</volume>(<issue>mar08 1</issue>):<fpage>c1004</fpage>&#8211;<lpage>c1004</lpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.c1004</pub-id>.<pub-id pub-id-type="pmid">20211953</pub-id><pub-id pub-id-type="pmcid">PMC2834887</pub-id></mixed-citation></ref><ref id="cit0110"><label>110.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Moberley</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Holden</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tatham</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Andrews</surname><given-names>RM</given-names></string-name></person-group>. <part-title>Vaccines for preventing pneumococcal infection in adults</part-title>. In: Cochrane Acute Respiratory Infections Group, editor. <source>The Cochrane Collaboration, ed. Cochrane Database of Systematic Reviews</source>. <publisher-loc>Chichester (UK)</publisher-loc>: <publisher-name>John Wiley &amp; Sons, Ltd,</publisher-name>; <year>2008</year>. p. <fpage>CD000422</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD000422.pub2</pub-id><pub-id pub-id-type="pmid">18253977</pub-id></mixed-citation></ref><ref id="cit0111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>See</surname><given-names>KC</given-names></string-name></person-group>. <article-title>Pneumococcal vaccination in adults: a narrative review of considerations for individualized decision-making</article-title>. <source>Vaccines</source>. <year>2023</year>;<volume>11</volume>(<issue>5</issue>):<fpage>908</fpage>. doi:<pub-id pub-id-type="doi">10.3390/vaccines11050908</pub-id>.<pub-id pub-id-type="pmid">37243012</pub-id><pub-id pub-id-type="pmcid">PMC10223523</pub-id></mixed-citation></ref><ref id="cit0112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Daniels</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Rogers</surname><given-names>PD</given-names></string-name>, <string-name name-style="western"><surname>Shelton</surname><given-names>CM</given-names></string-name></person-group>. <article-title>A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens</article-title>. <source>J Pediatr Pharmacol Ther</source>. <year>2016</year>;<volume>21</volume>(<issue>1</issue>):<fpage>27</fpage>&#8211;<lpage>35</lpage>. doi:<pub-id pub-id-type="doi">10.5863/1551-6776-21.1.27</pub-id>.<pub-id pub-id-type="pmid">26997927</pub-id><pub-id pub-id-type="pmcid">PMC4778694</pub-id></mixed-citation></ref><ref id="cit0113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Micoli</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Stefanetti</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>MacLennan</surname><given-names>CA</given-names></string-name></person-group>. <article-title>Exploring the variables influencing the immune response of traditional and innovative glycoconjugate vaccines</article-title>. <source>Front Mol Biosci</source>. <year>2023</year>;<volume>10</volume>:<fpage>1201693</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fmolb.2023.1201693</pub-id>.<pub-id pub-id-type="pmid">37261327</pub-id><pub-id pub-id-type="pmcid">PMC10227950</pub-id></mixed-citation></ref><ref id="cit0114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alicino</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Paganino</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Orsi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Astengo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Trucchi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Icardi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ansaldi</surname><given-names>F</given-names></string-name></person-group>. <article-title>The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on hospitalization for pneumonia in children: a systematic review and meta-analysis</article-title>. <source>Vaccine</source>. <year>2017</year>;<volume>35</volume>(<issue>43</issue>):<fpage>5776</fpage>&#8211;<lpage>5785</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2017.09.005</pub-id>.<pub-id pub-id-type="pmid">28911902</pub-id></mixed-citation></ref><ref id="cit0115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reyburn</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Tsatsaronis</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Von Mollendorf</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Mulholland</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Russell</surname><given-names>FM</given-names></string-name></person-group>. <article-title>ARI Review group. Systematic review on the impact of the pneumococcal conjugate vaccine ten valent (PCV10) or thirteen valent (PCV13) on all-cause, radiologically confirmed and severe pneumonia hospitalisation rates and pneumonia mortality in children 0-9 years old</article-title>. <source>J Glob Health</source>. <year>2023</year>;<volume>13</volume>:<fpage>05002</fpage> doi:<pub-id pub-id-type="doi">10.7189/jogh.13.05002</pub-id>.<pub-id pub-id-type="pmid">36734192</pub-id><pub-id pub-id-type="pmcid">PMC9896304</pub-id></mixed-citation></ref><ref id="cit0116"><label>116.</label><mixed-citation publication-type="webpage"><article-title>Changes in invasive pneumococcal disease incidence following introduction of PCV10 and 1170 PCV13 in children and adults globally: the pserenade project</article-title>. [<date-in-citation>accessed 2024 <month>May</month><day>14</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cslide.ctimeetingtech.com/isppd22/attendee/eposter/poster/852" ext-link-type="uri">https://cslide.ctimeetingtech.com/isppd22/attendee/eposter/poster/852</ext-link>.</mixed-citation></ref><ref id="cit0117"><label>117.</label><mixed-citation publication-type="webpage"><article-title>Weuphoria launching ceremony successfully held</article-title>. [<date-in-citation>accessed 2024 <month>May</month><day>14</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://en.walvax.com/news/weuphoria-launching-ceremony-successfully-held-in-thailand.html" ext-link-type="uri">https://en.walvax.com/news/weuphoria-launching-ceremony-successfully-held-in-thailand.html</ext-link>.</mixed-citation></ref><ref id="cit0118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tin Tin Htar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Morato Mart&#237;nez</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Theilacker</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Schmitt</surname><given-names>H-J</given-names></string-name>, <string-name name-style="western"><surname>Swerdlow</surname><given-names>D</given-names></string-name></person-group>. <article-title>Serotype evolution in Western Europe: perspectives on invasive pneumococcal diseases (IPD)</article-title>. <source>Expert Rev Vaccines</source>. <year>2019</year>;<volume>18</volume>(<issue>11</issue>):<fpage>1145</fpage>&#8211;<lpage>1155</lpage>. doi:<pub-id pub-id-type="doi">10.1080/14760584.2019.1688149</pub-id>.<pub-id pub-id-type="pmid">31682762</pub-id></mixed-citation></ref><ref id="cit0119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hanquet</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Krizova</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Dalby</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ladhani</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Nuorti</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Danis</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Mereckiene</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Knol</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Winje</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Ciruela</surname><given-names>P</given-names></string-name>, et al</person-group>. <article-title>Serotype replacement after introduction of 10-valent and 13-valent pneumococcal conjugate vaccines in 10 countries, Europe</article-title>. <source>Emerg Infect Dis</source>. <year>2022</year>;<volume>28</volume>(<issue>1</issue>):<fpage>137</fpage>&#8211;<lpage>138</lpage>. doi:<pub-id pub-id-type="doi">10.3201/eid2801.210734</pub-id>.<pub-id pub-id-type="pmid">34932457</pub-id><pub-id pub-id-type="pmcid">PMC8714201</pub-id></mixed-citation></ref><ref id="cit0120"><label>120.</label><mixed-citation publication-type="book"><article-title>U.S. FDA Approves Merck&#8217;s VAXNEUVANCE<sup>TM</sup> (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of invasive pneumococcal disease in infants and children</article-title>. <publisher-name>Merck.com</publisher-name> [<date-in-citation>accessed 2024 <month>Aug</month><day>8</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.merck.com/news/u-s-fda-approves-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-infants-and-children/" ext-link-type="uri">https://www.merck.com/news/u-s-fda-approves-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-infants-and-children/</ext-link>.</mixed-citation></ref><ref id="cit0121"><label>121.</label><mixed-citation publication-type="webpage"><article-title>Prevnar 20 FDA Approval History</article-title>. <source>Drugs.com</source>. [<date-in-citation>accessed 2024 <month>Aug</month><day>8</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.drugs.com/history/prevnar-20.html" ext-link-type="uri">https://www.drugs.com/history/prevnar-20.html</ext-link>.</mixed-citation></ref><ref id="cit0122"><label>122.</label><mixed-citation publication-type="webpage"><article-title>VAXNEUVANCE Prescribing Information</article-title>. [<date-in-citation>accessed 2024 <month>May</month><day>14</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.merck.com/product/usa/pi_circulars/v/vaxneuvance/vaxneuvance_pi.pdf" ext-link-type="uri">https://www.merck.com/product/usa/pi_circulars/v/vaxneuvance/vaxneuvance_pi.pdf</ext-link>.</mixed-citation></ref><ref id="cit0123"><label>123.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Prevnar 20</collab></person-group>. [<date-in-citation>accessed 2024 <month>May</month><day>14</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.prevnar20.com/" ext-link-type="uri">https://www.prevnar20.com/</ext-link>.</mixed-citation></ref><ref id="cit0124"><label>124.</label><mixed-citation publication-type="webpage"><article-title>U.S. FDA approves PREVNAR 20&#174;, Pfizer&#8217;s 20-valent Pneumococcal conjugate vaccine for infants and children</article-title>. [<date-in-citation>accessed 2024 <month>May</month><day>14</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20r-pfizers-20-valent-pneumococcal" ext-link-type="uri">https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20r-pfizers-20-valent-pneumococcal</ext-link>.</mixed-citation></ref><ref id="cit0125"><label>125.</label><mixed-citation publication-type="webpage"><article-title>U.S. FDA approves PREVNAR 20<sup>TM</sup>, Pfizer&#8217;s Pneumococcal 20 valent conjugate vaccine for adults ages 18 years or older</article-title>. [<date-in-citation>accessed 2024 <month>May</month><day>14</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20tm-pfizers-pneumococcal-20-valent" ext-link-type="uri">https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20tm-pfizers-pneumococcal-20-valent</ext-link>.</mixed-citation></ref><ref id="cit0126"><label>126.</label><mixed-citation publication-type="webpage"><article-title>DCGI approves BE&#8217;s 14-valent pneumococcal conjugate vaccine</article-title>. [<date-in-citation>accessed 2024 <month>Aug</month><day>8</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.biologicale.com/news.html" ext-link-type="uri">https://www.biologicale.com/news.html</ext-link>.</mixed-citation></ref><ref id="cit0127"><label>127.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Tergene Biotech Pvt</collab></person-group>. <article-title>Ltd. a Joint Venture company, receives SEC recommendation for pneumococcal 15 valent (PCV15) vaccine</article-title>. [<date-in-citation>accessed 2024 <month>Aug</month><day>8</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://nsearchives.nseindia.com/corporate/AUROPHARMA_27122022115948_LtrToSEsPressReleaseTergene27122022.pdf" ext-link-type="uri">https://nsearchives.nseindia.com/corporate/AUROPHARMA_27122022115948_LtrToSEsPressReleaseTergene27122022.pdf</ext-link>.</mixed-citation></ref><ref id="cit0128"><label>128.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>U.S</collab></person-group>. <article-title>FDA approves CAPVAXIVE<sup>TM</sup> (Pneumococcal 21-valent Conjugate Vaccine) for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults</article-title>. <source>Merck.com</source>. [<date-in-citation>accessed 2024 <month>Aug</month><day>8</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.merck.com/news/u-s-fda-approves-capvaxive-pneumococcal-21-valent-conjugate-vaccine-for-prevention-of-invasive-pneumococcal-disease-and-pneumococcal-pneumonia-in-adults/" ext-link-type="uri">https://www.merck.com/news/u-s-fda-approves-capvaxive-pneumococcal-21-valent-conjugate-vaccine-for-prevention-of-invasive-pneumococcal-disease-and-pneumococcal-pneumonia-in-adults/</ext-link>.</mixed-citation></ref><ref id="cit0129"><label>129.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>R&amp;D pipeline</collab></person-group>. [<date-in-citation>accessed 2024 <month>Aug</month><day>8</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.panaceabiotec.com/en/products/pipeline" ext-link-type="uri">https://www.panaceabiotec.com/en/products/pipeline</ext-link>.</mixed-citation></ref><ref id="cit0130"><label>130.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Vaccines</collab></person-group>. [<date-in-citation>accessed 2024 <month>Jul</month><day>7</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://techinvention.biz/rnd-vaccines.html" ext-link-type="uri">https://techinvention.biz/rnd-vaccines.html</ext-link>.</mixed-citation></ref><ref id="cit0131"><label>131.</label><mixed-citation publication-type="webpage"><article-title>SK bioscience-Sanofi announce positive results from phase II study of 21-valent pneumococcal conjugate vaccine candidate</article-title>. [<date-in-citation>accessed 2024 <month>Aug</month><day>8</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.skbioscience.com/en/news/news_01_01" ext-link-type="uri">https://www.skbioscience.com/en/news/news_01_01</ext-link>.</mixed-citation></ref><ref id="cit0132"><label>132.</label><mixed-citation publication-type="webpage"><article-title>GSK completes acquisition of Affinivax, Inc</article-title>. [<date-in-citation>accessed 2024 <month>May</month><day>14</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-affinivax-inc/" ext-link-type="uri">https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-affinivax-inc/</ext-link>.</mixed-citation></ref><ref id="cit0133"><label>133.</label><mixed-citation publication-type="report"><article-title>Vaxcyte reports positive data from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate, VAX-24, in adults aged 65 and older and full six-month safety data from adult phase 1/2 and phase 2 studies</article-title>. <date-in-citation>[accessed 2024 <month>May</month><day>14</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-reports-positive-data-phase-2-study-its-24-valent/" ext-link-type="uri">https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-reports-positive-data-phase-2-study-its-24-valent/</ext-link>.</mixed-citation></ref><ref id="cit0134"><label>134.</label><mixed-citation publication-type="webpage"><article-title>Vaxcyte doses first participants in phase 1/2 clinical study evaluating VAX-31 for the prevention of invasive pneumococcal disease in adults</article-title>. [<date-in-citation>accessed 2024 <month>May</month><day>14</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-doses-first-participants-phase-12-clinical-study-0/" ext-link-type="uri">https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-doses-first-participants-phase-12-clinical-study-0/</ext-link>.</mixed-citation></ref><ref id="cit0135"><label>135.</label><mixed-citation publication-type="webpage"><article-title>Vaxcyte announces FDA clearance of investigational new drug application for VAX-31 for the prevention of invasive pneumococcal disease in adults</article-title>. [<date-in-citation>accessed 2024 <month>May</month><day>14</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-announces-fda-clearance-investigational-new-drug-1/" ext-link-type="uri">https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-announces-fda-clearance-investigational-new-drug-1/</ext-link>.</mixed-citation></ref><ref id="cit0136"><label>136.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McGuinness</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kaufhold</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>McHugh</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Winters</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Giovarelli</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Musey</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Skinner</surname><given-names>JM</given-names></string-name></person-group>. <article-title>Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice</article-title>. <source>Vaccine</source>. <year>2021</year>;<volume>39</volume>(<issue>30</issue>):<fpage>4231</fpage>&#8211;<lpage>4237</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2021.04.067</pub-id>.<pub-id pub-id-type="pmid">34074546</pub-id></mixed-citation></ref><ref id="cit0137"><label>137.</label><mixed-citation publication-type="webpage"><article-title>Inventprise completes vaccination of participants in a phase 2 dose ranging study of its 25 valent pneumococcal vaccine candidate</article-title>. <date-in-citation>[accessed 2024 <month>Aug</month><day>9</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://inventprise.com/2024/01/02/inventprise-completes-vaccination-of-participants-in-a-phase-2-dose-ranging-study-of-its-25-valent-pneumococcal-vaccine-candidate/" ext-link-type="uri">https://inventprise.com/2024/01/02/inventprise-completes-vaccination-of-participants-in-a-phase-2-dose-ranging-study-of-its-25-valent-pneumococcal-vaccine-candidate/</ext-link>.</mixed-citation></ref><ref id="cit0138"><label>138.</label><mixed-citation publication-type="webpage"><article-title>Conjugate vaccine introduction &amp; use</article-title>. [<date-in-citation>accessed 2025 <month>Jan</month><day>18</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://view-hub.org/vaccine/pcv" ext-link-type="uri">https://view-hub.org/vaccine/pcv</ext-link>.</mixed-citation></ref><ref id="cit0139"><label>139.</label><mixed-citation publication-type="webpage"><article-title>Pneumococcal Conjugate Vaccine (PCV) Review of impact evidence (PRIME) summary of findings from systematic review October 2017</article-title>. [<date-in-citation>accessed 2025 <month>Jan</month><day>18</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://terrance.who.int/mediacentre/data/sage/SAGE_Docs_Ppt_Oct2017/9_session_PCV/Oct2019_session9_PCV_PRIMEsummary.pdf" ext-link-type="uri">https://terrance.who.int/mediacentre/data/sage/SAGE_Docs_Ppt_Oct2017/9_session_PCV/Oct2019_session9_PCV_PRIMEsummary.pdf</ext-link>.</mixed-citation></ref><ref id="cit0140"><label>140.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Duke</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Avci</surname><given-names>FY</given-names></string-name></person-group>. <article-title>Emerging vaccine strategies against the incessant pneumococcal disease</article-title>. <source>NPJ Vaccines</source>. <year>2023</year>;<volume>8</volume>(<issue>1</issue>):<fpage>122</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41541-023-00715-w</pub-id>.<pub-id pub-id-type="pmid">37591986</pub-id><pub-id pub-id-type="pmcid">PMC10435554</pub-id></mixed-citation></ref><ref id="cit0141"><label>141.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WALVAX Package Insert</collab></person-group>. [<date-in-citation>accessed 2024 <month>May</month><day>14</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://en.walvax.com/media/upload/product/Package%2520Insert%2520of%2520PPSV23.pdf" ext-link-type="uri">https://en.walvax.com/media/upload/product/Package%20Insert%20of%20PPSV23.pdf</ext-link>.</mixed-citation></ref><ref id="cit0142"><label>142.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Pneumococcal Conjugate Vaccine (PCV)</collab></person-group>. [<date-in-citation>accessed 2024 <month>May</month><day>14</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://view-hub.org/vaccine/pcv/product" ext-link-type="uri">https://view-hub.org/vaccine/pcv/product</ext-link>.</mixed-citation></ref><ref id="cit0143"><label>143.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rao</surname><given-names>MIS</given-names></string-name>, <string-name name-style="western"><surname>Kasi</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Dhir</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Wadhwa</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rajsekhar</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Lalwani</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shenoy</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kesavan</surname><given-names>TMA</given-names></string-name>, <string-name name-style="western"><surname>Kalyani</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP): recommended immunization schedule (2023) and update on immunization for children aged 0 through 18 years</article-title>. <source>Indian Pediatr</source>. <year>2024</year>;<volume>61</volume>(<issue>2</issue>):<fpage>113</fpage>&#8211;<lpage>125</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13312-024-3104-5</pub-id>.<pub-id pub-id-type="pmid">38243749</pub-id></mixed-citation></ref><ref id="cit0144"><label>144.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Affordable Vaccine platform</collab></person-group>. [<date-in-citation>accessed 2024 <month>Aug</month><day>8</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.tergene.com/news3.html" ext-link-type="uri">http://www.tergene.com/news3.html</ext-link>.</mixed-citation></ref><ref id="cit0145"><label>145.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Curry</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kaufhold</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Monslow</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>McGuinness</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Nawrocki</surname><given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>McHugh</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Briggs</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>WJ</given-names></string-name>, et al</person-group>. <article-title>Preclinical evaluation of an investigational 21-valent pneumococcal conjugate vaccine, V116, in adult-rhesus monkey, rabbit, and mouse models</article-title>. <source>Vaccine</source>. <year>2023</year>;<volume>41</volume>(<issue>4</issue>):<fpage>903</fpage>&#8211;<lpage>913</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2022.12.017</pub-id>.<pub-id pub-id-type="pmid">36566163</pub-id></mixed-citation></ref><ref id="cit0146"><label>146.</label><mixed-citation publication-type="webpage"><article-title>Permission to conduct clinical trial of new drug or investigational new drug</article-title>. [<date-in-citation>accessed 2024 <month>Aug</month><day>8</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCTApprovals/39_Panacea%2520Biotech%2520Pneumococcal.pdf" ext-link-type="uri">https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCTApprovals/39_Panacea%20Biotech%20Pneumococcal.pdf</ext-link>.</mixed-citation></ref><ref id="cit0147"><label>147.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Intellectual property</collab></person-group>. [<date-in-citation>accessed 2024 <month>Aug</month><day>9</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://techinvention.biz/intellectual-property.html" ext-link-type="uri">https://techinvention.biz/intellectual-property.html</ext-link>.</mixed-citation></ref><ref id="cit0148"><label>148.</label><mixed-citation publication-type="webpage"><article-title>Composition of multivalent pneumococcal polysacaride-protein conjugate</article-title>. [<date-in-citation>accessed 2024 <month>Aug</month><day>8</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/patent/BR-112020014978-A2" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/patent/BR-112020014978-A2</ext-link>.</mixed-citation></ref><ref id="cit0149"><label>149.</label><mixed-citation publication-type="webpage"><article-title>GSK - A phase 2 study to evaluate the safety, tolerability, and immunogenicity of AFX3772 vaccine in healthy infants</article-title>. [<date-in-citation>accessed 2024 <month>May</month><day>14</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.gsk-studyregister.com/en/trial-details/?id=219651" ext-link-type="uri">https://www.gsk-studyregister.com/en/trial-details/?id=219651</ext-link>.</mixed-citation></ref><ref id="cit0150"><label>150.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fairman</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Agarwal</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Barbanel</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Behrens</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Berges</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Burky</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Davey</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Fernsten</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Grainger</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23)</article-title>. <source>Vaccine</source>. <year>2021</year>;<volume>39</volume>(<issue>23</issue>):<fpage>3197</fpage>&#8211;<lpage>3206</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2021.03.070</pub-id>.<pub-id pub-id-type="pmid">33965258</pub-id></mixed-citation></ref><ref id="cit0151"><label>151.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jain</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>VK</given-names></string-name>, <string-name name-style="western"><surname>Kante</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Jana</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Patil</surname><given-names>RH</given-names></string-name></person-group>. <article-title>Current trends in development and manufacturing of higher-valent pneumococcal polysaccharide conjugate vaccine and its challenges</article-title>. <source>Biol J Int Assoc Biol Stand</source>. <year>2024</year>;<volume>87</volume>:<fpage>101784</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biologicals.2024.101784</pub-id>.<pub-id pub-id-type="pmid">39053122</pub-id></mixed-citation></ref><ref id="cit0152"><label>152.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Datta</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kapre</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Andi-Lolo</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Kapre</surname><given-names>S</given-names></string-name></person-group>. <article-title>Multi-valent pneumococcal conjugate vaccine for global health: From problem to platform to production</article-title>. <source>Hum Vaccines Immunother</source>. <year>2022</year>;<volume>18</volume>(<issue>4</issue>):<fpage>2117949</fpage>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2022.2117949</pub-id>.<pub-id pub-id-type="pmcid">PMC9721430</pub-id><pub-id pub-id-type="pmid">36239596</pub-id></mixed-citation></ref><ref id="cit0153"><label>153.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Behrens</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fairman</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Agarwal</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Arulkumar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Barbanel</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bautista</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Berges</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Burky</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Davey</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Grainger</surname><given-names>C</given-names></string-name>, et al</person-group>. <article-title>1047. Development of a next generation 30+ valent pneumococcal
conjugate vaccine (VAX-XP) using site-specific carrier protein conjugation</article-title>. <source>Open Forum Infect Dis</source>. <year>2021</year>;<volume>8</volume>(<issue>Supplement_1</issue>):<fpage>S615</fpage>&#8211;<lpage>S615</lpage>. doi:<pub-id pub-id-type="doi">10.1093/ofid/ofab466.1241</pub-id>.</mixed-citation></ref><ref id="cit0154"><label>154.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Pneumococcal Vaccines</collab></person-group>. [<date-in-citation>accessed 2024 <month>Aug</month><day>28</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2024-06-26-28/01-Pneumococcal-Loehr-508.pdf" ext-link-type="uri">https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2024-06-26-28/01-Pneumococcal-Loehr-508.pdf</ext-link>.</mixed-citation></ref><ref id="cit0155"><label>155.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Feemster</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Buchwald</surname><given-names>UK</given-names></string-name>, <string-name name-style="western"><surname>Banniettis</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Joyce</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Velentgas</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Chapman</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Yildirim</surname><given-names>I</given-names></string-name></person-group>. <article-title>Immunogenicity of current and next generation pneumococcal conjugate vaccines in children: current challenges and upcoming opportunities</article-title>. <source>Open Forum Infect Dis</source>. <year>2024</year>;<volume>11</volume>(<issue>5</issue>):<fpage>ofae220</fpage>. doi:<pub-id pub-id-type="doi">10.1093/ofid/ofae220</pub-id>.<pub-id pub-id-type="pmid">38770212</pub-id><pub-id pub-id-type="pmcid">PMC11103622</pub-id></mixed-citation></ref><ref id="cit0156"><label>156.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wassil</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sisti</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fairman</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rankin</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Clark</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Migone</surname><given-names>T-S</given-names></string-name>, <string-name name-style="western"><surname>Nguyen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Paschenko</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>A phase 2, randomized, blinded, dose-finding, controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults 65 years and older</article-title>. <source>Vaccine</source>. <year>2024</year>;<volume>42</volume>(<issue>25</issue>):<fpage>126124</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2024.07.025</pub-id>.<pub-id pub-id-type="pmid">39025698</pub-id></mixed-citation></ref><ref id="cit0157"><label>157.</label><mixed-citation publication-type="webpage"><article-title>Investigational pneumococcal vaccine broadens coverage without
reducing immunogenicity</article-title>. [<date-in-citation>accessed 2024 <month>Dec</month><day>13</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.contagionlive.com/view/investigational-pneumococcal-vaccine-broadens-coverage-without-reducing-immunogenicity" ext-link-type="uri">https://www.contagionlive.com/view/investigational-pneumococcal-vaccine-broadens-coverage-without-reducing-immunogenicity</ext-link>.</mixed-citation></ref><ref id="cit0158"><label>158.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Akkoyunlu</surname><given-names>M</given-names></string-name></person-group>. <article-title>State of pneumococcal vaccine immunity</article-title>. <source>Hum Vaccines Immunother</source>. <year>2024</year>;<volume>20</volume>(<issue>1</issue>):<fpage>2336358</fpage>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2024.2336358</pub-id>.<pub-id pub-id-type="pmcid">PMC10993918</pub-id><pub-id pub-id-type="pmid">38567485</pub-id></mixed-citation></ref><ref id="cit0159"><label>159.</label><mixed-citation publication-type="report"><article-title>Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines Replacement of WHO Technical Report Series, No. 927, Annex 2</article-title>. <date-in-citation>[accessed 2024 <month>Dec</month><day>13</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cdn.who.int/media/docs/default-source/biologicals/vaccine-standardization/pneumococcus/trs_977_annex_3.pdf" ext-link-type="uri">https://cdn.who.int/media/docs/default-source/biologicals/vaccine-standardization/pneumococcus/trs_977_annex_3.pdf</ext-link>.</mixed-citation></ref><ref id="cit0160"><label>160.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Golden</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Adam</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Karlowsky</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Baxter</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nichol</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Demczuk</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Van Caeseele</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gubbay</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Lefebvre</surname><given-names>B</given-names></string-name>, et al</person-group>. <article-title>Molecular characterization of predominant Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011&#8211;15</article-title>. <source>J Antimicrob Chemother</source>. <year>2018</year>;<volume>73</volume>(<issue>suppl_7</issue>):<fpage>vii20</fpage>&#8211;<lpage>31</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/dky157</pub-id>.<pub-id pub-id-type="pmid">29982573</pub-id></mixed-citation></ref><ref id="cit0161"><label>161.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chochua</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Metcalf</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Walker</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tran</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>McGee</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Beall</surname><given-names>B</given-names></string-name></person-group>. <article-title>Invasive serotype 35B pneumococci including an expanding serotype switch lineage, United States, 2015&#8211;2016</article-title>. <source>Emerg Infect Dis</source>. <year>2017</year>;<volume>23</volume>(<issue>6</issue>):<fpage>922</fpage>&#8211;<lpage>930</lpage>. doi:<pub-id pub-id-type="doi">10.3201/eid2306.170071</pub-id>.<pub-id pub-id-type="pmid">28516866</pub-id><pub-id pub-id-type="pmcid">PMC5443455</pub-id></mixed-citation></ref><ref id="cit0162"><label>162.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lagousi</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Basdeki</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Routsias</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Spoulou</surname><given-names>V</given-names></string-name></person-group>. <article-title>Novel protein-based pneumococcal vaccines: assessing the use of distinct protein fragments instead of full-length proteins as vaccine antigens</article-title>. <source>Vaccines</source>. <year>2019</year>;<volume>7</volume>(<issue>1</issue>):<fpage>9</fpage>. doi:<pub-id pub-id-type="doi">10.3390/vaccines7010009</pub-id>.<pub-id pub-id-type="pmid">30669439</pub-id><pub-id pub-id-type="pmcid">PMC6466302</pub-id></mixed-citation></ref><ref id="cit0163"><label>163.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Feemster</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Weaver</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Buchwald</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Banniettis</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Cox</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>McIntosh</surname><given-names>ED</given-names></string-name>, <string-name name-style="western"><surname>Spoulou</surname><given-names>V</given-names></string-name></person-group>. <article-title>Pneumococcal vaccine breakthrough and failure in infants and children: a narrative review</article-title>. <source>Vaccines</source>. <year>2023</year>;<volume>11</volume>(<issue>12</issue>):<fpage>1750</fpage>. doi:<pub-id pub-id-type="doi">10.3390/vaccines11121750</pub-id>.<pub-id pub-id-type="pmid">38140155</pub-id><pub-id pub-id-type="pmcid">PMC10747311</pub-id></mixed-citation></ref><ref id="cit0164"><label>164.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Oligbu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Hsia</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Folgori</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Collins</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ladhani</surname><given-names>S</given-names></string-name></person-group>. <article-title>Pneumococcal conjugate vaccine failure in children: a systematic review of the literature</article-title>. <source>Vaccine</source>. <year>2016</year>;<volume>34</volume>(<issue>50</issue>):<fpage>6126</fpage>&#8211;<lpage>6132</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.10.050</pub-id>.<pub-id pub-id-type="pmid">27838066</pub-id></mixed-citation></ref><ref id="cit0165"><label>165.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Aceil</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Avci</surname><given-names>FY</given-names></string-name></person-group>. <article-title>Pneumococcal surface proteins as virulence factors, immunogens, and conserved vaccine targets</article-title>. <source>Front Cell Infect Microbiol</source>. <year>2022</year>;<volume>12</volume>:<fpage>832254</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fcimb.2022.832254</pub-id>.<pub-id pub-id-type="pmid">35646747</pub-id><pub-id pub-id-type="pmcid">PMC9133333</pub-id></mixed-citation></ref><ref id="cit0166"><label>166.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dagan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Poolman</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Siegrist</surname><given-names>C-A</given-names></string-name></person-group>. <article-title>Glycoconjugate vaccines and immune interference: a review</article-title>. <source>Vaccine</source>. <year>2010</year>;<volume>28</volume>(<issue>34</issue>):<fpage>5513</fpage>&#8211;<lpage>5523</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2010.06.026</pub-id>.<pub-id pub-id-type="pmid">20600514</pub-id></mixed-citation></ref><ref id="cit0167"><label>167.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Musher</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Feldman</surname><given-names>C</given-names></string-name></person-group>. <article-title>The remarkable history of pneumococcal vaccination: an ongoing challenge</article-title>. <source>Pneumonia</source>. <year>2022</year>;<volume>14</volume>(<issue>1</issue>):<fpage>5</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s41479-022-00097-y</pub-id>.<pub-id pub-id-type="pmid">36153636</pub-id><pub-id pub-id-type="pmcid">PMC9509586</pub-id></mixed-citation></ref><ref id="cit0168"><label>168.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jang</surname><given-names>A-Y</given-names></string-name>, <string-name name-style="western"><surname>Ahn</surname><given-names>KB</given-names></string-name>, <string-name name-style="western"><surname>Zhi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ji</surname><given-names>H-J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>JH</given-names></string-name>, et al</person-group>. <article-title>Serotype-independent protection against invasive pneumococcal infections conferred by live Vaccine with lgt deletion</article-title>. <source>Front Immunol</source>. <year>2019</year>;<volume>10</volume>:<fpage>1212</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2019.01212</pub-id>.<pub-id pub-id-type="pmid">31191555</pub-id><pub-id pub-id-type="pmcid">PMC6549034</pub-id></mixed-citation></ref><ref id="cit0169"><label>169.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kumraj</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Pathak</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shah</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Majumder</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Jain</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bhati</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hanif</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mukherjee</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname><given-names>S</given-names></string-name></person-group>. <article-title>Capacity building for vaccine manufacturing across developing countries: the way forward</article-title>. <source>Hum Vaccines Immunother</source>. <year>2022</year>;<volume>18</volume>(<issue>1</issue>):<fpage>2020529</fpage>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2021.2020529</pub-id>.<pub-id pub-id-type="pmcid">PMC8986212</pub-id><pub-id pub-id-type="pmid">35086416</pub-id></mixed-citation></ref><ref id="cit0170"><label>170.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nishimoto</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Rosch</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Tuomanen</surname><given-names>EI</given-names></string-name></person-group>. <article-title>Pneumolysin: pathogenesis and therapeutic target</article-title>. <source>Front Microbiol</source>. <year>2020</year>;<volume>11</volume>:<fpage>1543</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fmicb.2020.01543</pub-id>.<pub-id pub-id-type="pmid">32714314</pub-id><pub-id pub-id-type="pmcid">PMC7343714</pub-id></mixed-citation></ref><ref id="cit0171"><label>171.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pereira</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Leong</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Sousa</surname><given-names>S</given-names></string-name></person-group>. <article-title>The Yin and Yang of pneumolysin during pneumococcal infection</article-title>. <source>Front Immunol</source>. <year>2022</year>;<volume>13</volume>:<fpage>878244</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2022.878244</pub-id>.<pub-id pub-id-type="pmid">35529870</pub-id><pub-id pub-id-type="pmcid">PMC9074694</pub-id></mixed-citation></ref><ref id="cit0172"><label>172.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Araujo</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Oliveira</surname><given-names>MLS</given-names></string-name>, <string-name name-style="western"><surname>Miyaji</surname><given-names>EN</given-names></string-name></person-group>. <article-title>Negligible role for pneumococcal surface protein a (PspA) and pneumococcal surface protein C (PspC) in the nasopharyngeal colonization of mice with a serotype 6B pneumococcal strain</article-title>. <source>Microb Pathog</source>. <year>2023</year>;<volume>185</volume>:<fpage>106391</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.micpath.2023.106391</pub-id>.<pub-id pub-id-type="pmid">37839762</pub-id></mixed-citation></ref><ref id="cit0173"><label>173.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Du</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Vilhena</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>King</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sahag&#250;n-Ruiz</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hammerschmidt</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Skerka</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zipfel</surname><given-names>PF</given-names></string-name></person-group>. <article-title>Molecular analyses identifies new domains and structural differences among Streptococcus pneumoniae immune evasion proteins PspC and Hic</article-title>. <source>Sci Rep</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>1701</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-020-79362-3</pub-id>.<pub-id pub-id-type="pmid">33462258</pub-id><pub-id pub-id-type="pmcid">PMC7814132</pub-id></mixed-citation></ref><ref id="cit0174"><label>174.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khan</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Filkins</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Pichichero</surname><given-names>ME</given-names></string-name></person-group>. <article-title>PcpA of Streptococcus pneumoniae mediates adherence to nasopharyngeal and lung epithelial cells and elicits functional antibodies in humans</article-title>. <source>Microbes Infect</source>. <year>2012</year>;<volume>14</volume>(<issue>12</issue>):<fpage>1102</fpage>&#8211;<lpage>1110</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.micinf.2012.06.007</pub-id>.<pub-id pub-id-type="pmid">22796387</pub-id><pub-id pub-id-type="pmcid">PMC3490615</pub-id></mixed-citation></ref><ref id="cit0175"><label>175.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Afshar</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rafiee</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Kheirandish</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ohadian Moghadam</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Azarsa</surname><given-names>M</given-names></string-name></person-group>. <article-title>Autolysin (lytA) recombinant protein: a potential target for developing vaccines against pneumococcal infections</article-title>. <source>Clin Exp Vaccine Res</source>. <year>2020</year>;<volume>9</volume>(<issue>2</issue>):<fpage>76</fpage>. doi:<pub-id pub-id-type="doi">10.7774/cevr.2020.9.2.76</pub-id>.<pub-id pub-id-type="pmid">32864363</pub-id><pub-id pub-id-type="pmcid">PMC7445314</pub-id></mixed-citation></ref><ref id="cit0176"><label>176.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Seo</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Somarathne</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Vonkchalee</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Jackson</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Olivier</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Fitzkee</surname><given-names>NC</given-names></string-name>, <string-name name-style="western"><surname>Thornton</surname><given-names>JA</given-names></string-name></person-group>. <article-title>Pneumococcal surface adhesion a protein (PsaA) interacts with human Annexin A2 on airway epithelial cells</article-title>. <source>Virulence</source>. <year>2021</year>;<volume>12</volume>(<issue>1</issue>):<fpage>1947176</fpage>. doi:<pub-id pub-id-type="doi">10.1080/21505594.2021.1947176</pub-id>.<pub-id pub-id-type="pmcid">PMC8274441</pub-id><pub-id pub-id-type="pmid">34233589</pub-id></mixed-citation></ref><ref id="cit0177"><label>177.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Waz</surname><given-names>NT</given-names></string-name>, <string-name name-style="western"><surname>Milani</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Assoni</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Coelho</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Sciani</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Parisotto</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ferraz</surname><given-names>LFC</given-names></string-name>, <string-name name-style="western"><surname>Hakansson</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Converso</surname><given-names>TR</given-names></string-name>, <string-name name-style="western"><surname>Darrieux</surname><given-names>M</given-names></string-name></person-group>. <article-title>Pneumococcal surface protein a (PspA) prevents killing of Streptococcus pneumoniae by indolicidin</article-title>. <source>Sci Rep</source>. <year>2024</year>;<volume>14</volume>(<issue>1</issue>):<fpage>23517</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-024-73564-9</pub-id>.<pub-id pub-id-type="pmid">39384882</pub-id><pub-id pub-id-type="pmcid">PMC11464550</pub-id></mixed-citation></ref><ref id="cit0178"><label>178.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Adamou</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Heinrichs</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Erwin</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Walsh</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Gayle</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Dormitzer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dagan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Brewah</surname><given-names>YA</given-names></string-name>, <string-name name-style="western"><surname>Barren</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lathigra</surname><given-names>R</given-names></string-name>, et al</person-group>. <article-title>dentification and characterization of a novel family of pneumococcal proteins that are protective against sepsis</article-title>. <source>Infect Immun</source>. <year>2001</year>;<volume>69</volume>(<issue>2</issue>):<fpage>949</fpage>&#8211;<lpage>958</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.69.2.949-958.2001</pub-id>.<pub-id pub-id-type="pmid">11159990</pub-id><pub-id pub-id-type="pmcid">PMC97974</pub-id></mixed-citation></ref><ref id="cit0179"><label>179.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Melin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Di Paolo</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Tikkanen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Jarva</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Neyt</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>K&#228;yhty</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Meri</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Poolman</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>V&#228;kev&#228;inen</surname><given-names>M</given-names></string-name></person-group>. <article-title>Interaction of pneumococcal histidine triad proteins with human complement</article-title>. <source>Infect Immun</source>. <year>2010</year>;<volume>78</volume>(<issue>5</issue>):<fpage>2089</fpage>&#8211;<lpage>2098</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.00811-09</pub-id>.<pub-id pub-id-type="pmid">20194599</pub-id><pub-id pub-id-type="pmcid">PMC2863542</pub-id></mixed-citation></ref><ref id="cit0180"><label>180.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khan</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Pichichero</surname><given-names>ME</given-names></string-name></person-group>. <article-title>Vaccine candidates PhtD and PhtE of Streptococcus pneumoniae are adhesins that elicit functional antibodies in humans</article-title>. <source>Vaccine</source>. <year>2012</year>;<volume>30</volume>(<issue>18</issue>):<fpage>2900</fpage>&#8211;<lpage>2907</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2012.02.023</pub-id>.<pub-id pub-id-type="pmid">22349524</pub-id><pub-id pub-id-type="pmcid">PMC3490617</pub-id></mixed-citation></ref><ref id="cit0181"><label>181.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Afshari</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ahangari Cohan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Shams Nosrati</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Mousavi</surname><given-names>SF</given-names></string-name></person-group>. <article-title>Development of a bivalent protein-based vaccine candidate against invasive pneumococcal diseases based on novel pneumococcal surface protein a in combination with pneumococcal histidine triad protein D</article-title>. <source>Front Immunol</source>. <year>2023</year>;<volume>14</volume>:<fpage>1187773</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2023.1187773</pub-id>.<pub-id pub-id-type="pmid">37680628</pub-id><pub-id pub-id-type="pmcid">PMC10480505</pub-id></mixed-citation></ref><ref id="cit0182"><label>182.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gingerich</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Royer</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Paschall</surname><given-names>AV</given-names></string-name>, <string-name name-style="western"><surname>Pena-Briseno</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Avci</surname><given-names>FY</given-names></string-name>, <string-name name-style="western"><surname>Mousa</surname><given-names>JJ</given-names></string-name></person-group>. <article-title>Broadly reactive human monoclonal antibodies targeting the pneumococcal histidine triad protein protect against fatal pneumococcal infection</article-title>. <source>Infect Immun</source>. <year>2021</year>;<volume>89</volume>(<issue>5</issue>):<fpage>e00747</fpage>&#8211;<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.00747-20</pub-id>.<pub-id pub-id-type="pmid">33649050</pub-id><pub-id pub-id-type="pmcid">PMC8091081</pub-id></mixed-citation></ref><ref id="cit0183"><label>183.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Eijkelkamp</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Pederick</surname><given-names>VG</given-names></string-name>, <string-name name-style="western"><surname>Plumptre</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Harvey</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Hughes</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Paton</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>McDevitt</surname><given-names>CA</given-names></string-name></person-group>. <article-title>The first histidine triad motif of PhtD is critical for Zinc homeostasis in streptococcus pneumoniae</article-title>. <source>Infect Immun</source>. <year>2016</year>;<volume>84</volume>(<issue>2</issue>):<fpage>407</fpage>&#8211;<lpage>415</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.01082-15</pub-id>.<pub-id pub-id-type="pmid">26573735</pub-id><pub-id pub-id-type="pmcid">PMC4730578</pub-id></mixed-citation></ref><ref id="cit0184"><label>184.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nagai</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Domon</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Maekawa</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hiyoshi</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tamura</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yonezawa</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Habuka</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Saitoh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Terao</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Immunization with pneumococcal elongation factor Tu enhances serotype-independent protection against Streptococcus pneumoniae infection</article-title>. <source>Vaccine</source>. <year>2019</year>;<volume>37</volume>(<issue>1</issue>):<fpage>160</fpage>&#8211;<lpage>168</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2018.11.015</pub-id>.<pub-id pub-id-type="pmid">30442480</pub-id></mixed-citation></ref><ref id="cit0185"><label>185.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Salha</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Szeto</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Myers</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Claus</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sheung</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ljutic</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hanwell</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ogilvie</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ming</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Neutralizing antibodies elicited by a novel detoxified pneumolysin derivative, PlyD1, provide protection against both pneumococcal infection and lung injury</article-title>. <source>Infect Immun</source>. <year>2012</year>;<volume>80</volume>(<issue>6</issue>):<fpage>2212</fpage>&#8211;<lpage>2220</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.06348-11</pub-id>.<pub-id pub-id-type="pmid">22473606</pub-id><pub-id pub-id-type="pmcid">PMC3370579</pub-id></mixed-citation></ref><ref id="cit0186"><label>186.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Min</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name></person-group>. <article-title>Engineering detoxified pneumococcal pneumolysin derivative &#916;A146PLY for self-biomineralization of calcium phosphate: assessment of their protective efficacy in murine infection models</article-title>. <source>Biomaterials</source>. <year>2018</year>;<volume>155</volume>:<fpage>152</fpage>&#8211;<lpage>164</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biomaterials.2017.11.018</pub-id>.<pub-id pub-id-type="pmid">29179131</pub-id></mixed-citation></ref><ref id="cit0187"><label>187.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hermand</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Vandercammen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mertens</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Di Paolo</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Verlant</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Deno&#235;l</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Godfroid</surname><given-names>F</given-names></string-name></person-group>. <article-title>Preclinical evaluation of a chemically detoxified pneumolysin as pneumococcal vaccine antigen</article-title>. <source>Hum Vaccines Immunother</source>. <year>2017</year>;<volume>13</volume>(<issue>1</issue>):<fpage>220</fpage>&#8211;<lpage>228</lpage>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2016.1234553</pub-id>.<pub-id pub-id-type="pmcid">PMC5287308</pub-id><pub-id pub-id-type="pmid">27768518</pub-id></mixed-citation></ref><ref id="cit0188"><label>188.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Min</surname><given-names>X</given-names></string-name></person-group>. <article-title>Subcutaneous immunization with the fusion protein &#916;A146Ply-SP0148 confers protection against Streptococcus pneumoniae infection</article-title>. <source>Microb Pathog</source>. <year>2022</year>;<volume>162</volume>:<fpage>105325</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.micpath.2021.105325</pub-id>.<pub-id pub-id-type="pmid">34848296</pub-id></mixed-citation></ref><ref id="cit0189"><label>189.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kirkham</surname><given-names>L-A</given-names></string-name>, <string-name name-style="western"><surname>Kerr</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Douce</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Paterson</surname><given-names>GK</given-names></string-name>, <string-name name-style="western"><surname>Dilts</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>D-F</given-names></string-name>, <string-name name-style="western"><surname>Mitchell</surname><given-names>TJ</given-names></string-name></person-group>. <article-title>Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines</article-title>. <source>Infect Immun</source>. <year>2006</year>;<volume>74</volume>(<issue>1</issue>):<fpage>586</fpage>&#8211;<lpage>593</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.74.1.586-593.2006</pub-id>.<pub-id pub-id-type="pmid">16369015</pub-id><pub-id pub-id-type="pmcid">PMC1346677</pub-id></mixed-citation></ref><ref id="cit0190"><label>190.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thanawastien</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Joyce</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Cartee</surname><given-names>RT</given-names></string-name>, <string-name name-style="western"><surname>Haines</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Pelton</surname><given-names>SI</given-names></string-name>, <string-name name-style="western"><surname>Tweten</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Killeen</surname><given-names>KP</given-names></string-name></person-group>. <article-title>Preclinical in vitro and in vivo profile of a highly-attenuated, broadly efficacious pneumolysin genetic toxoid</article-title>. <source>Vaccine</source>. <year>2021</year>;<volume>39</volume>(<issue>11</issue>):<fpage>1652</fpage>&#8211;<lpage>1660</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2020.04.064</pub-id>.<pub-id pub-id-type="pmid">32532546</pub-id><pub-id pub-id-type="pmcid">PMC8237519</pub-id></mixed-citation></ref><ref id="cit0191"><label>191.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Verhoeven</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Perry</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pichichero</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Plotkin</surname><given-names>SA</given-names></string-name></person-group>. <article-title>Contributions to protection from streptococcus pneumoniae infection using the monovalent recombinant protein vaccine candidates PcpA, PhtD, and PlyD1 in an infant murine model during challenge</article-title>. <source>Clin Vaccine Immunol</source>. <year>2014</year>;<volume>21</volume>(<issue>8</issue>):<fpage>1037</fpage>&#8211;<lpage>1045</lpage>. doi:<pub-id pub-id-type="doi">10.1128/CVI.00052-14</pub-id>.<pub-id pub-id-type="pmid">24850621</pub-id><pub-id pub-id-type="pmcid">PMC4135924</pub-id></mixed-citation></ref><ref id="cit0192"><label>192.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mann</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Orihuela</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Antikainen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Sublett</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Korhonen</surname><given-names>TK</given-names></string-name>, <string-name name-style="western"><surname>Tuomanen</surname><given-names>E</given-names></string-name></person-group>. <article-title>Multifunctional Role of Choline Binding Protein G in Pneumococcal Pathogenesis</article-title>. <source>Infect Immun</source>. <year>2006</year>;<volume>74</volume>(<issue>2</issue>):<fpage>821</fpage>&#8211;<lpage>829</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.74.2.821-829.2006</pub-id>.<pub-id pub-id-type="pmid">16428724</pub-id><pub-id pub-id-type="pmcid">PMC1360319</pub-id></mixed-citation></ref><ref id="cit0193"><label>193.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kazemian</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Afshar</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Garcia</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Pourmand</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Jeddi-Tehrani</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Aminharati</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Shokri</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Yazdi</surname><given-names>MH</given-names></string-name></person-group>. <article-title>CbpM and CbpG of Streptococcus Pneumoniae elicit a high protection in Mice challenged with a serotype 19F pneumococcus</article-title>. <source>Iran J Allergy Asthma Immunol</source>. <year>2018</year>;<volume>17</volume>:<fpage>574</fpage>&#8211;<lpage>585</lpage>. doi:<pub-id pub-id-type="doi">10.18502/ijaai.v17i6.622</pub-id>.<pub-id pub-id-type="pmid">30644702</pub-id></mixed-citation></ref><ref id="cit0194"><label>194.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yuan</surname><given-names>ZQ</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>ZY</given-names></string-name>, <string-name name-style="western"><surname>Gan</surname><given-names>HQ</given-names></string-name>, <string-name name-style="western"><surname>Xian</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>KX</given-names></string-name>, <string-name name-style="western"><surname>Mai</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>XB</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>ZD</given-names></string-name></person-group>. <article-title>Intranasal immunization with autolysin (LytA) in mice model induced protection against five prevalent Streptococcus pneumoniae serotypes in China</article-title>. <source>Immunol Res</source>. <year>2011</year>;<volume>51</volume>(<issue>1</issue>):<fpage>108</fpage>. doi:<pub-id pub-id-type="doi">10.1007/s12026-011-8234-x</pub-id>.<pub-id pub-id-type="pmid">21748446</pub-id></mixed-citation></ref><ref id="cit0195"><label>195.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Corsini</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Aguinagalde</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ruiz</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Domenech</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Antequera</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Fenoll</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Garc&#237;a</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Garc&#237;a</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Yuste</surname><given-names>J</given-names></string-name></person-group>. <article-title>Immunization with LytB protein of Streptococcus pneumoniae activates complement-mediated phagocytosis and induces protection against pneumonia and sepsis</article-title>. <source>Vaccine</source>. <year>2016</year>;<volume>34</volume>(<issue>50</issue>):<fpage>6148</fpage>&#8211;<lpage>6157</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.001</pub-id>.<pub-id pub-id-type="pmid">27840016</pub-id></mixed-citation></ref><ref id="cit0196"><label>196.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Balachandran</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Brooks-Walter</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Virolainen-Julkunen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hollingshead</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Briles</surname><given-names>DE</given-names></string-name></person-group>. <article-title>Role of pneumococcal surface Protein C in Nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae</article-title>. <source>Infect Immun</source>. <year>2002</year>;<volume>70</volume>(<issue>5</issue>):<fpage>2526</fpage>&#8211;<lpage>2534</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.70.5.2526-2534.2002</pub-id>.<pub-id pub-id-type="pmid">11953392</pub-id><pub-id pub-id-type="pmcid">PMC127914</pub-id></mixed-citation></ref><ref id="cit0197"><label>197.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ogunniyi</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Woodrow</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Poolman</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Paton</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Tuomanen</surname><given-names>EI</given-names></string-name></person-group>. <article-title>Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA</article-title>. <source>Infect Immun</source>. <year>2001</year>;<volume>69</volume>(<issue>10</issue>):<fpage>5997</fpage>&#8211;<lpage>6003</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.69.10.5997-6003.2001</pub-id>.<pub-id pub-id-type="pmid">11553536</pub-id><pub-id pub-id-type="pmcid">PMC98727</pub-id></mixed-citation></ref><ref id="cit0198"><label>198.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>Y</given-names></string-name></person-group>. <article-title>CD4+ T lymphocytes mediated protection against invasive pneumococcal infection induced by mucosal immunization with ClpP and CbpA</article-title>. <source>Vaccine</source>. <year>2009</year>;<volume>27</volume>(<issue>21</issue>):<fpage>2838</fpage>&#8211;<lpage>2844</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2009.02.093</pub-id>.<pub-id pub-id-type="pmid">19366577</pub-id></mixed-citation></ref><ref id="cit0199"><label>199.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>De L&#250;cia Hernani</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ferreira</surname><given-names>PCD</given-names></string-name>, <string-name name-style="western"><surname>Ferreira</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Miyaji</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Ho</surname><given-names>PL</given-names></string-name>, <string-name name-style="western"><surname>Oliveira</surname><given-names>MLS</given-names></string-name></person-group>. <article-title>Nasal immunization of mice with Lactobacillus casei expressing the pneumococcal surface protein C primes the immune system and decreases pneumococcal nasopharyngeal colonization in mice</article-title>. <source>FEMS Immunol Med Microbiol</source>. <year>2011</year>;<volume>62</volume>(<issue>3</issue>):<fpage>263</fpage>&#8211;<lpage>272</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1574-695X.2011.00809.x</pub-id>.<pub-id pub-id-type="pmid">21492260</pub-id></mixed-citation></ref><ref id="cit0200"><label>200.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brooks-Walter</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Briles</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Hollingshead</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Fischetti</surname><given-names>VA</given-names></string-name></person-group>. <article-title>The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA 1535 and provides immunity to Pneumococcal Bacteremia</article-title>. <source>Infect Immun</source>. <year>1999</year>;<volume>67</volume>(<issue>12</issue>):<fpage>6533</fpage>&#8211;<lpage>6542</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.67.12.6533-6542.1999</pub-id>.<pub-id pub-id-type="pmid">10569772</pub-id><pub-id pub-id-type="pmcid">PMC97064</pub-id></mixed-citation></ref><ref id="cit0201"><label>201.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ferreira</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Darrieux</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Silva</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Leite</surname><given-names>LCC</given-names></string-name>, <string-name name-style="western"><surname>Ferreira</surname><given-names>JMC</given-names></string-name>, <string-name name-style="western"><surname>Ho</surname><given-names>PL</given-names></string-name>, <string-name name-style="western"><surname>Miyaji</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Oliveira</surname><given-names>MLS</given-names></string-name></person-group>. <article-title>Characterization of protective mucosal and systemic immune responses elicited by Pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in Mice</article-title>. <source>Clin Vaccine Immunol</source>. <year>2009</year>;<volume>16</volume>(<issue>5</issue>):<fpage>636</fpage>&#8211;<lpage>645</lpage>. doi:<pub-id pub-id-type="doi">10.1128/CVI.00395-08</pub-id>.<pub-id pub-id-type="pmid">19279169</pub-id><pub-id pub-id-type="pmcid">PMC2681601</pub-id></mixed-citation></ref><ref id="cit0202"><label>202.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Briles</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Hollingshead</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>King</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Swift</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Braun</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ferguson</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Nahm</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nabors</surname><given-names>G</given-names></string-name></person-group>. <article-title>Immunization of humans with recombinant Pneumococcal surface protein a (rPspA) elicits antibodies that passively protect Mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA</article-title>. <source>J Infect Dis</source>. <year>2000</year>;<volume>182</volume>(<issue>6</issue>):<fpage>1694</fpage>&#8211;<lpage>1701</lpage>. doi:<pub-id pub-id-type="doi">10.1086/317602</pub-id>.<pub-id pub-id-type="pmid">11069242</pub-id></mixed-citation></ref><ref id="cit0203"><label>203.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nagano</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kawabata</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sugita</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Tsuruhara</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ohori</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jimura</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Miyashita</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kurono</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tomonaga</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Briles</surname><given-names>DE</given-names></string-name>, et al</person-group>. <article-title>Transcutaneous immunization with pneumococcal surface protein A in mice</article-title>. <source>The Laryngoscope</source>. <year>2018</year>;<volume>128</volume>(<issue>3</issue>). doi:<pub-id pub-id-type="doi">10.1002/lary.26971</pub-id>.<pub-id pub-id-type="pmid">29226330</pub-id></mixed-citation></ref><ref id="cit0204"><label>204.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kong</surname><given-names>IG</given-names></string-name>, <string-name name-style="western"><surname>Sato</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yuki</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Nochi</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Takahashi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sawada</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mejima</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kurokawa</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Okada</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sato</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae</article-title>. <source>Infect Immun</source>. <year>2013</year>;<volume>81</volume>(<issue>5</issue>):<fpage>1625</fpage>&#8211;<lpage>1634</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.00240-13</pub-id>.<pub-id pub-id-type="pmid">23460513</pub-id><pub-id pub-id-type="pmcid">PMC3647999</pub-id></mixed-citation></ref><ref id="cit0205"><label>205.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Figueiredo</surname><given-names>DBD</given-names></string-name>, <string-name name-style="western"><surname>Kaneko</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Rodrigues</surname><given-names>TDC</given-names></string-name>, <string-name name-style="western"><surname>MacLoughlin</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Miyaji</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Saleem</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Gon&#231;alves</surname><given-names>VM</given-names></string-name></person-group>. <article-title>Pneumococcal surface protein A-hybrid nanoparticles protect Mice from lethal challenge after mucosal immunization targeting the lungs</article-title>. <source>Pharmaceutics</source>. <year>2022</year>;<volume>14</volume>(<issue>6</issue>):<fpage>1238</fpage>. doi:<pub-id pub-id-type="doi">10.3390/pharmaceutics14061238</pub-id>.<pub-id pub-id-type="pmid">35745810</pub-id><pub-id pub-id-type="pmcid">PMC9230107</pub-id></mixed-citation></ref><ref id="cit0206"><label>206.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Leenhouts</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Van Roosmalen</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kong</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Y</given-names></string-name></person-group>. <article-title>A Novel PspA protein vaccine intranasal delivered by bacterium-like particles provides broad protection against pneumococcal pneumonia in Mice</article-title>. <source>Immunol Invest</source>. <year>2018</year>;<volume>47</volume>(<issue>4</issue>):<fpage>403</fpage>&#8211;<lpage>415</lpage>. doi:<pub-id pub-id-type="doi">10.1080/08820139.2018.1439505</pub-id>.<pub-id pub-id-type="pmid">29498560</pub-id></mixed-citation></ref><ref id="cit0207"><label>207.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kong</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Broad protective immune responses elicited by bacterium-like particle-based intranasal pneumococcal particle vaccine displaying PspA2 and PspA4 fragments</article-title>. <source>Hum Vaccines Immunother</source>. <year>2019</year>;<volume>15</volume>(<issue>2</issue>):<fpage>371</fpage>&#8211;<lpage>380</lpage>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2018.1526556</pub-id>.<pub-id pub-id-type="pmcid">PMC6422497</pub-id><pub-id pub-id-type="pmid">30235046</pub-id></mixed-citation></ref><ref id="cit0208"><label>208.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Anish</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Upadhyay</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Sehgal</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Panda</surname><given-names>AK</given-names></string-name></person-group>. <article-title>Influences of process and formulation parameters on powder flow properties and immunogenicity of spray dried polymer particles entrapping recombinant pneumococcal surface protein a</article-title>. <source>Int J Pharm</source>. <year>2014</year>;<volume>466</volume>(<issue>1&#8211;2</issue>):<fpage>198</fpage>&#8211;<lpage>210</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijpharm.2014.03.025</pub-id>.<pub-id pub-id-type="pmid">24631054</pub-id></mixed-citation></ref><ref id="cit0209"><label>209.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rodrigues</surname><given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>Oliveira</surname><given-names>MLS</given-names></string-name>, <string-name name-style="western"><surname>Soares-Schanoski</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chavez-Rico</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Figueiredo</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Gon&#231;alves</surname><given-names>VM</given-names></string-name>, <string-name name-style="western"><surname>Ferreira</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Kunda</surname><given-names>NK</given-names></string-name>, <string-name name-style="western"><surname>Saleem</surname><given-names>IY</given-names></string-name>, <string-name name-style="western"><surname>Miyaji</surname><given-names>EN</given-names></string-name>, et al</person-group>. <article-title>Mucosal immunization with PspA (Pneumococcal surface protein a)-adsorbed nanoparticles targeting the lungs for protection against pneumococcal infection</article-title>. <source>PLoS One</source>. <year>2018</year>;<volume>13</volume>(<issue>1</issue>):<fpage>e0191692</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0191692</pub-id>.<pub-id pub-id-type="pmid">29360883</pub-id><pub-id pub-id-type="pmcid">PMC5779684</pub-id></mixed-citation></ref><ref id="cit0210"><label>210.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tada</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Suzuki</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Takahashi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Negishi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kiyono</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kunisawa</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Aramaki</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Nasal vaccination with pneumococcal surface protein a in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice</article-title>. <source>Int Immunopharmacol</source>. <year>2018</year>;<volume>61</volume>:<fpage>385</fpage>&#8211;<lpage>393</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.intimp.2018.06.027</pub-id>.<pub-id pub-id-type="pmid">29945026</pub-id></mixed-citation></ref><ref id="cit0211"><label>211.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wagner-Mu&#241;iz</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Haughney</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Kelly</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Wannemuehler</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Narasimhan</surname><given-names>B</given-names></string-name></person-group>. <article-title>Room temperature stable PspA-based Nanovaccine induces protective immunity</article-title>. <source>Front Immunol</source>. <year>2018</year>;<volume>9</volume>:<fpage>325</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2018.00325</pub-id>.<pub-id pub-id-type="pmid">29599766</pub-id><pub-id pub-id-type="pmcid">PMC5863507</pub-id></mixed-citation></ref><ref id="cit0212"><label>212.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fukuyama</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yuki</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Katakai</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Harada</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Takahashi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Takeda</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mejima</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Joo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kurokawa</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sawada</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Nanogel-based pneumococcal surface protein a nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against Streptococcus pneumoniae in macaques</article-title>. <source>Mucosal Immunol</source>. <year>2015</year>;<volume>8</volume>(<issue>5</issue>):<fpage>1144</fpage>&#8211;<lpage>1153</lpage>. doi:<pub-id pub-id-type="doi">10.1038/mi.2015.5</pub-id>.<pub-id pub-id-type="pmid">25669148</pub-id><pub-id pub-id-type="pmcid">PMC4762909</pub-id></mixed-citation></ref><ref id="cit0213"><label>213.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Seo</surname><given-names>S-U</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>J-J</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kwon</surname><given-names>H-J</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J-Y</given-names></string-name>, <string-name name-style="western"><surname>Curtiss Iii</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kweon</surname><given-names>M-N</given-names></string-name></person-group>. <article-title>Effective protection against secondary pneumococcal pneumonia by oral vaccination with attenuated Salmonella delivering PspA antigen in mice</article-title>. <source>Vaccine</source>. <year>2012</year>;<volume>30</volume>(<issue>48</issue>):<fpage>6816</fpage>&#8211;<lpage>6823</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2012.09.015</pub-id>.<pub-id pub-id-type="pmid">23000127</pub-id></mixed-citation></ref><ref id="cit0214"><label>214.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Darrieux</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Miyaji</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Ferreira</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Lopes</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Lopes</surname><given-names>APY</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Briles</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Hollingshead</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Leite</surname><given-names>LCC</given-names></string-name></person-group>. <article-title>Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition</article-title>. <source>Infect Immun</source>. <year>2007</year>;<volume>75</volume>(<issue>12</issue>):<fpage>5930</fpage>&#8211;<lpage>5938</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.00940-07</pub-id>.<pub-id pub-id-type="pmid">17923518</pub-id><pub-id pub-id-type="pmcid">PMC2168346</pub-id></mixed-citation></ref><ref id="cit0215"><label>215.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nakahashi-Ouchida</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Uchida</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yuki</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Katakai</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yamanoue</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ogawa</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Munesue</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Nakano</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Hanari</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Miyazaki</surname><given-names>T</given-names></string-name>, et al</person-group>. <article-title>A nanogel-based trivalent PspA nasal vaccine protects macaques from intratracheal challenge with pneumococci</article-title>. <source>Vaccine</source>. <year>2021</year>;<volume>39</volume>(<issue>25</issue>):<fpage>3353</fpage>&#8211;<lpage>3364</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2021.04.069</pub-id>.<pub-id pub-id-type="pmid">34016473</pub-id></mixed-citation></ref><ref id="cit0216"><label>216.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Piao</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Akeda</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Takeuchi</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ishii</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Ubukata</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Briles</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Tomono</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Oishi</surname><given-names>K</given-names></string-name></person-group>. <article-title>Protective properties of a fusion pneumococcal surface protein a (PspA) vaccine against pneumococcal challenge by five different PspA clades in mice</article-title>. <source>Vaccine</source>. <year>2014</year>;<volume>32</volume>(<issue>43</issue>):<fpage>5607</fpage>&#8211;<lpage>5613</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2014.07.108</pub-id>.<pub-id pub-id-type="pmid">25132335</pub-id></mixed-citation></ref><ref id="cit0217"><label>217.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Oliveira</surname><given-names>MLS</given-names></string-name>, <string-name name-style="western"><surname>Miyaji</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Ferreira</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Moreno</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Ferreira</surname><given-names>PCD</given-names></string-name>, <string-name name-style="western"><surname>Lima</surname><given-names>FA</given-names></string-name>, <string-name name-style="western"><surname>Santos</surname><given-names>FL</given-names></string-name>, <string-name name-style="western"><surname>Sakauchi</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Takata</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Higashi</surname><given-names>HG</given-names></string-name>, et al</person-group>. <article-title>Combination of pneumococcal surface protein a (PspA) with whole cell pertussis vaccine increases protection against Pneumococcal challenge in Mice</article-title>. <source>PLOS ONE</source>. <year>2010</year>;<volume>5</volume>(<issue>5</issue>):<fpage>e10863</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0010863</pub-id>.<pub-id pub-id-type="pmid">20523738</pub-id><pub-id pub-id-type="pmcid">PMC2877721</pub-id></mixed-citation></ref><ref id="cit0218"><label>218.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Talkington</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Tharpe</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Koenig</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Russell</surname><given-names>H</given-names></string-name></person-group>. <article-title>Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin a (PsaA)</article-title>. <source>Microb Pathog</source>. <year>1996</year>;<volume>21</volume>(<issue>1</issue>):<fpage>17</fpage>&#8211;<lpage>22</lpage>. doi:<pub-id pub-id-type="doi">10.1006/mpat.1996.0038</pub-id>.<pub-id pub-id-type="pmid">8827703</pub-id></mixed-citation></ref><ref id="cit0219"><label>219.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Scarpellini</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Torres-Escobar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Roland</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Curtiss</surname><given-names>R</given-names></string-name></person-group>. <article-title>Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine</article-title>. <source>Infect Immun</source>. <year>2010</year>;<volume>78</volume>(<issue>7</issue>):<fpage>3258</fpage>&#8211;<lpage>3271</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.00176-10</pub-id>.<pub-id pub-id-type="pmid">20479086</pub-id><pub-id pub-id-type="pmcid">PMC2897375</pub-id></mixed-citation></ref><ref id="cit0220"><label>220.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gor</surname><given-names>DO</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Sultana</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mambula</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Bram</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Greenspan</surname><given-names>NS</given-names></string-name></person-group>. <article-title>Enhanced immunogenicity of pneumococcal surface adhesin a (PsaA) in mice via fusion to recombinant human B lymphocyte stimulator (BLyS)</article-title>. <source>Biol Direct</source>. <year>2011</year>;<volume>6</volume>(<issue>1</issue>):<fpage>9</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1745-6150-6-9</pub-id>.<pub-id pub-id-type="pmid">21306646</pub-id><pub-id pub-id-type="pmcid">PMC3055212</pub-id></mixed-citation></ref><ref id="cit0221"><label>221.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>X</given-names></string-name></person-group>. <article-title>Intranasal vaccination with Chitosan-DNA nanoparticles expressing Pneumococcal surface antigen a protects Mice against nasopharyngeal colonization by Streptococcus pneumoniae</article-title>. <source>Clin Vaccine Immunol</source>. <year>2011</year>;<volume>18</volume>(<issue>1</issue>):<fpage>75</fpage>&#8211;<lpage>81</lpage>. doi:<pub-id pub-id-type="doi">10.1128/CVI.00263-10</pub-id>.<pub-id pub-id-type="pmid">21047997</pub-id><pub-id pub-id-type="pmcid">PMC3019786</pub-id></mixed-citation></ref><ref id="cit0222"><label>222.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>J-H</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>W-J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>X-Y</given-names></string-name></person-group>. <article-title>Mucosal immunization with PsaA protein, using Chitosan as a delivery system, increases protection against acute Otitis media and invasive infection by Streptococcus pneumoniae</article-title>. <source>Scand J Immunol</source>. <year>2015</year>;<volume>81</volume>(<issue>3</issue>):<fpage>177</fpage>&#8211;<lpage>185</lpage>. doi:<pub-id pub-id-type="doi">10.1111/sji.12267</pub-id>.<pub-id pub-id-type="pmid">25565478</pub-id></mixed-citation></ref><ref id="cit0223"><label>223.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Andr&#233;</surname><given-names>GO</given-names></string-name>, <string-name name-style="western"><surname>Borges</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Assoni</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ferraz</surname><given-names>LFC</given-names></string-name>, <string-name name-style="western"><surname>Sakshi</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Adamson</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Ogunniyi</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Venter</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Converso</surname><given-names>TR</given-names></string-name>, et al</person-group>. <article-title>Protective role of PhtD and its amino and carboxyl fragments against pneumococcal sepsis</article-title>. <source>Vaccine</source>. <year>2021</year>;<volume>39</volume>(<issue>27</issue>):<fpage>3626</fpage>&#8211;<lpage>3632</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2021.04.068</pub-id>.<pub-id pub-id-type="pmid">34045100</pub-id></mixed-citation></ref><ref id="cit0224"><label>224.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Malekan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Siadat</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Aghasadeghi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Shahrokhi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Afrough</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Behrouzi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ahmadi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Mousavi</surname><given-names>SF</given-names></string-name></person-group>. <article-title>Evaluation of protective immunity responses against pneumococcal PhtD and its C-terminal in combination with outer-membrane vesicles as adjuvants</article-title>. <source>J Med Microbiol</source>. <year>2020</year>;<volume>69</volume>(<issue>3</issue>):<fpage>465</fpage>&#8211;<lpage>477</lpage>. doi:<pub-id pub-id-type="doi">10.1099/jmm.0.001103</pub-id>.<pub-id pub-id-type="pmid">32100705</pub-id></mixed-citation></ref><ref id="cit0225"><label>225.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khan</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Pichichero</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Camilli</surname><given-names>A</given-names></string-name></person-group>. <article-title>CD4 T Cell Memory and Antibody Responses Directed against the Pneumococcal Histidine Triad Proteins PhtD and PhtE following Nasopharyngeal colonization and immunization and their role in protection against Pneumococcal colonization in Mice</article-title>. <source>Infect Immun</source>. <year>2013</year>;<volume>81</volume>(<issue>10</issue>):<fpage>3781</fpage>&#8211;<lpage>3792</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.00313-13</pub-id>.<pub-id pub-id-type="pmid">23897609</pub-id><pub-id pub-id-type="pmcid">PMC3811773</pub-id></mixed-citation></ref><ref id="cit0226"><label>226.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hamel</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Charland</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Pineau</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Ouellet</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Rioux</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Brodeur</surname><given-names>BR</given-names></string-name></person-group>. <article-title>Prevention of Pneumococcal disease in Mice immunized with conserved surface-accessible proteins</article-title>. <source>Infect Immun</source>. <year>2004</year>;<volume>72</volume>(<issue>5</issue>):<fpage>2659</fpage>&#8211;<lpage>2670</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.72.5.2659-2670.2004</pub-id>.<pub-id pub-id-type="pmid">15102774</pub-id><pub-id pub-id-type="pmcid">PMC387903</pub-id></mixed-citation></ref><ref id="cit0227"><label>227.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rose</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shivshankar</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Hinojosa</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Rodriguez</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sanchez</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Orihuela</surname><given-names>CJ</given-names></string-name></person-group>. <article-title>Antibodies against PsrP, a Novel Streptococcus pneumoniae Adhesin, block adhesion and protect Mice against Pneumococcal challenge</article-title>. <source>J Infect Dis</source>. <year>2008</year>;<volume>198</volume>(<issue>3</issue>):<fpage>375</fpage>&#8211;<lpage>383</lpage>. doi:<pub-id pub-id-type="doi">10.1086/589775</pub-id>.<pub-id pub-id-type="pmid">18507531</pub-id></mixed-citation></ref><ref id="cit0228"><label>228.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lee</surname><given-names>C-J</given-names></string-name>, <string-name name-style="western"><surname>Lock</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Andrew</surname><given-names>PW</given-names></string-name>, <string-name name-style="western"><surname>Mitchell</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Hansman</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Paton</surname><given-names>JC</given-names></string-name></person-group>. <article-title>Protection of infant mice from challenge with Strptococcus pneumoniae type 19F by immunization with a type 19F polysaccharide&#8212;pneumolysoid conjugate</article-title>. <source>Vaccine</source>. <year>1994</year>;<volume>12</volume>(<issue>10</issue>):<fpage>875</fpage>&#8211;<lpage>878</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0264-410X(94)90028-0</pub-id>.<pub-id pub-id-type="pmid">7975828</pub-id></mixed-citation></ref><ref id="cit0229"><label>229.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Michon</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Fusco</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Minetti</surname><given-names>CASA</given-names></string-name>, <string-name name-style="western"><surname>Laude-Sharp</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Uitz</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>C-H</given-names></string-name>, <string-name name-style="western"><surname>D&#8217;Ambra</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Moore</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Remeta</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Heron</surname><given-names>I</given-names></string-name>, et al</person-group>. <article-title>Multivalent pneumococcal capsular polysaccharide conjugate vaccines employing genetically detoxified pneumolysin as a carrier protein</article-title>. <source>Vaccine</source>. <year>1998</year>;<volume>16</volume>(<issue>18</issue>):<fpage>1732</fpage>&#8211;<lpage>1741</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0264-410X(98)00225-4</pub-id>.<pub-id pub-id-type="pmid">9778749</pub-id></mixed-citation></ref><ref id="cit0230"><label>230.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kuo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Douglas</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ree</surname><given-names>HK</given-names></string-name>, <string-name name-style="western"><surname>Lindberg</surname><given-names>AA</given-names></string-name></person-group>. <article-title>Characterization of a recombinant pneumolysin and its use as a protein carrier for pneumococcal type 18C conjugate vaccines</article-title>. <source>Infect Immun</source>. <year>1995</year>;<volume>63</volume>(<issue>7</issue>):<fpage>2706</fpage>&#8211;<lpage>2713</lpage>. doi:<pub-id pub-id-type="doi">10.1128/iai.63.7.2706-2713.1995</pub-id>.<pub-id pub-id-type="pmid">7790088</pub-id><pub-id pub-id-type="pmcid">PMC173362</pub-id></mixed-citation></ref><ref id="cit0231"><label>231.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Qiu</surname><given-names>C</given-names></string-name></person-group>. <article-title>Immunogenicity and protective immunity against otitis media caused by pneumococcus in mice of Hib conjugate vaccine with PsaA protein carrier</article-title>. <source>Front Med</source>. <year>2016</year>;<volume>10</volume>(<issue>4</issue>):<fpage>490</fpage>&#8211;<lpage>498</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11684-016-0470-y</pub-id>.<pub-id pub-id-type="pmid">27650380</pub-id></mixed-citation></ref><ref id="cit0232"><label>232.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Deno&#235;l</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Philipp</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Doyle</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Carletti</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Poolman</surname><given-names>JT</given-names></string-name></person-group>. <article-title>A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae</article-title>. <source>Vaccine</source>. <year>2011</year>;<volume>29</volume>(<issue>33</issue>):<fpage>5495</fpage>&#8211;<lpage>5501</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.05.051</pub-id>.<pub-id pub-id-type="pmid">21624422</pub-id><pub-id pub-id-type="pmcid">PMC5061031</pub-id></mixed-citation></ref><ref id="cit0233"><label>233.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hill</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Entwisle</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Pang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Joachim</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>McIlgorm</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dalton</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Burbidge</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Colaco</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Goldblatt</surname><given-names>D</given-names></string-name>, et al</person-group>. <article-title>Immunogenicity and mechanisms of action of PnuBioVax, a multi-antigen serotype-independent prophylactic vaccine against infection with Streptococcus pneumoniae</article-title>. <source>Vaccine</source>. <year>2018</year>;<volume>36</volume>(<issue>29</issue>):<fpage>4255</fpage>&#8211;<lpage>4264</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2018.05.122</pub-id>.<pub-id pub-id-type="pmid">29895498</pub-id></mixed-citation></ref><ref id="cit0234"><label>234.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mann</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Heath</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>King</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Maissoneuve</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Alderson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tate</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hollingshead</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Tweten</surname><given-names>RK</given-names></string-name>, et al</person-group>. <article-title>Multivalent Pneumococcal protein vaccines comprising Pneumolysoid with epitopes/fragments of CbpA and/or PspA elicit strong and broad protection</article-title>. <source>Clin Vaccine Immunol</source>. <year>2015</year>;<volume>22</volume>(<issue>10</issue>):<fpage>1079</fpage>&#8211;<lpage>1089</lpage>. doi:<pub-id pub-id-type="doi">10.1128/CVI.00293-15</pub-id>.<pub-id pub-id-type="pmid">26245351</pub-id><pub-id pub-id-type="pmcid">PMC4580740</pub-id></mixed-citation></ref><ref id="cit0235"><label>235.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Briles</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Ades</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Paton</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Sampson</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Carlone</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Huebner</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Virolainen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Swiatlo</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Hollingshead</surname><given-names>SK</given-names></string-name></person-group>. <article-title>Intranasal immunization of Mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against Nasopharyngeal Carriage of Streptococcus pneumoniae</article-title>. <source>Infect Immun</source>. <year>2000</year>;<volume>68</volume>(<issue>2</issue>):<fpage>796</fpage>&#8211;<lpage>800</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.68.2.796-800.2000</pub-id>.<pub-id pub-id-type="pmid">10639448</pub-id><pub-id pub-id-type="pmcid">PMC97207</pub-id></mixed-citation></ref><ref id="cit0236"><label>236.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Kong</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Y</given-names></string-name></person-group>. <article-title>A pneumococcal vaccine combination with two proteins containing PspA families 1 and 2 can potentially protect against a wide range of Streptococcus pneumoniae strains</article-title>. <source>Immunol Res</source>. <year>2018</year>;<volume>66</volume>(<issue>4</issue>):<fpage>528</fpage>&#8211;<lpage>536</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12026-018-9016-5</pub-id>.<pub-id pub-id-type="pmid">30128745</pub-id></mixed-citation></ref><ref id="cit0237"><label>237.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zane</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kraschowetz</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Trentini</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Alves</surname><given-names>VDS</given-names></string-name>, <string-name name-style="western"><surname>Araujo</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Goulart</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Leite</surname><given-names>LCDC</given-names></string-name>, <string-name name-style="western"><surname>Gon&#231;alves</surname><given-names>VM</given-names></string-name></person-group>. <article-title>Peptide linker increased the stability of pneumococcal fusion protein vaccine candidate</article-title>. <source>Front Bioeng Biotechnol</source>. <year>2023</year>;<volume>11</volume>:<fpage>1108300</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fbioe.2023.1108300</pub-id>.<pub-id pub-id-type="pmid">36777254</pub-id><pub-id pub-id-type="pmcid">PMC9909212</pub-id></mixed-citation></ref><ref id="cit0238"><label>238.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mann</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Thornton</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Heath</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wade</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Tweten</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>El Kasmi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Jordan</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Mitrea</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Kriwacki</surname><given-names>R</given-names></string-name>, et al</person-group>. <article-title>Broadly protective protein-based Pneumococcal vaccine composed of Pneumolysin Toxoid&#8211;CbpA peptide recombinant fusion protein</article-title>. <source>J Infect Dis</source>. <year>2014</year>;<volume>209</volume>(<issue>7</issue>):<fpage>1116</fpage>&#8211;<lpage>1125</lpage>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jit502</pub-id>.<pub-id pub-id-type="pmid">24041791</pub-id><pub-id pub-id-type="pmcid">PMC3952665</pub-id></mixed-citation></ref><ref id="cit0239"><label>239.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ogunniyi</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Grabowicz</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Briles</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Cook</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Paton</surname><given-names>JC</given-names></string-name></person-group>. <article-title>Development of a vaccine against invasive Pneumococcal disease based on combinations of virulence proteins</article-title>. <source>Infect Immun</source>. <year>2007</year>;<volume>75</volume>(<issue>1</issue>):<fpage>350</fpage>&#8211;<lpage>357</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.01103-06</pub-id>.<pub-id pub-id-type="pmid">17088353</pub-id><pub-id pub-id-type="pmcid">PMC1828427</pub-id></mixed-citation></ref><ref id="cit0240"><label>240.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Verhoeven</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Pichichero</surname><given-names>ME</given-names></string-name></person-group>. <article-title>Vaccination with a Streptococcus pneumoniae trivalent recombinant PcpA, PhtD and PlyD1 protein vaccine candidate protects against lethal pneumonia in an infant murine model</article-title>. <source>Vaccine</source>. <year>2014</year>;<volume>32</volume>(<issue>26</issue>):<fpage>3205</fpage>&#8211;<lpage>3210</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2014.04.004</pub-id>.<pub-id pub-id-type="pmid">24731814</pub-id></mixed-citation></ref><ref id="cit0241"><label>241.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Surendran</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Verhoeven</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Klapa</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ochs</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pichichero</surname><given-names>ME</given-names></string-name></person-group>. <article-title>Trivalent pneumococcal protein recombinant vaccine protects against lethal Streptococcus pneumoniae pneumonia and correlates with phagocytosis by neutrophils during early pathogenesis</article-title>. <source>Vaccine</source>. <year>2015</year>;<volume>33</volume>(<issue>8</issue>):<fpage>993</fpage>&#8211;<lpage>1000</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2015.01.014</pub-id>.<pub-id pub-id-type="pmid">25597944</pub-id></mixed-citation></ref><ref id="cit0242"><label>242.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Pryharski</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Pichichero</surname><given-names>ME</given-names></string-name></person-group>. <article-title>Trivalent pneumococcal protein vaccine protects against experimental acute otitis media caused by Streptococcus pneumoniae in an infant murine model</article-title>. <source>Vaccine</source>. <year>2017</year>;<volume>35</volume>(<issue>2</issue>):<fpage>337</fpage>&#8211;<lpage>344</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.046</pub-id>.<pub-id pub-id-type="pmid">27919628</pub-id></mixed-citation></ref><ref id="cit0243"><label>243.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Visan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Rouleau</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Proust</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Peyrot</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Donadieu</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ochs</surname><given-names>M</given-names></string-name></person-group>. <article-title>Antibodies to PcpA and PhtD protect mice against Streptococcus pneumoniae by a macrophage- and complement-dependent mechanism</article-title>. <source>Hum Vaccines Immunother</source>. <year>2018</year>;<volume>14</volume>(<issue>2</issue>):<fpage>489</fpage>&#8211;<lpage>494</lpage>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2017.1403698</pub-id>.<pub-id pub-id-type="pmcid">PMC5806646</pub-id><pub-id pub-id-type="pmid">29135332</pub-id></mixed-citation></ref><ref id="cit0244"><label>244.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kong</surname><given-names>FT</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>P</given-names></string-name>, et al</person-group>. <article-title>Protective immune responses elicited by fusion protein containing PsaA and PspA fragments</article-title>. <source>Immunol Invest</source>. <year>2015</year>;<volume>44</volume>(<issue>5</issue>):<fpage>482</fpage>&#8211;<lpage>496</lpage>. doi:<pub-id pub-id-type="doi">10.3109/08820139.2015.1037956</pub-id>.<pub-id pub-id-type="pmid">26107747</pub-id></mixed-citation></ref><ref id="cit0245"><label>245.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Olafsdottir</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Lingnau</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Nagy</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Jonsdottir</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Camilli</surname><given-names>A</given-names></string-name></person-group>. <article-title>Novel protein-based Pneumococcal vaccines administered with the Th1-promoting adjuvant IC31 induce protective immunity against Pneumococcal disease in neonatal</article-title>. <source>Infect Immun</source>. <year>2012</year>;<volume>80</volume>(<issue>1</issue>):<fpage>461</fpage>&#8211;<lpage>468</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.05801-11</pub-id>.<pub-id pub-id-type="pmid">22025519</pub-id><pub-id pub-id-type="pmcid">PMC3255653</pub-id></mixed-citation></ref><ref id="cit0246"><label>246.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jomaa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yuste</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Paton</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dougan</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>JS</given-names></string-name></person-group>. <article-title>Antibodies to the iron uptake ABC transporter Lipoproteins PiaA and PiuA promote Opsonophagocytosis of Streptococcus pneumoniae</article-title>. <source>Infect Immun</source>. <year>2005</year>;<volume>73</volume>(<issue>10</issue>):<fpage>6852</fpage>&#8211;<lpage>6859</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.73.10.6852-6859.2005</pub-id>.<pub-id pub-id-type="pmid">16177364</pub-id><pub-id pub-id-type="pmcid">PMC1230898</pub-id></mixed-citation></ref><ref id="cit0247"><label>247.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brown</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Ogunniyi</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Woodrow</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Holden</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Paton</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Tuomanen</surname><given-names>EI</given-names></string-name></person-group>. <article-title>Immunization with components of two iron uptake ABC transporters protects Mice against systemic Streptococcus pneumoniae infection</article-title>. <source>Infect Immun</source>. <year>2001</year>;<volume>69</volume>(<issue>11</issue>):<fpage>6702</fpage>&#8211;<lpage>6706</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.69.11.6702-6706.2001</pub-id>.<pub-id pub-id-type="pmid">11598041</pub-id><pub-id pub-id-type="pmcid">PMC100046</pub-id></mixed-citation></ref><ref id="cit0248"><label>248.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jomaa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Terry</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hale</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dougan</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>J</given-names></string-name></person-group>. <article-title>Immunization with the iron uptake ABC transporter proteins PiaA and PiuA prevents respiratory infection with Streptococcus pneumoniae</article-title>. <source>Vaccine</source>. <year>2006</year>;<volume>24</volume>(<issue>24</issue>):<fpage>5133</fpage>&#8211;<lpage>5139</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2006.04.012</pub-id>.<pub-id pub-id-type="pmid">16707196</pub-id></mixed-citation></ref><ref id="cit0249"><label>249.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Malley</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lipsitch</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stack</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Saladino</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Fleisher</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Pelton</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Thompson</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Briles</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>P</given-names></string-name></person-group>. <article-title>Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated Pneumococci</article-title>. <source>Infect Immun</source>. <year>2001</year>;<volume>69</volume>(<issue>8</issue>):<fpage>4870</fpage>&#8211;<lpage>4873</lpage>. doi:<pub-id pub-id-type="doi">10.1128/IAI.69.8.4870-4873.2001</pub-id>.<pub-id pub-id-type="pmid">11447162</pub-id><pub-id pub-id-type="pmcid">PMC98576</pub-id></mixed-citation></ref><ref id="cit0250"><label>250.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>HogenEsch</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Dunham</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hansen</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Maisonneuve</surname><given-names>J-F</given-names></string-name>, <string-name name-style="western"><surname>Hem</surname><given-names>SL</given-names></string-name></person-group>. <article-title>Formulation of a killed whole cell pneumococcus vaccine - effect of aluminum adjuvants on the antibody and IL-17 response</article-title>. <source>J Immune Based Ther Vaccines</source>. <year>2011</year>;<volume>9</volume>(<issue>1</issue>):<fpage>5</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1476-8518-9-5</pub-id>.<pub-id pub-id-type="pmid">21801401</pub-id><pub-id pub-id-type="pmcid">PMC3161839</pub-id></mixed-citation></ref><ref id="cit0251"><label>251.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lu</surname><given-names>Y-J</given-names></string-name>, <string-name name-style="western"><surname>Yadav</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Clements</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Forte</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Srivastava</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Thompson</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Seid</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Look</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Alderson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tate</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated Pneumococcal whole-cell vaccine</article-title>. <source>Clin Vaccine Immunol</source>. <year>2010</year>;<volume>17</volume>(<issue>6</issue>):<fpage>1005</fpage>&#8211;<lpage>1012</lpage>. doi:<pub-id pub-id-type="doi">10.1128/CVI.00036-10</pub-id>.<pub-id pub-id-type="pmid">20427625</pub-id><pub-id pub-id-type="pmcid">PMC2884428</pub-id></mixed-citation></ref><ref id="cit0252"><label>252.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name></person-group>. <article-title>Serotype-independent protection against pneumococcal infections elicited by intranasal immunization with ethanol-killed pneumococcal strain, SPY1</article-title>. <source>J Microbiol</source>. <year>2014</year>;<volume>52</volume>(<issue>4</issue>):<fpage>315</fpage>&#8211;<lpage>323</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12275-014-3583-5</pub-id>.<pub-id pub-id-type="pmid">24682994</pub-id></mixed-citation></ref><ref id="cit0253"><label>253.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>E-H</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>S-Y</given-names></string-name>, <string-name name-style="western"><surname>Kwon</surname><given-names>M-K</given-names></string-name>, <string-name name-style="western"><surname>Tran</surname><given-names>TDH</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>S-S</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>K-J</given-names></string-name>, <string-name name-style="western"><surname>Bae</surname><given-names>S-M</given-names></string-name>, <string-name name-style="western"><surname>Briles</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Rhee</surname><given-names>D-K</given-names></string-name></person-group>. <article-title>Streptococcus pneumoniae pep27 mutant as a live vaccine for serotype-independent protection in mice</article-title>. <source>Vaccine</source>. <year>2012</year>;<volume>30</volume>(<issue>11</issue>):<fpage>2008</fpage>&#8211;<lpage>2019</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.11.073</pub-id>.<pub-id pub-id-type="pmid">22154770</pub-id></mixed-citation></ref><ref id="cit0254"><label>254.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>S-J</given-names></string-name>, <string-name name-style="western"><surname>Seon</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Luong</surname><given-names>TT</given-names></string-name>, <string-name name-style="western"><surname>Ghosh</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Pyo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rhee</surname><given-names>D-K</given-names></string-name></person-group>. <article-title>Immunization with attenuated non-transformable pneumococcal pep27 and comD mutant provides serotype-independent protection against pneumococcal infection</article-title>. <source>Vaccine</source>. <year>2019</year>;<volume>37</volume>(<issue>1</issue>):<fpage>90</fpage>&#8211;<lpage>98</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2018.11.027</pub-id>.<pub-id pub-id-type="pmid">30467061</pub-id></mixed-citation></ref><ref id="cit0255"><label>255.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Amonov</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Simbak</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Wan Hassan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Rahman</surname><given-names>NI</given-names></string-name>, <string-name name-style="western"><surname>Clarke</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Yeo</surname><given-names>CC</given-names></string-name></person-group>. <article-title>Disruption of the cpsE and endA genescattenuates Streptococcus pneumoniae virulence: towards the development of a live attenuated vaccine candidate</article-title>. <source>Vaccines</source>. <year>2020</year>;<volume>8</volume>(<issue>2</issue>):<fpage>187</fpage>. doi:<pub-id pub-id-type="doi">10.3390/vaccines8020187</pub-id>.<pub-id pub-id-type="pmid">32326482</pub-id><pub-id pub-id-type="pmcid">PMC7349068</pub-id></mixed-citation></ref><ref id="cit0256"><label>256.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ramos-Sevillano</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ercoli</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Guerra-Assun&#231;&#227;o</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Felgner</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ramiro de Assis</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Nakajima</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Goldblatt</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Tetteh</surname><given-names>KKA</given-names></string-name>, <string-name name-style="western"><surname>Heyderman</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>SB</given-names></string-name>, et al</person-group>. <article-title>Protective Effect of Nasal Colonisation with &#8710;cps/piaA and &#8710;cps/proAbcstreptococcus pneumoniae Strains against Recolonisation and Invasive Infection</article-title>. <source>Vaccines</source>. <year>2021</year>;<volume>9</volume>(<issue>3</issue>):<fpage>261</fpage>. doi:<pub-id pub-id-type="doi">10.3390/vaccines9030261</pub-id>.<pub-id pub-id-type="pmid">33804077</pub-id><pub-id pub-id-type="pmcid">PMC8000150</pub-id></mixed-citation></ref><ref id="cit0257"><label>257.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kamtchoua</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Bologa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hopfer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Neveu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sheng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Corde</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Pouzet</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zimmermann</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gurunathan</surname><given-names>S</given-names></string-name></person-group>. <article-title>Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults</article-title>. <source>Vaccine</source>. <year>2013</year>;<volume>31</volume>(<issue>2</issue>):<fpage>327</fpage>&#8211;<lpage>333</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2012.11.005</pub-id>.<pub-id pub-id-type="pmid">23153437</pub-id></mixed-citation></ref><ref id="cit0258"><label>258.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Entwisle</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hill</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Joachim</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>McIlgorm</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Colaco</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Goldblatt</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>De Gorguette D&#8217;Argoeuves</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bailey</surname><given-names>C</given-names></string-name></person-group>. <article-title>Safety and immunogenicity of a novel multiple antigen pneumococcal vaccine in adults: A Phase 1 randomised clinical trial</article-title>. <source>Vaccine</source>. <year>2017</year>;<volume>35</volume>(<issue>51</issue>):<fpage>7181</fpage>&#8211;<lpage>7186</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2017.10.076</pub-id>.<pub-id pub-id-type="pmid">29132988</pub-id></mixed-citation></ref><ref id="cit0259"><label>259.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Prymula</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Pazdiora</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Traskine</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>R&#252;ggeberg</surname><given-names>JU</given-names></string-name>, <string-name name-style="western"><surname>Borys</surname><given-names>D</given-names></string-name></person-group>. <article-title>Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial</article-title>. <source>Vaccine</source>. <year>2014</year>;<volume>32</volume>(<issue>25</issue>):<fpage>3025</fpage>&#8211;<lpage>3034</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2014.03.066</pub-id>.<pub-id pub-id-type="pmid">24699466</pub-id></mixed-citation></ref><ref id="cit0260"><label>260.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Seiberling</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bologa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Brookes</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ochs</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Go</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Neveu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kamtchoua</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lashley</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Gurunathan</surname><given-names>S</given-names></string-name></person-group>. <article-title>Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults</article-title>. <source>Vaccine</source>. <year>2012</year>;<volume>30</volume>(<issue>52</issue>):<fpage>7455</fpage>&#8211;<lpage>7460</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2012.10.080</pub-id>.<pub-id pub-id-type="pmid">23131206</pub-id></mixed-citation></ref><ref id="cit0261"><label>261.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bologa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kamtchoua</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hopfer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sheng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Hicks</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bixler</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Pehlic</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Gurunathan</surname><given-names>S</given-names></string-name></person-group>. <article-title>Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein a (PcpA) vaccine and bivalent PcpA&#8211;pneumococcal histidine triad protein D vaccine</article-title>. <source>Vaccine</source>. <year>2012</year>;<volume>30</volume>(<issue>52</issue>):<fpage>7461</fpage>&#8211;<lpage>7468</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2012.10.076</pub-id>.<pub-id pub-id-type="pmid">23123106</pub-id></mixed-citation></ref><ref id="cit0262"><label>262.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brooks</surname><given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>L-J</given-names></string-name>, <string-name name-style="western"><surname>Sheng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Hopfer</surname><given-names>R</given-names></string-name></person-group>. <article-title>Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: a phase I randomized controlled study</article-title>. <source>Vaccine</source>. <year>2015</year>;<volume>33</volume>(<issue>36</issue>):<fpage>4610</fpage>&#8211;<lpage>4617</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2015.06.078</pub-id>.<pub-id pub-id-type="pmid">26143615</pub-id></mixed-citation></ref><ref id="cit0263"><label>263.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pichichero</surname><given-names>ME</given-names></string-name></person-group>. <article-title>Pneumococcal whole-cell and protein-based vaccines: changing the paradigm</article-title>. <source>Expert Rev Vaccines</source>. <year>2017</year>;<volume>16</volume>(<issue>12</issue>):<fpage>1181</fpage>&#8211;<lpage>1190</lpage>. doi:<pub-id pub-id-type="doi">10.1080/14760584.2017.1393335</pub-id>.<pub-id pub-id-type="pmid">29130395</pub-id><pub-id pub-id-type="pmcid">PMC6277969</pub-id></mixed-citation></ref><ref id="cit0264"><label>264.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Leroux-Roels</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Devaster</surname><given-names>J-M</given-names></string-name>, <string-name name-style="western"><surname>Leroux-Roels</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Verlant</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Henckaerts</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Moris</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Hermand</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Van Belle</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Poolman</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Vandepapeli&#232;re</surname><given-names>P</given-names></string-name>, et al</person-group>. <article-title>Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: Randomised, controlled trials</article-title>. <source>Vaccine</source>. <year>2015</year>;<volume>33</volume>(<issue>4</issue>):<fpage>577</fpage>&#8211;<lpage>584</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2013.10.052</pub-id>.<pub-id pub-id-type="pmid">24176494</pub-id></mixed-citation></ref><ref id="cit0265"><label>265.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Leroux-Roels</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Maes</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>De Boever</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Traskine</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>R&#252;ggeberg</surname><given-names>JU</given-names></string-name>, <string-name name-style="western"><surname>Borys</surname><given-names>D</given-names></string-name></person-group>. <article-title>Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study</article-title>. <source>Vaccine</source>. <year>2014</year>;<volume>32</volume>(<issue>50</issue>):<fpage>6838</fpage>&#8211;<lpage>6846</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2014.02.052</pub-id>.<pub-id pub-id-type="pmid">24607003</pub-id></mixed-citation></ref><ref id="cit0266"><label>266.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pauksens</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Nilsson</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Caubet</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pascal</surname><given-names>TG</given-names></string-name>, <string-name name-style="western"><surname>Van Belle</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Poolman</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Vandepapeli&#232;re</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Verlant</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Vink</surname><given-names>PE</given-names></string-name></person-group>. <article-title>Randomized controlled study of the safety and immunogenicity of Pneumococcal vaccine formulations containing PhtD and detoxified Pneumolysin with alum or adjuvant system AS02V in elderly adults</article-title>. <source>Clin Vaccine Immunol</source>. <year>2014</year>;<volume>21</volume>(<issue>5</issue>):<fpage>651</fpage>&#8211;<lpage>660</lpage>. doi:<pub-id pub-id-type="doi">10.1128/CVI.00807-13</pub-id>.<pub-id pub-id-type="pmid">24599529</pub-id><pub-id pub-id-type="pmcid">PMC4018883</pub-id></mixed-citation></ref><ref id="cit0267"><label>267.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Odutola</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ota</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ogundare</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Antonio</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Owiafe</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Worwui</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Greenwood</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Alderson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Traskine</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Verlant</surname><given-names>V</given-names></string-name>, et al</person-group>. <article-title>Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2&#8211;4 years: a phase II randomized study</article-title>. <source>Hum Vaccines Immunother</source>. <year>2016</year>;<volume>12</volume>(<issue>2</issue>):<fpage>393</fpage>&#8211;<lpage>402</lpage>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2015.1111496</pub-id>.<pub-id pub-id-type="pmcid">PMC5049746</pub-id><pub-id pub-id-type="pmid">26618243</pub-id></mixed-citation></ref><ref id="cit0268"><label>268.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Odutola</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ota</surname><given-names>MOC</given-names></string-name>, <string-name name-style="western"><surname>Antonio</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ogundare</surname><given-names>EO</given-names></string-name>, <string-name name-style="western"><surname>Saidu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Foster-Nyarko</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Owiafe</surname><given-names>PK</given-names></string-name>, <string-name name-style="western"><surname>Ceesay</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Worwui</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Idoko</surname><given-names>OT</given-names></string-name>, et al</person-group>. <article-title>Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: a phase 2, randomized, controlled, observer-blind study</article-title>. <source>Vaccine</source>. <year>2017</year>;<volume>35</volume>(<issue>19</issue>):<fpage>2531</fpage>&#8211;<lpage>2542</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2017.03.071</pub-id>.<pub-id pub-id-type="pmid">28389097</pub-id></mixed-citation></ref><ref id="cit0269"><label>269.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Odutola</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ota</surname><given-names>MOC</given-names></string-name>, <string-name name-style="western"><surname>Antonio</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ogundare</surname><given-names>EO</given-names></string-name>, <string-name name-style="western"><surname>Saidu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Owiafe</surname><given-names>PK</given-names></string-name>, <string-name name-style="western"><surname>Worwui</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Idoko</surname><given-names>OT</given-names></string-name>, <string-name name-style="western"><surname>Owolabi</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Kampmann</surname><given-names>B</given-names></string-name>, et al</person-group>. <article-title>Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines &#8211; a phase II, randomised, observer-blind study in Gambian infants</article-title>. <source>Vaccine</source>. <year>2019</year>;<volume>37</volume>(<issue>19</issue>):<fpage>2586</fpage>&#8211;<lpage>2599</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2019.03.033</pub-id>.<pub-id pub-id-type="pmid">30975570</pub-id></mixed-citation></ref><ref id="cit0270"><label>270.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hammitt</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Campbell</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Borys</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Weatherholtz</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Reid</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Goklish</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Moulton</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Traskine</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Swinnen</surname><given-names>K</given-names></string-name>, et al</person-group>. <article-title>Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: a phase IIb randomized study</article-title>. <source>Vaccine</source>. <year>2019</year>;<volume>37</volume>(<issue>51</issue>):<fpage>7482</fpage>&#8211;<lpage>7492</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2019.09.076</pub-id>.<pub-id pub-id-type="pmid">31629570</pub-id></mixed-citation></ref><ref id="cit0271"><label>271.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Borys</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rupp</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Smulders</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chichili</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Kovanda</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Santos</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Malinoski</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Siber</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Malley</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sebastian</surname><given-names>S</given-names></string-name></person-group>. <article-title>Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: a phase 1 randomized controlled trial</article-title>. <source>Vaccine</source>. <year>2024</year>;<volume>42</volume>(<issue>10</issue>):<fpage>2560</fpage>&#8211;<lpage>2571</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2024.02.001</pub-id>.<pub-id pub-id-type="pmid">38360475</pub-id></mixed-citation></ref><ref id="cit0272"><label>272.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chichili</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Smulders</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Santos</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Cywin</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kovanda</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Van Sant</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Malinoski</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Sebastian</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Siber</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Malley</surname><given-names>R</given-names></string-name></person-group>. <article-title>Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years</article-title>. <source>Vaccine</source>. <year>2022</year>;<volume>40</volume>(<issue>31</issue>):<fpage>4190</fpage>&#8211;<lpage>4198</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2022.05.079</pub-id>.<pub-id pub-id-type="pmid">35690500</pub-id></mixed-citation></ref><ref id="cit0273"><label>273.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Miyaji</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Oliveira</surname><given-names>MLS</given-names></string-name>, <string-name name-style="western"><surname>Carvalho</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ho</surname><given-names>PL</given-names></string-name></person-group>. <article-title>Serotype-independent pneumococcal vaccines</article-title>. <source>Cell Mol Life Sci</source>. <year>2013</year>;<volume>70</volume>(<issue>18</issue>):<fpage>3303</fpage>&#8211;<lpage>3326</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00018-012-1234-8</pub-id>.<pub-id pub-id-type="pmid">23269437</pub-id><pub-id pub-id-type="pmcid">PMC11113425</pub-id></mixed-citation></ref><ref id="cit0274"><label>274.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>G-L</given-names></string-name>, <string-name name-style="western"><surname>Seon</surname><given-names>S-H</given-names></string-name>, <string-name name-style="western"><surname>Rhee</surname><given-names>D-K</given-names></string-name></person-group>. <article-title>Pneumonia and Streptococcus pneumoniae vaccine</article-title>. <source>Arch Pharm Res</source>. <year>2017</year>;<volume>40</volume>(<issue>8</issue>):<fpage>885</fpage>&#8211;<lpage>893</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12272-017-0933-y</pub-id>.<pub-id pub-id-type="pmid">28735461</pub-id><pub-id pub-id-type="pmcid">PMC7090487</pub-id></mixed-citation></ref><ref id="cit0275"><label>275.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vo&#223;</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Kohler</surname><given-names>TP</given-names></string-name>, <string-name name-style="western"><surname>Meyer</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Abdullah</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>van Opzeeland</surname><given-names>FJ</given-names></string-name>, <string-name name-style="western"><surname>Saleh</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Michalik</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>van Selm</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Schmidt</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>de Jonge</surname><given-names>MI</given-names></string-name>, et al</person-group>. <article-title>Intranasal vaccination with lipoproteins confers protection against Pneumococcal colonisation</article-title>. <source>Front Immunol</source>. <year>2018</year>;<volume>9</volume>:<fpage>2405</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2018.02405</pub-id>.<pub-id pub-id-type="pmid">30405609</pub-id><pub-id pub-id-type="pmcid">PMC6202950</pub-id></mixed-citation></ref><ref id="cit0276"><label>276.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kohler</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Vo&#223;</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>G&#243;mez Mejia</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Hammerschmidt</surname><given-names>S</given-names></string-name></person-group>. <article-title>Pneumococcal lipoproteins involved in bacterial fitness, virulence, and immune evasion</article-title>. <source>FEBS Lett</source>. <year>2016</year>;<volume>590</volume>(<issue>21</issue>):<fpage>3820</fpage>&#8211;<lpage>3839</lpage>. doi:<pub-id pub-id-type="doi">10.1002/1873-3468.12352</pub-id>.<pub-id pub-id-type="pmid">27508940</pub-id></mixed-citation></ref><ref id="cit0277"><label>277.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moffitt</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Malley</surname><given-names>R</given-names></string-name></person-group>. <article-title>Rationale and prospects for novel pneumococcal vaccines</article-title>. <source>Hum Vaccines Immunother</source>. <year>2016</year>;<volume>12</volume>(<issue>2</issue>):<fpage>383</fpage>&#8211;<lpage>392</lpage>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2015.1087625</pub-id>.<pub-id pub-id-type="pmcid">PMC5049723</pub-id><pub-id pub-id-type="pmid">26535755</pub-id></mixed-citation></ref><ref id="cit0278"><label>278.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Keech</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Morrison</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Tate</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Flores</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Goldblatt</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Briles</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hural</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Malley</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Alderson</surname><given-names>MR</given-names></string-name></person-group>. <article-title>A Phase 1 Randomized, Placebo-controlled, Observer-blinded trial to evaluate the safety and immunogenicity of inactivated Streptococcus pneumoniae whole-cell vaccine in adults</article-title>. <source>Pediatr Infect Dis J</source>. <year>2020</year>;<volume>39</volume>(<issue>4</issue>):<fpage>345</fpage>&#8211;<lpage>351</lpage>. doi:<pub-id pub-id-type="doi">10.1097/INF.0000000000002567</pub-id>.<pub-id pub-id-type="pmid">31895881</pub-id></mixed-citation></ref><ref id="cit0279"><label>279.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morais</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Texeira</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Suarez</surname><given-names>N</given-names></string-name></person-group>. <article-title>Next-generation whole-cell Pneumococcal vaccine</article-title>. <source>Vaccines</source>. <year>2019</year>;<volume>7</volume>(<issue>4</issue>):<fpage>151</fpage>. doi:<pub-id pub-id-type="doi">10.3390/vaccines7040151</pub-id>.<pub-id pub-id-type="pmid">31623286</pub-id><pub-id pub-id-type="pmcid">PMC6963273</pub-id></mixed-citation></ref><ref id="cit0280"><label>280.</label><mixed-citation publication-type="webpage"><article-title>Dose-Finding Study of S. Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers</article-title>. [<date-in-citation>accessed 2024 <month>Dec</month><day>13</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT02097472" ext-link-type="uri">https://clinicaltrials.gov/study/NCT02097472</ext-link>.</mixed-citation></ref><ref id="cit0281"><label>281.</label><mixed-citation publication-type="webpage"><article-title>A Study of a Vaccine for Pneumonia in Adults and Toddlers in Kenya</article-title>. [<date-in-citation>accessed 2024 <month>Dec</month><day>13</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT02543892" ext-link-type="uri">https://clinicaltrials.gov/study/NCT02543892</ext-link>.</mixed-citation></ref><ref id="cit0282"><label>282.</label><mixed-citation publication-type="webpage"><article-title>Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adults</article-title>. [<date-in-citation>accessed 2024 <month>Dec</month><day>13</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT00896064" ext-link-type="uri">https://clinicaltrials.gov/study/NCT00896064</ext-link>.</mixed-citation></ref></ref-list></back></article></pmc-articleset>